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Murine gamaherpesvirus-68 (MHV-68) is natural pathogen of small free living
rodents. Like Epstein-Barr virus, MHV-68 is B-cell tropic with respect to latency
and sensitive to the anti-viral acyclovir (ACV). The aim of this project was to
evaluate the potency of a new anti-viral called 2'-deoxy-5-ethyl-P-4'-thiouridine (4'-
s-EtdU) as an inhibitor ofMHV-68 replication both in vitro and in vivo. Finally to
utilise the anti-viral activity of 4'-s-EtdU, to be able to study disease associated with
gammaherpesvirus latency in immunocompromised mice, without the complications
associated with lytic virus replication. The potency of 4'-s-EtdU as an inhibitor of
the lytic replication was determined to be 15 times greater than ACV by EC50 assay,
giving a value of 0.13pM (35ng/ml). Treatment of infected cell lines lead to the
elimination of detectable productive viral replication. However, virus genomic
DNA, which remained capable of reactivation after treatment withdrawal, was not
eliminated. Not only was this true for cell lines which MHV-68 is known to
establish latency, but also cell lines previously known only to support lytic
replication. The nature of the viral persistence appeared different for the different
cell lines both with respect to virus reactivation after withdrawal of treatment and to
the spontaneous generation of 4'-s-EtdU resistant viral variants. The data leads to
the possibility of MHV-68 being capable of episomal maintenance whilst in a
perpetual state of attempted productive replication. Spontaneously arising 4'-s-EtdU
resistant virus variants were cloned and isolated and found to remained sensitive to
the anti-viral effects of ACV. However, further characterisation of these viral
variants was not undertaken. Treatment of mice with 4'-s-EtdU (0.3mg/ml in
drinking water) from 3 days post infection (in), rapidly eliminated productive virus
replication in the lung tissue, but failed to prevent the establishment and long-term
maintenance of viral latency in the lymphoid compartments. Treatment also failed to
prevent the post acute splenomegaly commonly observed in MHV-68 infected mice.
However, prophylactic treatment of mice prior to infection (in), did prevent virus
dissemination to the spleen as well as preventing splenomegaly. Viral DNA
remained absent from the spleen for as long as treatment was maintained, up to 54
14
days post infection, as determined by both co-cultivation assay and nested PCR.
However, virus DNA was detected in the lung tissue of the same mice.
Dissemination of virus to the spleen, on withdrawal of treatment correlated with the
production of MHV-68 specific antibodies, as determined by whole virus ELISA.
The experiments provided evidence for both chronic and latent infections of the lung
tissue of the mice infected via the intra-nasal route. The evidence demonstrated the
importance of productive virus replication in the establishment of viral latency in
circulating B-cells and hence development of IM like syndromes even when MHV-
68 was administered via the intra-peritoneal route. Although 4'-s-EtdU treatment
protected SCID mice from an otherwise lethal MHV-68 infection, it was not possible
to determine the role of productive virus replication in oncogenesis since lymphomas
failed to develop in both long-term infected transiently immunosuppressed, C57BL/6
mice and in SCID mice recipients of syngeneic splenocytes. The study failed to
reproduce the earlier studies (Sunil-Chandra et al, 1993). Surprisingly, viral latency
appeared to be maintained in normal healthy BALB/c mice more efficiently than in
SCID mice transiently repopulated with BALB/c splenocytes. Hence it was not
possible to investigate either the therapeutic benefit or establish the role of
productive virus replication in the development ofMHV-68 associated tumours.
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Chapter 1: General Introduction
1.1.1 The herpesviruses
Herpesviruses are a ubiquitous group of highly infectious large enveloped viruses
with a genome comprised of deoxyribonucleic acid (DNA). Herpesviruses have been
isolated from all major vertebrate groups, such as fish, amphibians, reptiles, birds
and mammals (see Table 1.1). To date there have been 8 herpesviruses isolated, the
natural host ofwhich is man. The human herpesviruses (HHV) have been designated
HHV1 to 8 but are commonly referred to as herpes simplex virus (HSV) 1 & 2,
Varicella-zoster virus (VZV), human cytomegalovirus (CMV or HCMV), Epstein-
Barr virus (EBV), HHV6, HHV7 and Kaposi's sarcoma associated herpesvirus
(KSHV), respectively. Primary infection can lead to the development of diseases
such as chicken pox, with VZV, and infectious mononucleosis (IM), with EBV,
however most primary infections are asymptomatic. Viral infection of the host is life
long, a feature common to all herpesviruses, and can lead to spontaneous recurrent
disease, such as cold sores with HSV and shingles with VZV. Virus levels are
controlled by the host's immune system and immunosuppression can lead to fatal
diseases such as disseminating infection with HCMV, lymphoproliferative (LPD)
disease, with EBV and ocular disease with HSV. Herpesviruses have also been
associated with a number of malignancies such as endemic Burkitt's lymphoma
(eBL) and nasopharyngeal carcinoma (NPC), with EBV and Kaposi's sarcoma (KS),
with KSHV.
1.1.2 Herpesvirus structure and genome architecture
Herpesvirus particles consist of a linear double stranded (ds) DNA genome contained
within an icosahedral capsid comprised of 162 capsomeres. The capsid is enclosed
within a glycoprotein embedded lipid envelope, separated by an amorphous protein
tegument (Roizman et al, 1996). The viral genomes range, in size from 125 kilobase
pairs (kb) for VZV to 230kb for HCMV, and in G+C content (molar ratio) from 42%
28
Table 1.1* Examples of vertebrate herpesviruses that have been isolated and
at least partially characterised.





Ictalurid herpesvirus 1 Channel catfish HV 56 130
Salmonid herpesvirus 1 HV salmonis
Cypinid herpesvirus Carp pox HV
Amphibian herpesviruses
Ranid herpesvirus 1 Lucke frog HV 46
Ranid herpesvirus 2 Frog HV 4 56
Reptilian herpesviruses
Iguanid herpesvirus 1 Green iguana HV
Elapid herpesvirus Indian cobra HV
Avian herpesviruses




Strigid herpesvirus 1 Owl hepatosplenitis virus 61
Mammalian herpesviruses
Macropodid herpesvirus 2 Dorcopsis wallaby HV 50 135
Murid herpesvirus 1 Mouse cytomegalovirus 59 235
Leporid herpesvirus 1 HV sylvilagus 33 145
Suid herpesvirus 1 Pseudorabies virus 74 140
Equid herpesvirus 1 Equine abortion HV 57 142
Bovine herpesvirus 1 Infectious bovine
rhinotracheitis HV
72 140
Felid herpesvirus 1 Feline rhinotracheitis HV 46 135
Aotine herpesvirus 1 HV aotus 1 55 220
* Table adaptedfrom Roizman et al, 1996.
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in HHV6 to 75% in pseudorabies virus (Roizman et al, 1996). There are a number of
different genomic structural arrangements commonly found within the
Herpesviridae. These have been termed type 'A' to 'F' and denote, in order of
complexity, the number, positions and relative orientations of repeat sequences as
well as unique or quasi unique coding regions, within the viral genome. Type A
arrangements are found in herpesviruses such as Channel catfish virus (CCV),
believed to represent an ancestral herpesvirus group, the gammaherpesvirus equine
herpesvirus (EHV) 2 and the betaherpesvirus subgroup Roseoloviruses, which
includes HHV 6 & 7. B type arrangements are found in many y-2 herpesviruses
(.Rhadinoviruses), such as herpesvirus (HV) Saimiri (HVS) and HV ateles. Type C
arrangements are found in the y-1 herpesviruses (Lymphocryptoviruses), such as
EBV, HV pan and HV papio. Type D arrangements are common to the
alphaherpesvirus sub-group Varicelloviruses, such as VZV and EHV1. Type E
arrangements are common to the alphaherpesvirus subgroup Simplexviruses, such as
HSV1 & 2 and bovine herpesvirus (BHV) 2 as well as the f3— 1 herpesviruses
(Cytomegaloviruses), such as HCMV and HV aotus type 1. Type F arrangements are
found in the betaherpesvirus subgroup Muromegalovirus, such as murine CMV 1 &
2 and tupaia herpesvirus, and the gammaherpesvirus EHV-5 (Roizman et al, 1996 &
Telford et al, 1993).
1.1.3 The herpesvirus sub-families
There are essentially 3 herpesvirus sub-families: alpha, beta and gamma. The
groupings were originally organised on the basis of their biological properties, both
in vivo and in vitro. This form of classification still holds true in many cases but
does not allow for tropism diversity with in sub-families. Modern classification is
now based on genetic determinants, such as the relative order of conserved blocks of
genes, common to all herpesviruses (Chee et al, 1990 & Gomples et al, 1995).
The alphaherpesviruses generally have a variable host range, short reproductive cycle
which leads to lysis of the host cells. They are generally neurotropic with respect to
30
in vivo latent infections (primarily in sensory ganglia) and are readily propagated in
permissive cell lines, in vitro. Examples of species members of the
Alphaherpesvirinae are HSV 1, HSV 2, VZV, BHV 2, EHV 1 and Marek's disease
herpesvirus (MDV) 1. Human alphaherpesviruses are responsible for cold sores,
chicken pox and shingles, ocular disease and encephalitis in man. MDV induces T-
cell lymphomas in chickens.
The betaherpesviruses generally have a restricted host range and a long replicative
cycle in tissue culture. A productive infection of cells induces cytomegalia
(enlargement) and persistently infected cell lines are readily established in vitro. The
common sites of persistence in vivo are secretary glands, lymphoreticular cells, the
kidneys and the lungs. Members of the Betaherpesvirinae are HCMV, HHV 6, HHV
7 and murine CMV. Betaherpesviruses are responsible for foetal deformities,
childhood roseola and disseminating infection related disease and encephalitis in
immunosuppressed / immunocompromised individuals.
The gammaherpesviruses generally have a highly restricted host range, limited to the
family/ order, to which the natural host belongs. Though they often replicate poorly
in tissue culture, some will productively infect epithelial and fibroblastoid cells in
vitro. Latent infections of lymphocytes can be established both in vivo and in vitro
and lymphoid tissue is often the site of viral latency in vivo. A common feature of
the subfamily is the ability to immortalise / transform lymphocytes in vitro and in
vivo and have been associated with numerous lymphoproliferative and malignant
conditions both in humans and animals. Examples of the Gammaherpesvirinae are
EBV, HV papio, KSHV, HVS, HV ateles, BHV 4, Alcelaphine herpesvirus (AHV),
EHV 2 & 5 and murine gammaherpesvirus 68 (MHV-68) (see Table 1.4).
1.1.4 Herpesvirus conserved gene blocks
It has been observed that homologies to a number of 'core' genes exist in all
sequenced mammalian herpesviruses. These genes generally code for the
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fundamental structural proteins and enzymes required for productive viral
replication. The conserved genes occur in blocks and within the blocks they are
generally co-linear with respect to order and orientation. Initially 3 blocks were
described (Davidson et al, 1987) but as more sequencing data became available,
these were broken up into 7 blocks (Chee et al, 1990). The relative order and
orientation of these conserved gene blocks is specific to the 3 herpesvirus sub-groups
and forms the basis of the modern classification system by which mammalian and
avian herpesviruses are assigned a sub-grouping. The order and alignment of the
blocks is taken from the betaherpesviruses since the (3-2 herpesviruses have an 'A'
type genome structure, which is believed to represent the ancestral herpesvirus
genome structure. The order therefore, in which betaherpesviruses encode the
conserved blocks is I, II, III, IV, V, VI, VII. For alphaherpesviruses it is III, I, II',
IV',V',VI, VII and for gammaherpesviruses it is II', IV', V', VI, VII, III', I (where
blocks' are encoded in the inverse direction) (Gompels et al, 1995).
1.1.5 Conserved and partially conserved herpesvirus genes
Block I contains the genes for the large subunit of the enzyme ribonucleotide
reductase (RR) as well as a number of virion structural protein genes. Block II
contains the genes for the herpesvirus specific DNA polymerase, glycoprotein B (gB)
and the single stranded DNA binding protein (ssDBP). Blocks III, IV and V contain
the genes for dUTPase, the major capsid protein (MCP) and glycoprotein H (gH),
respectively. Block VI contains the genes for the viral DNA packing proteins,
alkaline exonuclease and the herpesvirus specific kinase, responsible for the
phosphorylation of gancyclovir (GCV). Block VII contains the genes for Uracil
DNA glucosidase and glycoprotein L (gL) (for the breakdown of the conserved viral
gene blocks, see Table 1.2).
There are also a number of partially conserved genes found in at least two of the
herpesvirus sub-groups (see Table 1.3), such as the thymidine kinase (TK)
homologue which is encoded by both alpha and gammaherpesviruses, but not the
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Table 1.2* The herpesvirus core gene homologues, in block order, as encoded




Gene FunctionHCMV HHV6 HVS EBV vzv HSV-1
1 UL44 UL27 ORF59 BMRF1 ORF16 UL42 DNA replication protein2
1 UL45 UL28 ORF61 BORF2 ORF19 UL39 RR (large)142
1 UL46 UL29 ORF62 BORF1 ORF20 UL38 Capsid assembly / DNA
maturation protein142
1 UL47 UL30 ORF63 BORF1 ORF21 UL37 Myosin1 / Tp2
1 UL48 UL31 ORF64 BPLF1 ORF22 UL37 Tp142
1 UL49 UL33 ORF66 BFRF2 ORF23 UL35 Cp1
1 UL50 UL34 ORF67 BFRF1 ORF24 UL34 Tp2
1 UL52 UL36 ORF68 BFLF1 ORF26 UL32 Gp2
1 UL53 UL37 ORF69 BFLF2 ORF27 UL31
2 UL54 UL38 ORF9 BALF5 ORF28 UL30 DNA polymerase142
2 UL55 UL39 ORF8 BALF4 ORF31 UL27 Gp B142
2 UL56 UL40 ORF7 BALF3 ORF30 UL28 transport protein142
2 UL57 UL41 ORF6 BALF2 ORF29 UL29 ssDNA binding protein142
3 UL69 UL42 ORF57 BMLF1 ORF4 UL54 IE2 transactivator1
3 UL70 UL43 ORF56 BSLF1 ORF6 UL52 Helicase/Primase1
3 UL71 UL44 ORF55 BSRF1 ORF7 UL51
3 UL72 UL45 ORF54 BLLF2 ORF8 UL50 dUTPase1&2
3 UL73 UL46 ORF53 BLRF1 ORF9A UL49A Membrane/secreated
protein1
4 UL75 UL48 ORF22 BXLF2 ORF37 UL22 Gp H1&2
4 UL76 UL49 ORF20 BXRF1 ORF35 UL24 fusion protein1
4 UL77 UL50 ORF19 BVRF1 ORF34 UL25 Tp2
4 UL80 UL53 ORF17 BVRF2 ORF33 UL26 Cp2/assembly protein1
5 UL85 UL56 ORF26 BDLF1 ORF41 UL18 Cp142






Gene FunctionHCMV HHV6 HVS EBV vzv HSV-1
6 UL89
EX2
UL60 ORF29b BDRF1 ORF42 UL15
EX2
DNA packing protein1&2
6 UL93 UL64 ORF32 BDLF1 ORF43 UL17
6 UL94 UL65 ORF33 BGLF2 ORF44 UL16
6 UL89
EX1
UL66 ORF29a BGRF1 ORF45 UL15
EX1
DNA packing protein1&2
6 UL95 UL67 ORF34 BGLF3 ORF46 UL14
6 UL97 UL69 ORF36 BGLF4 ORF47 UL13 GCV kinase1&2
6 UL98 UL70 ORF37 BGLF5 ORF48 UL12 Alkaline exonuclease1&2
6 UL100 UL72 ORF39 BGRF3 ORF50 UL10 Gp M1&2
6 UL102 UL74 ORF41 BBLF3 ORF52 UL8 Helicase/Primase1&2
6 UL103 UL75 ORF42 BBRF2 ORF53 UL7
6 UL104 UL76 ORF43 BBRF1 ORF54 UL6 Cp2
6 UL105 UL77 ORF44 BBLF4 ORF55 UL5 Helicase/Primasel&2
7 UL114 UL81 ORF46 BKRF3 ORF59 UL2 Uracil DNA glucosidaseI&2
7 UL115 UL82 ORF47 BKRF2 ORF60 UL1 Gp L1&2
* Table adaptedfrom Gompels, et al, 1995.
Key: Cp, Capsid protein; Gp, glycoprotein; Tp, Tegument protein; RR,
Ribonucleotide reductase; IE, Immediate early; GCV, Gancyclovir;1 Gompels, U.A.,
et al, (1995) Virology 209, 29-51; 2Russo, J.J., et al, (1996) Proc. Natl. Acad. Sci.
USA 93, 14862-14867).
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Table 1.3* The partially conserved herpesvirus gene homologues as encoded
by two representative a, (3 and y herpesviruses.
Block
p-Herpesviruses y-Herpesviruses a-Herpesviruses
Gene FunctionHCMV HHV6 HVS EBV vzv HSV-1
1 UL51 UL35 ORF25 UL33
1 ORF60 BaRFl ORF18 UL40 RR (small) 2
4 ORF21 BXLF1 ORF36 UL23 Thymidine Kinase 2
4 UL79 UL52 ORF18 BVRF1.5
5/6 UL87 UL58 ORF24 BcRFl
6 UL92 UL63 ORF31 BDLF4
6 UL96 UL68 ORF35 BGLF3.5
* Table adaptedfrom Gompels, et al, 1995.
Key: RR, Ribonucleotide reductase; 2Russo, J.J., et al, (1996) Proc. Natl. Acad.
Sci. USA 93, 14862-14867).
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betaherpesviruses. However, most of the partially conserved genes do not code for a
protein with an assigned function.
1.1.6 Herpesvirus replication
The herpesvirus infectious cycle, can be regarded as a multi-step process - 1/
attachment, 2/ penetration, 3/ cytoplasmic migration to the nucleus, 4/ uncoating and
genomic circularisation and 5/ the establishment of latency or initiation of productive
replication. Productive replication or post-latency reactivation leads to 6/ genomic
replication, 11 lytic cycle viral transcription, 8/ progeny DNA concatamer cleavage
and encapsidation, 9/ glycosylation of envelope proteins, 10/ nuclear budding, 11/
cytoplasmic migration to plasma membrane and 12/ egress.
1.1.7 Herpesvirus entry and uncoating
Attachment occurs via viral envelope glycoprotein binding host cell receptors. The
receptor for HSV is heparin sulphate (WuDunn et al, 1989) and the receptor for EBV
is the B-lymphocyte marker CD21 (Nemerow et al, 1987). The viral ligand
responsible for initial receptor binding of HSV to the target cell is gB and
glycoprotein C (gC) (Cai et al, 1988). Initial binding of EBV is carried out by
glycoprotein (gp) 350/220 (Nemerow et al, 1987). Entry into the cell can occur by
direct fusion with the plasma membrane, as is the case with HSV(Morgan et al,
1968), where gB, glycoprotein D (gD) and gH all playing an essential role (Cai et al,
1988, Campadelli-finme et al, 1988, Desia et al, 1988). Conversely, entry can be
mediated by endocytosis, as is the case for EBV (Tanner et al, 1987). Infection of
peripheral B-lymphocytes is initiated by multiple gp350/220 molecules crosslink cell
surface CD21. This induces a capping response from the B-cell, internalising the
bound virus particle via a cellular vesicle (Tanner et al, 1987). Fusion between the
vesicle membrane and the viral envelope is then mediated by gp85 (Miller et al,
1988) and in part by gp350/220. EBV can also enter cells by direct fusion, for
example when super-infecting Burkitt's lymphoma (BL) derived cell lines, in vitro,
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such as RAJI cells. However, direct fusion may not reflect any in vivo situations for
EBV.
On entry into the cytoplasm, the herpes virion migrates through the cytoplasm to the
nuclear pores (Tognon et al, 1981) and are probably transported by the host cell
cytoskeleton (Kristensson 1986). The viral DNA is then released into the
nucleoplasm where it circularises (Jacob et al, 1977 and 1979). In the case of EBV,
the latent gene product termed EBV nuclear antigen (EBNA) 1 is necessary for
episomal establishment (Reisman et al, 1984 and Yates et al, 1985).
1.1.8 Herpesvirus productive viral genome replication
Herpesvirus productive genome replication requires several viral encoded products
for nucleotide metabolism and DNA replication. The viral genes that encode these
enzymes, such as their own DNA polymerase (Davidson et al, 1987 and Kouzarides
et al, 1987), and homologues to alkaline exonuclease, dUTPase and RR, comprise
many of the core or partially conserved herpesvirus genes (Davidson et al, 1987).
Genome replication is achieved by rolling circle technique producing concatamer
daughter strands (Jacob et al, 1977 and 1979, Seigel et al, 1981). Capsids assemble
in the nucleus and the concatameric viral DNA is cleaved and packaged to form new
virions. Cleavage and packaging is coded for by consensus sequences upstream of
the cleavage site. Homologous sequences exist in HSV 1 and 2, EBV, HVS, BHV1,
HCMV and VZV (Davidson et al, 1984, Desin et al, 1986, Matsuo et al, 1984 and
Spaete et al, 1985). The HSV and CMV cleavage and packaging sequences have
been shown to be interchangeable (Spaete et al, 1985). The model for concatamer
cleavage and packaging, called the double stranded break-gap repair model (Deiss et
al, 1986), strictly speaking, only applies to HSV-1. Since there is such a high degree
of consensus sequence homology across the Herpesviridae, PAC1 and PAC2 being
homologous to Ub and Uc respectively, it is assumed, the other herpesviruses follow
a similar pattern. The packaging complex traverses along the concatameric viral
DNA, starting from any point, until it reaches the first Uc signal in Junction 1.
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Concatameric scanning and packaging, into a ready assembled capsid, initiates
consecutively in a Long to Short unique sequence direction. Packaging is then
terminated at Junction 2, of the same concatamer. The two Junctions become
aligned and juxtaposed, so the Ub and Uc sequences, of both junctions, directly face
one another. The strands are cleaved, invade the homologous region of the
juxtaposed strand and use it as a template to amplify the a region. The resultant
Holliday structures are resolved and cleavage between the two a sequences of the
two adjoining concatamers ensures neither concatameric daughter strand has an a
sequence at both terminals (see figure 1.1 for schematic diagram of the double
stranded break gap repair model). Encapsidation can then be completed, causing a
conformational change. This allows maturation of the virion and budding through the
nuclear inner lamellae (Vlazny et al, 1982).
1.1.9 Herpesvirus assembly and Egress
Glycoprotein synthesis and assimilation occurs in the cytoplasm. Glycoproteins get
O- and N- linked glycosylations, though generally N- link predominate (Kari et al,
1988, Serafini-cessi et al, 1988 & 1989) The glycoproteins embed in membranes
which the virions bud into so acquiring there envelope (Gong et al, 1990 and
Kousoulas et al, 1983) and completed glycoprotein processing is required for viral
egress (Kousoulas et al, 1983). Initially, the virions enter the cytoplasm by budding
into the nuclear envelope. In the case of HSV, immature glycoproteins embed into
the nuclear membrane, and the mature capsids bud through the membrane acquiring
both envelope and glycoproteins. The immature virus particles, then pass through
the Golgi apparatus, on route to the plasma membrane, where viral glycoproteins
become processed to maturity (Desai et al, 1988, Kousoulas et al, 1983). The
mature viruses travel to the plasma membrane, via a Golgi derived vesicle and are
released into the extra-cellular space by a process of reverse phagocytosis (Johnson
et al, 1982).






































Invasion of the complimentory
J2 region and displacement
the homologous J2 strand
Elongation of the
invading Jl strand
Jl strand, using the displaced J2
strand as a template
Resolution of the resultant
Holliday structure
Amplification of Junction 2
(initialising with the cleavage
of the J2 Uc site)
Cleavage of both junctions
at the Uc site, releasing
a full linear genome for
encapsulation
Figure 1.1 shows the molecular mechanism by which HSV converts concatameric genome daughter
strands into full length linear viral genomes for packaging into virions, as described in the double
stranded break-gap repair model (Deiss et al,J986). The black lines represent concatameric viral
genomic DNA comprising the long unique region (L) and short unique region (S) up and down stream
of the L/S junction (J) 1 & 2. Thick lines represent DNA comprising / derivedfrom Jl and thin lines
represent DNA comprising / derived from the J2. Blue lines represent the amplification region
between the Ub and Uc sites and the red lines, the newly synthesis DNA. The black blocks represent
the cleavage site containing sequences ofJl and 2 directly flanking the amplification region. The
junction separating the long and short coding regions of the ultimate (Jl) and penultimate (J2)
concatameric genome segments become aligned andjuxtaposed (A). A Uc directed double stranded
cleavage occurs within the DR1 element ofJ1 (B). The Sfragment 3' end then invades the homologous
region ofJ2, displacing the J2 5' to 3' strand and annealing to the complementary J2 3' to 5' strand
(C). Using the J2 3' to 5' strand as a template, the invading Jl strand elongates until it reaches the
J2 Ub directed site in DR2 (D). The 3' end ofthe Jl L fragment then elongates, uses the displaced J2
strand as a template, until it reached the J2 Uc encoded stop site in DR1. The Jl 3' ends are re-
ligated to form a Holliday structure (E). The Holliday structure is resolved by recombination (F) the
entire process is repeated, starting with the Uc directed double stranded cleavage within the DR1
element of J2 (G). Both strands are cleaved in the DR element separating the two amplification
regions on each strand, (H) releasing two full length linear viral genomes two be packaged into
virions.
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members of the herpesvirus family become enveloped by the inner lamellae and then
de-enveloped by the outer lamellae so releasing non-enveloped mature capsids into
the cytoplasm (Stackpole et al, 1969). They become re-enveloped and egress by
budding at the plasma membrane, as is the case for EBV (Gong et al, 1990), or into
cytoplasmic vacuoles, as has been observed in many herpes species, such as HHV6,
MCMV and HVS (Biberfield et al, 1987, Papadimitrion et al, 1984, Tralka et al,
1977). Enveloped particles are often observed in close association with membrane
like structures (Schwartz et al, 1969) and it has been hypothesised that vesicles
transport virus to the plasma membrane and then vesicle allows egress (Johnson et
al, 1982, Desaieta/, 1988, Papadimitrion et al, 1984).
1.2.1 Herpesvirus Transmission
Herpesvirus transmission is generally associated with chronic viral replication, often
at sites of the initial infection. Although EBV predominately establishes a latent
infection in B-lymphocytes, it can also establish a low level chronic infection of the
oropharyngeal epithelium (Yao et al, 1985 & Tomas et al, 1991). This is particularly
apparent in chronic carriers and AIDS patients. Chronic replication in the epidermal
skin tissue has also been observed in HSV. Prolonged periods of virus shedding can
occur asymptomatically in normal healthy sera positives or symptomatically with
cold sore development.
1.2.2 Herpesvirus persistence in vivo.
One of the hall marks of herpesvirus infection in vivo, is their ability to establish a
life long infection of the host. Persistent viral infection strategies can generally be
categorised into 2 different types. The first is defined by viral persistence in
association with the continual presence of productively replicating virus. This is
termed a chronic productive infection and is commonly associated with the
lymphocytic choriomeningitis virus (LCMV) infection of mice, and the vertically
transmitted hepatitis B virus (HBV) infection of man (Buchmeier et al, 1980 &
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Beasley et al, 1977). The other strategy associated with persistent viral infections is
defined by the presence of viral genomes, which is capable of reactivating, but exists
in the absence of infectious virus, or virion particles. This is termed as a latent
infection, and is commonly associated with, and typified by, herpesvirus persistent
infections in vivo (Ahmed et al, 1990). Latent herpesviruses have genomes which,
unlike the linear genomes found in virions, are in a covalently closed circular form,
referred to as episomes (Kaschaka-Dierich et al 1982, Gardella et al, 1984, Harris et
al, 1988, Mellerick et al, 1987, Adams et al, 1987, Alfieri et al, 1991, Decker et al
1996 & Renne, et al, 1996). Gammaherpesvirus episomes replicate as a plasmid, in
latently infected, dividing cells, using the cellular replication enzymes. To achieve
this, viral genomes contain a plasmid origin of replication (ori P) (Yates et al, 1985
and Kung et al, 1996). This allows the virus genome to exist at a constant copy
number in the cell, without the need to express productive replication associated
gene products, such as the virus encoded DNA polymerase.
1.2.3 Evasion of the host's immune system.
To establish a life long persistent infection in vivo, the virus must be able to
successfully evade the host's immune responses. This is largely achieved, in latent
viral infections, by the virus establishing a pattern of highly restricted gene
expression, in the infected cell. Latency associated, restricted gene expression has
been observed in many different herpesviruses both in vivo and in vitro (Rowe et al,
1986, Kerr et al, 1992, Murthy et al, 1986, Stevens et al, 1987 & Zhong et al 1996).
Reduced viral gene expression, greatly reduces the amount of antigen presentation at
the surface of the cell, and so the infected cell goes unnoticed.
A second method of avoiding detection is to either specifically down regulate
cellular receptors/ligands essential for targeting of the infected cell by the cellular
immune system, or to infect cells where there expression is restricted. CD8
cytotoxic T-lymphocytes (CTL) are largely responsible for the destruction of virus
harbouring cells. Infected cells are recognised, by the CTLs, by the presentation of
41
the acute infection travel to the sensory ganglion neuronal somas, via retrograde
axonal transport, and establish latency (Cook et al, 1973). Latency is largely, though
not exclusively, established in sensory ganglion neurones (Lonsdale et al, 1979).
HSV1 normally establishes latency in the trigeminal ganglia, due to the oro-
respiratory transmission of infection, to the oropharyngeal mucosa. HSV 2 normally
establishes latency in the sacral ganglia, due to sexual transmission, of infection, to
the vaginal tract or penile skin.
1.2.5 HVS latent gene expression
Latent HSV genomes exist in a non-integrated, episomal form, in infected neuronal
nuclei (Mellerick et al, 1987). During latency the majority of the viral genome is
transcriptionally inactive. However, a site on the opposite strand, overlapping the
early (a) gene ICPO is transcriptionally active (Stevens et al, 1987 & Gordon et al,
1988). This has been termed the latency associated transcript (LAT) region. There
are 2 transcripts, transcribed from this region, major and minor LATs, and possibly a
third, believed to initiate from a site further up stream. The 2 predominant
transcripts, are 2.3 and 1.7 kb, respectively, the latter being derived from the former,
via a splicing event (Wagner et al, 1988). The LATs transcripts are not believed to
be polyadenylated or translated in vivo and are not necessary for both the
establishment and maintenance of latency, in vivo, (Javier et al, 1988) but may play a
role in reactivation. Reactivation of HSV is not fully understood, but is often
associated with localised stimuli, such as injury to tissue innovated by neurones
carrying latent virus, or more systemic stimuli, such as physical or emotional
stresses. Reactivated virus travels, via peripheral nerves, to the epidermis, where a
recurrent or recrudescent infection occurs. Recurrent infections will occur despite
the presence of cellular and humoral immunity. A recurrent infection may lead to
vesicular skin lesions and mucosal ulcerations. These lesions are generally caused
by viral mediated cell death and the associated inflammatory responses (Whitley et
al, 1990).
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1.2.6 Latency in non-neurotropic alphaherpesviruses
MDV and Turkey herpesvirus (HVT) latently infect lymphocytes and show strain
dependant transforming abilities (Calnek et al, 1979). Highly transforming strains of
MDV are the causative agent of Marek's disease, a T-cell lymphoma of chickens.
Upon infection, MDV lytically infects B-lymphocytes, often inducing a
splenomegaly, and transforms, via latent infection, activated CD4 positive / CD8
negative T lymphocytes. These go on to form lymphomas. MDV positive CD4
negative / CD8 positive and CD4 negative / CD8 negative T lymphocytes will also
spontaneously transform in vitro, when taken from chickens, with inflammatory
stimuli, during early infection time points (Schat et al, 1991). Genetic cluster
analysis ofMDV and HVT has shown them to belong to the alphaherpesviruses, not
the gammaherpesviruses, though they are lymphotropic in nature (Buckmaster et al,
1988).
1.2.7 Betaherpesvirus persistence and latency
Of the 3 herpesvirus sub-families, betaherpesvirus latency is least well understood.
Primary infection is largely asymptomatic, except during foetal development, where
it can result in birth defects. Primary infection results in the establishment of a life
long persistent infection. CMV persistence is associated with a number of tissues
and organs, such as bone marrow and monocytes, lung, spleen, salivary glands, heart,
kidney and adrenal glands. The establishment of latency, in vivo, appears to be
linked to the severity of the primary infection and sites of primary acute infection
(Balthesen et al, 1993, Matthias et al, 1994 and Ho et al, 1991). Recurrent infections
can occur during periods of immuno-suppression. Recurrent infections under these
conditions are often severe and can result in fatal CMV disease. CMV disease is
most commonly associated with bone marrow transplantation recipients, but is also
seen with solid organ transplants, such as lung, liver, kidney and heart (for review
see Ho et al, 1991). In these cases CMV recurrence is often associated with the
donor organ, due to, pre-established CMV latency. CMV recurrent infection and
44
disease is also associated with human immunodeficiency (HIV) infected patients
during the latter stages of acquired immunodeficiency syndrome (AIDS) (Hirsch et
al, 1991). Although the specific nature and cellular targets for CMV persistence
remain controversial, latent murine CMV genome has been observed in splenic
stromal cells (Pomeroy et al, 1991).
Persistence, in part, may be down to low level chronic infections, since the
presentation of the major immediate early protein, by MHC class I, can be
selectively down regulated, in persistently infected cells, in vitro (Gilbert et al,
1993). This in turn greatly reduces recognition by CD8 positive T lymphocytes,
which are the principal effectors, as opposed to antibody responses, in combating
both primary and recurrent infections (Reddehase et al, 1988, Mattius et al, 1994 &
Riddell et al, 1992). This mechanism of chronic persistence and immune evasion,
may well represent viral persistence in monocytes and lymphocytes in vivo, since
CMV infection results in the expression of the major immediate protein only (Rice et
al, 1984).
1.2.8 Gammaherpesvirus persistence and latency
The gammaherpesviruses establish latent infections in lymphoid cells (see Table
1.4). The 'HVS-like' y-2 herpesviruses of the new world monkeys, establish latency
in T-cells, as do the 'AHV 1-like', malignant catarrhal fever (MCF) associated y-2
herpesviruses. The 'EBV-like' y-1 herpesviruses of old world primates are B-cell
tropic (Kieff et al, 1995, Bocker et al, 1980, Rabin et al, 1978, Neubauer et al, 1979,
Ohno et al, 1979) as are the y-2 herpesviruses KSHV, EHV-2, EHV-5 and MHV-68
(Cesarman et al, 1995a, Mesri et al, 1996, Sunil-Chandra et al, 1992b). HV
sylvilagus will establish latency in both T and B lymphocytes (Kramp et al, 1985).
Latent gammaherpesvirus can also be associated with malignancies, both lymphoid
and epithelial (de-The et al, 1982, Fleckenstein et al, 1982, Chang, Y., et al 1994 &
Cesarman, E., et al 1995a) and infection of B and T lymphocytes by EBV and HVS,
respectively, in vitro, gives rise to transformed / immortalised cell lines (Pope et al.
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Table 1.4* The lymphocyte tropism, and diseases associated with the different
gammaherpesviruses.





EBV Human B-cell Infectious mononucleosis
B (& T) cell lymphomas
Epithelial carcinomas
HV pan Chimpanzee B-cell
HV pongo Orang-utan B-cell
HV gorilla Gorilla B-cell
HV papio Baboon B-cell
CHV 14 Rhesus monkey
CHV 15 African green
monkey
y-2 herpesviruses
KSHV Human B-cell Kaposi's sarcoma
B-cell lymphomas
HVS Squirrel monkey T-cell T-cell lymphomas in non-host
new world monkeys
HV ateles Spider monkey T-cell T-cell lymphomas in non-host
new world monkeys
HV aotus 2 Owl monkeys T-cell
OHV 2 Sheep T-cell Malignant catarrhal fever
in deer
HiHVl Roan antelope T-cells




EHV2 Horse B-cell# IM-like symptoms
EHV5 Horse B-cell# IM-like symptoms
HV sylvilagus Rabbit B & T cell lymphomas
HV marmota 1 Woodchuck
MHV-68 Mouse B-cell B-cell lymphomas + IM-like
symptoms
Table adaptedfrom Roizman et al„ 1995, Kieffet al, 1995, Baer et al, 1984, Bocker et al,
1980, Rabin et al, 1978, Rabin et al, 1980, Ohno et al, 1979, Neubauer et al, 1979, Gerber
et al, 1977, Russo et al, 1996, Albrecht et al, 1992, Fleckenstein et al, 1982, Bridgen et al,
1989, Reid et al, 1989, Reid et al, 1991, Li et al, 1995, Lomonte et al, 1996, Telford et al,
1993, Medveczky et al, 1989, Kramp et al, 1985, Efstathiou et al, 1990b & Sunil-Chandra et
al, 1994a. # notformally proved.
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1986, Schirm et al, 1984 & Biesinger et al, 1992). Unlike alphaherpesvirus, the
genes expressed during latency do not appear to be conserved between the different
groups of gammaherpesviruses. Neither KSHV, MHV-68 or EHV2 encode genes
with sequence homology to the main latency associated genes of either EBV or HVS.
1.2.9 Gamma-1 herpesviruses
The gammaherpesviruses are split into 2 groups based on their genome
arrangements, although both groups (y-1 and y-2) both conform to the same
conserved gene block order and orientation {see Table 1.2) (Gompels et al, 1988).
The y-1 herpesviruses are clearly distinct group of gammaherpesviruses, restricted to
the old world primates. They all share a similar genomic arrangement, with respect
to internal repeats, and form life long latent infections in the B-lymphocytes of their
natural host. The y-1 herpesvirus group includes EBV, HV gorilla, HV pan, HV
papio and E1V pongo, their natural hosts being man, gorilla, chimpanzee, baboon and
orang-utan, respectively. The y-1 herpesviruses can all directly transform their host's
peripheral B-lymphocytes, in vitro and peripheral blood leukocytes (PBL), from sera
positive individuals, spontaneously give rises to virally infected transformed B-cell
lymphoblastoid cell lines (LCL) when cultured, in vitro (Dillner et al, 1987, Rabin et
al, 1978, Neubaner et al, 1979 & Pope et al, 1968). They ail show between 35%-
45% colinear sequence homology (Heller et al, 1982, & 1978 & Neubaner et al,
1979), are antigenically similar (Rabin et al, 1980) and produce EBNA like proteins
in association with B-cell latency (Dillner et al, 1987).
1.3.1 Gamma-2 herpesviruses
The y-2 herpesviruses comprise a less clearly distinct group compared to the y-1
herpesviruses. The y-2 herpesviruses were originally defined as T-eell tropic
gammaherpesviruses with a 'B' type genome structure, as typified by HVS and HV
ateles. However, although many y-2 herpesviruses do conform to the 'B' type
genome structure, EHV-2 has an 'A' and EHV-5 has a 'F type genome structure.
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They are not universally T-cell tropic since KSHV and MHV-68 have been shown to
be B-cell and not T-cell tropic. An alternative definition of the y-2 herpesvirus sub¬
group would be any gammaherpesvirus, be it human, cebine, bovine, equine, ovine,
or murine, that is not specifically a y-1 herpesviruses.
1.3.2 Sub-groups within the gamma-2 herpesviruses
The y-2 herpesviruses is essentially comprised of a number of y-2-sub-groups.
These comprise of the 'HVS-like' gammaherpesviruses of the new world monkeys.
These form a distinct group analogous to the 'EBV-like' y-1 herpesviruses. The
recently isolated KSHV is probably a human form of a 'KSHV-like' y-2-sub-group
that infect old world monkeys (Rose et al, 1997) and is genetically closely related the
'HVS-like' y—2-sub-group (Russo et al, 1996).
The MCF inducing 'AHVl-iike' gammaherpesviruses also probably form a distinct
y-2 sub-group that infect ruminants. These include AHV1, AHV2, ovine herpesvirus
(OHV) 2 and Himalain herpesvirus (HiHV) 1, the sub-group does not include BHV4.
The 'AHV-l-like' gammaherpesviruses have many biological properties similar to
HVS. AHV-1 infection of T-cells gives rise to cell lines that will proliferate
indefinitely in the presence of interleukine (IL)-2, in vitro and infection of a non-host
ruminant can give rise to MCF, a lethal, viral initiated/driven lymphoproliferative /
autoimmune disorder.
The classification of other y-2 herpesviruses is less clear cut. EHV-2 and -5, despite
having different genomic architecture, also probable represent a distinct y-2-sub-
group. Despite being antigenically distinct from one another, they have greater
genetic similarity to each other than to any other gammaherpesvirus. Partial
sequencing of conserved areas of the EHV-2 and -5 genome, revealed them to be
only marginally more related to HVS than they are to EBV and that EHV, HVS and
EBV were essentially all equally genetically divergent (Telford et al, 1993).
Although EFTV-2 and -5 encode genes, homologues of which are only found in y-2
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herpesviruses, such as a G protein-coupled receptor (GCR), encoded by HVS
ORF74, they also encode a gene homologous to the EBV BCRF1 gene. This further
compounds the ambiguity in their classification since the EBV BCRF1 gene is
considered to be unique to the y-1 herpesviruses.
MHV-68 may well represent a distinct y-2-sub-group that infect rodents. MHV-68
was isolated as one of 5 antigenically related rodent isolates, MHV-60, 68, 72, 76
and 78 (Svobodova et al, 1982b), of which, other than MHV-68, only MHV-72 has
been studied (Mistrikova et al, 1993 & Reichel et al, 1994). Based on sequencing
data MHV-68 is more closely related to HVS than it is to EBV and contains a
number of y-2-spesific gene homologues. However, MHV-68 also encodes a
glycoprotein (ORFM7) which shows greater homology to EBV gp340/220,
considered unique to the y-1 herpesviruses, than the positional homologue of HVS
(Stewart et al, 1996). The genomic positioning of the MHV-68 encoded Bcl-2
homologue is also more similar to that ofEBV than to HVS or KSHV. The MHV-68
encoded TK homologue has also a greater functionally similarity to the EBV TK
homologue, with respect to anti-viral activation, than to the HVS TK homologue
(Sunil-Chandra et al, 1993).
1.3.3 Epstein-Barr virus
Of all the gammaherpesviruses, EBV has been studied the most, since it was, until
recently, the only known human garnmaherpesvirus and is responsible for human
disease. EBV has a 172kbp genome with a 60% G+C content. The coding quasi
region is flanked by 0.5kbp terminal direct repeats (TR) and contains a set of
reiterated 3kbp internal direct repeats (IR) which divide it into a long unique region
(LUR) and a short unique region (SUR). A group of 3 small internal repeats further
sub-divide the LUR sequence into a set of unique regions named U2-U5, with U1
being SUR. With the exception of the TR sequences, EBV shows a high degree of
co-linear homology with the other y-1 herpesviruses (Heller et at, 1981a, 1981b &
1982).
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1.3.4 EBV Genome and genetics
EBV was the first herpesvirus to be cloned and sequenced (Dambaugh et al, 1980,
Baer et al, 1984, Hatfull et al, 1988 & Parker et al, 1990). EBV codes for the full
compliment of 'core' herpesvirus gene products as well as the partially conserved
herpesvirus genes (see Tables 1.2 and 1.3). As well as the core genes EBV also
encodes 18 genes which are seemingly unique to the gammaherpesvirus. Of these
genes, BRLF1 codes for the EBV R-transactivator and BHRF1 codes for a
functionally active Bcl-2 homologue (Henderson et al, 1993 & Tarodi et al, 1994).
The remaining genes encoded by EBV are unique to the either the yl herpesviruses
or to EBV specifically. These include the BZLF1 gene, the BCRF1 gene and all the
genes which code for the latency associated proteins. The BZLF1 gene codes for the
protein associated with reactivation from latency, named the 'Z fragment EBV
reactivation antigen' (ZEBRA), and is believed to be closely related to the cellular
fos/jun family of proteins (Packham et al, 1990). As well as inducing the
reactivation of the latent EBV genome, ZEBRA also causes the induction of cellular
genes. Expression of ZEBRA has been shown to up regulate the expression of
tumour growth factor (TGF)-|3, which is a powerful immunosuppressing cytokine
(Cayrol et al, 1995). The BCRF1 gene codes for a cellular IL-10 homologue (Moore
et al, 1990 & 1992). This is a gene expressed during lytic replication as opposed to
during latency (Stewart et al, 1992 and 1994) and has been shown to increase the
efficiency by which EBV can infect / transform B-cells in vitro (Stuart et al, 1995).
BCRF1 expression may also act to partially suppress the action of CTL and NK cells,
since IL-10 is a Th2 cytokine and has been shown to down regulate IL-2 and
interferon (INF)-y production by T-cells and macrophages (Stuart et al, 1995 &
Moore et al, 1993). Unlike many of the y-2 herpesviruses, EBV does not code for a
GCR, cyciin D or a complement regulatory protein (CRP) homologue. However,
EBV does specifically up regulate 2 cellular GCR proteins (Birkenbach et al, 1993),
cyciin D2 (Sinclair et al, 1994) and complement receptor (CR) 2 (also termed CD21)
(Wang et al, 1990).
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1.3.5 In vitro infection of B-Iymphocytes and epithelial cell with EBV
Initial viral attachment to B-lymphocytes occurs through interactions between EBV
gp350 and the cellular CR 2 (CD21). However, penetration of the B-cell membrane
requires the three EBV glycoproteins, gH, gL, and gp42, in a complex. Cellular
MHC-class II, through an interaction with gp42, acts as an essential B-cell entry
associated co-factor (Li et ai, 1997). Despite being infected in vivo, epithelial cells
can not normally be infected in vitro. However, epithelial cell lines transfected with
CD21 can be directly infected with EBV (Li et al, 1992). Viral entry into the cell is
mediated via a different mechanism than with B-cells, since epithelial cells do not
express MHC class II. Monoclonal antibodies that bind gp42 block virus entry into
B-cells but not CD21 transfected epithelial cell lines. Moreover, monoclonal
antibodies that specifically bind the gL/gH complex will block virus entry into CD21
transfected epithelial cell lines but not B-cells (Li et al, 1995).
Upon infection of B-lymphocytes, the viral genome circularises to form a covalently
closed episome. Transcription initially starts from a promoter at the SUR end of the
IR1 sequence called the BamW promoter (Wp). The transcript undergoes multiple
splicing events. This can result in the generation of an ATG translation start site, by
frame shift, leading to the expression of the EBNA leader protein (EBNA LP), which
is coded for at the start of the U2 region. Alternatively, if splicing fails to generate
the EBNA LP AUG, EBNA-2, which is coded for down stream of EBNA LP, gets
expressed. EBNA-2 then transactivates the main EBNA transcriptional promoter,
the Bam C promoter (Cp), located in the U1 region. Multiple splicing of the
transcripts, initiated from Cp, allows the further expression of EBNA LP and 2.
Alternatively, EBNA 3a, 3b and 3c, with are coded sequentially along the U3 region,
and EBNA-1, which is coded for by an ORF spanning the IR3 region, can also be
expressed. EBNA-2 also transactivates the latent membrane proteins (LMP)-l, -2a
and -2b. LMP-1 is coded for on the opposite, overlapping strand to LMP-2a and -2b
at the TR end of U5. LMP-2a and -2b are generated by alternative splicing events
and the transcript spans the TR region ending in Ul. Also iocated in the U1 region
are the two short non-polyadenylated RNA genes, Epstein-Barr encoded RNA
(EBER)-l & -2 and ori P, located respectively, between the LMP2 ORFs and the IR1
region. The EBERs both contain a RNA polymerase III promoter region. RNA
polymerase III is believed to dominate the EBER transcription, however RNA
polymerase II also plays a role (Keiff et al, 1996).
1.3.6 EBV transformed lymphobiastoid cell lines
Infection of primate B-lymphocytes with EBV, in vitro, leads to the establishment of
a latent viral infection and transformation of the B-cell (Pope et al, 1968). EBV will
transform progenitor and pre-B-cells as well as mature B-cells (Ernberg et al, 1987)
and B-cell lines, infected with EBV, continue to differentiate and isotype switch in
the presence of IL-4 (Jabara et al, 1990 & Gauchat et al, 1992). Based on their
transforming efficiencies EBV isolates can be categorised in to two distinct groups.
These were originally designated type A and B, with type A having a much greater
transforming ability than type B. This has since been revised to Types 1 and 2.
EBV-1 is almost genetically identical to EBV-2 except for alterations in the EBNA
LP, 2, 3A, 3B and 3C genes. EBV-2 encoded EBNA-2, -3A, -3B and -3C differ from
those encoded by EBV-1 by 47%, 16%, 20%, 28%, respectively (Addinger et al,
1985 & Semple et al, 1990).
After infection, the single circularised EBV genome increases in copy number for 1
to 2 weeks finally reaching a constant level at about 50 copies per cell. Transformed
colonies, comprising of about 100 - 1000 cells, appear after approximately 21 days.
(For reviews ofEBV transformation ofB-cells, see Pope et al, 1986, Ring et al, 1994
and Sugden et al, 1994). EBNA-1 is the only transactivating factor required for
episomal maintenance. EBNA-1 binds two sites at the latent cycle origin of
replication (ori P). From here it enhances it's own transcription, along with the other
latent transcripts, by acting as an enhancer to the type 3 latency specific,
transcriptional promoter. EBNA-2 and -3c are also transcriptional activators, with
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differences in the EBNA-2 gene being largely responsible for the different
transforming efficiencies ofEBV type 1 & 2 (Rickinson et al, 1987).
EBNA-2 transactivates LMP-1 expression and with it, up regulates the B-cell
activation marker CD23. From all the EBV latent gene products LMP-1 has the most
transforming properties. Although LMP-1 expression alone is insufficient to
transform B-cells, it can transform immortal rodent fibroblast lines. LMP-1
expression in these cells, greatly reduces their levels of contact inhibition, anchorage
dependence and allows them to grow in soft agar (Baichwal et al, 1988). LMP-1
expression in LCL and in BL cell lines, when artificially up regulated, increases
levels of homotypic adhesion molecules, such as ICAM1, LFA1 and LFA3. This
greatly increases their immunogenecity to T-lymphocytes. (The properties of the
EBV latent gene products, is review by Ring et al, 1994). LCL cell lines are
'immortal', as they replicate indefinitely , in vitro, never reaching crisis. They are
also 'transformed', since they form tumours when grafted into an
immunocompromised host. However, they are not 'malignant', since they do not
form tumours in non-immunocompromised syngeneic graft recipients.
1.3.7 EBV associated latency strategies
Latent EBV can take 1 of 3 forms, in vitro (Kerr et al, 1992), all 3 involve different
latent gene expression and are controlled by 2 different viral promoters. All 3
latency patterns, exist in cells, in vivo as well as in vitro and result in different cell
phenotypes, though the three classic forms of latency only tend to be observed in
conjunction with neoplastic cells which may not represent latency in 'normal' tissue
/ cells. All 3 types of latency can be artificially generated, in vitro, using EBV
infected somatic cell hybrids (Kerr et al, 1992).
1.3.8 EBV iatency type 3
With latency type 3, the full range of latency associated, and restricted, viral gene
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expression is observed. These comprise of the 6 EBNA genes, -1, -2, -3a (-3), -3b (-
4), -3c (-6) & LP, 3 LMP genes, -1, -2a & -2b, and 2 EBER species. Type 3 latency
is generally associated with cells of a lymphoblastoid, transformed phenotype, of B-
cell origin. LCLs can be generated in vitro, by culturing PBLs, from EBV sera
positive individuals or by directly infecting them with EBV (Pope et al, 1968). After
infection, the first latent transcripts detectable are EBNA-2 and EBNA-LP. These
are followed by the other EBNA transcripts, then LMP-1 and finally after 70 hours
post infection LMP-2a & -2b. All the latency associated transcripts have been shown
to be necessary for immortalisation and out growth of in vitro infected B-cell, except
for EBNA-3c, LMP-2a & -2b and the EBERs. Type 3 latency is associated with,
largely non-malignant, polyclonal, LPD in immunosuppressed transplant patients
(Cleary et al, 1986) and AIDS patients (Hamilton-Dutoit et al, 1993). Similar LPD
occurs in experimental EBV infections of cotton-top tamarins (Somguinus Oedipus
oedipus) (Cleary et al, 1985), and with the adoptive transfer ofPBLs, from EBV sera
positive donors, or LCLs into severely immunocompromised inbred (SCID) mice
strains (Purtilo et al, 1991 & Rowe et al, 1991).
1.3.9 EBV latency type 1
Type 1 latency is associated with EBV positive BL cells, in vivo, and BL cell lines
that have retained their BL phenotype, in vitro (Rowe et al, 1987). Type 1 latency is
also commonly associated with AIDS related, malignant "Burkitt's like" lymphomas
(Hamilton-Dutoit et al, 1993). EBV latent gene expression is restricted to EBNA-1
and the EBERs. The latency transcriptional promoter, used in both type 1 and 2
latency, the Bam F promoter (Fp) is different to the one used in type 3 latency (Kerr
1992). EBNA-1 negatively feeds back on Fp promoted transcription, by binding a
low affinity site, in the Q locus, 200bp down stream of the Fp transcriptional start
site. In this way the episomal copy number per cell can be maintained at a constant
level without over production ofEBNA-1 in non-replicating cells (Sung et al, 1994).
This is believed to play a critical role in the prevention of host clearance of latently
infected B-cells, in healthy, sera-positive individuals. When cells infected with
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EBV, in type 1 latency, start to under go cell division, the cell cycle specific
transactivator, E2F, displaces EBNA-1 from the Q locus so allowing Fp driven
EBNA-1 expression to occur again (Sung et al, 1994). This may explain why none
of the three 'classical' forms of latent gene expression are observed in the resting
pool of latently infected B-cells in normal healthy EBV sera positive individuals.
Latent virus is restricted to resting B-cells which are CD19 positive but CD80 (B7)
negative. The latent viral gene expression is restricted to only the EBERs and
LMP2A (Miyashita et al, 1995 & Decker et al, 1996). Because resting B-cells do not
generally replicate, there is no need for EBNA-1 expression. Expression of LMP2A
is believed to prevent the virus from reactivating by blocking stimulatory' cellular
transduction pathway signalling (Miller et al., 1995).
1.4.1 EBV latency type 2
Latency type 2, in many respects is similar to type 1. It is associated with EBV
positive Hodgkin's disease lymphomas, undifferentiated nasophorangeal carcinoma
(50%) and up to 25% of AIDS related malignant "Burkitfs like" lymphomas
(Deacon et al, 1993, Brooks et al, 1992 & Hamilton-Dutoit et al, 1993). Type 2
latency has also been observed in cloned sub-populations of EBV infected CD21
transfected epithelial cells (Knox et al, 1996). Type 2 gene expression consists of
EBNA-1, LMP-l,-2a & -2b and the EBERs. Given that LMP-1 can induce
morphological transformation in human keratinocytes, inhibit differentiation in
epithelial cells and is associated with the development of hyperplastic dermatitis, in
transgenic mice (Ring et al, 1994), it is possible that it's expression may play a role
in the development of these malignancies.
1.4.2 Reactivation of EBV from latency
It has been hypothesised that spontaneous changes in latency, in EBV infected B-
cells, may account for the fact that healthy sera positive individuals never completely
eliminate EBV from their B-cell population and the levels of latent gene product-
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specific, memory T-cells, remain high throughout an infected individuals life.
Though type 3 latently infected cell may be able to directly give rise to latency type 1
cells only the converse has only been shown to occur, using in vitro BL derived cell
lines, that loose there BL like phenotype (Rowe et al, 1987). Infected B-cells
derived from healthy sera positive individuals, will spontaneously give rise to LCL
cell lines, which contain EBV in a type 3 latent state, in vitro (Rickinson et al, 1986),
but to achieve this they have to reactivate and infect surrounding B-cells. This may
well represent the in vivo situation since BZLF1, the gene responsible for viral
reactivation, expression can be detected in B-cells during IM along with late viral
gene expression (Schwarzmann et al, 1996).
Stable EBV latency, in B-cells, can be disrupted by a number of chemical reagents in
vitro and reactivation is believed to occur spontaneously, in vivo, in the oropharynx,
to allow sporadic shedding of infectious virus. A number of chemicals, such as Iodo-
2'-deoxyuridine (IUdR) and n-Butyric acid (n-BA), as well as phorbol esters, such as
12-0- tetradecanoylphorbol 13-acetate (TPA) can induce a low level productive
infection in EBV positive B-cells, in vitro (Bauer et al, 1982 & Hansen et al, 1978).
These chemicals are highly toxic and cannot be used in vivo. Anti-immunoglobulin,
crosslinking antibodies, serum factors and bryostatin 1 have also been shown to
induce productive replication in latently infected cell lines, in vitro (Bauer et al,
1982 & Stewart et al, 1993). The viral gene product responsible for the switch, from
latent infection to productive infection, is encoded by the BZLF1 gene and has been
termed the Z fragment Epstein-Barr reactivator (ZEBRA) protein (Countryman et al,
1987). The re-seeding of productive virus to the oropharynx, to allow sporadic viral
replication in the epithelial cells and virus shedding into saliva, is believed to occur
due to reactivation of latently infected B-cells, at this site. Though this is still theory,
reactivation of latently infected B-cells to produce infectious virus has been shown to
occur in vitro (Rickenson et al, 1986) and in vivo (Schwarzmann et al, 1996).
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i .4.3 n,BV primary infection and associated diseases
Primary infection with EBV during early childhood is generally considered to be
asymptomatic. However, 50% of individuals, who become primarily infected post-
puberty, develop IM. Primary EBV infection is believed to initiate at the
oropharyngeal epithelium. From here it establishes a life long latent infection of
peripheral blood B-lymphocytes. During IM, there are high viral titres, shed in the
oropharynx. This is believed to be due to productive infection of the oropharyngeal
epithelium. CD21 transfected epithelial cell lines infected with EBV in vitro, will
spontaneously enter into productive virus replication (Knox et al, 1995).
The symptoms of IM, being malaise, fever, pharyngitis, lymphoadenopathy and
splenomegaly, are thought to be a result of an over stimulation of the cellular
immune system, in response to the EBV infection. The over stimulation results in a
large scale, polyclonal activation of a non-specific humoral and cellular immune
response. There is also a polyclonal expansion of latently infected B-lymphocytes, in
the blood and lymphoid organs during IM. The expansion normally results in up to
1/100 host B-cells being EBV positive, but can be as high as 1/10. The proliferating
latently infected B-cells are probably expressing the full complement of latent genes,
since EBNA specific humoral responses are mounted during IM, and CTLs can be
isolated which are LCL specific, by direct cytotoxicity assay (Svedmyr et al, 1975).
EBV infected B-cells are highly immunogenic, when in this state of latency, and are
probably responsible for the over stimulation of the cellular immune system, giving
rise to elevated levels of atypical, thymic derived, circulating and tissue infiltrating
lymphocytes. IM lasts for about 4 weeks, by which time the levels of latently
infected B-lymphocytes are very greatly reduced by CTL activity. Though latently
infected B-cells are never completely cleared from sera positive individuals, their
numbers in peripheral blood are generally very low and any further non-malignant
proliferations, are generally prevented by the hosts immune system (Rickinson et al,
1986).
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For prolonged periods of time after the acute infection, virus is sporadically shed
from the oropharynx. Although no further disease occurs, in normal EBV sera
positive individuals, the infection is never cleared, and because of this, it is believed
that up to 95% of the world's human population carry the virus. The number of
latently infected B-celis during convalescence ranges from 10 - 500 infected B-cells
per 107 peripheral B-lymphocytes (Khan et al, 1996). It was also observed that
although frequencies varied quite markedly between different individuals. The
variation that occurs within single individuals however, over time contributes less
than 10% of the variation seen within the population as a whole.
1.4.4 Non-malignant disease associated with immunocompromised hosts
There are essentially 3 forms of fatal IM (FIM), all of which are very rare. The 2
standard forms are sporadic FIM, which affects both males and females, of a median
age of 13 years old, and X-linked lymphoproliferative syndrome (XLP), which
affects only males, of a median age of 2 years old. The third form of FIM is
exclusively encountered by young EBV sera-negative, immunosuppressed, renal
transplant patients, and is a fatal LPD like syndrome. FIM is commonly associated
with severe splenomegaly, with 25%-40% of cases suffering splenic rupture. XLP is
caused by an X-associated gene that results in an unknown form of
immunodeficiency, hence the disease is generally only seen in male whose young
age reflects their very high susceptibility to infection. Sporadic FIM tends to effect
males and female at about the same frequency and often shows familial patterning.
This has lead to the belief that it too, is a genetic based form of unknown
immunodeficiency, though more subtle, in nature, than the XLP associated
immunodeficiency. All 3 forms are assisted with bone marrow and lymphoid cell
necrosis and are histopathologically similar (Weisenburgen et al, 1986).
EBV is also believed to be the causative agent in multi-focal, B-cell LPD, which is
associated with EBV sera-positive transplant and AIDS patients (Cleary el al, 1986
& Hamilton-Dutoit et al, 1993a). The lymphomas associated with LPD tend to be
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polyclonal, non-neoplastic and cellular replication is largely if not exclusively viral
driven. This is very different from the, EBV positive, Burkitt's Tike' lymphomas,
which are spontaneous in development, monoclonal and highly neoplastic, always
being associated with tumour cell genetic / chromosomal alterations. EBV positive
LPD has been associated with kidney, heart, heart / lung and liver transplants, as well
as with patients with immunosuppressed bone marrow. Being non-neoplastic in
nature, they will often regress in response to alleviation from the post
transplantational immunosuppressive regimes. If the levels of immunosuppression
are not reduced, transplant related LPD tends to be fatal (Cleary et al, 1986). LPD
associated with the latter stages of AIDS are invariably fatal and commonly involve
the central nervous system. Systemic immunoblast rich / large cell lymphomas are
also reasonably common and are up to 80% associated with EBV. In general LPD in
AIDS patients is similar to that of transplantation associated LPD, showing similar
patterns of EBV latent gene expression, and cellular proliferation being essentially
virus driven (Hamilton-Dutoit et al, 1993). Another EBV induced, AIDS related
condition, is oral hairy leukoplakia (Thomas et al, 1991). Within the tissue, EBV
continuously replicates causing tissue damage to the oral epithelium and the
shedding of high titres of infectious virus into the saliva of the patient.
1.4.5 EBV associated malignant conditions
EBV is associated with a number ofmalignant conditions, one of the most prevalent
being with eBL. Ninety six percent of eBL cases are EBV DNA positive, at the
cellular level (de-The et al, 1978). Other forms of BL are also directly associated
with EBV, at the cellular level. There is about a 40%-50% EBV association with
AIDS related Burkitt's Tike' lymphoma (Hamilton-Dutoit et al, 1991a) and a 15%
association with sporadic BL (sBL) (Lenier et al, 1986 & Toren et al, 1994). Other
malignant conditions that are associated with EBV are undifferentiated NPC,
Hodgkin's disease and peripheral T-cell lymphomas. NPC is highly associated with
EBV and is the most common cancer in Chinese males and second most in females.
Hodgkin's disease and peripheral T-cell lymphomas have a lower association (de-
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The et al, 1982, Hamilton-Dutoit et al, 1991b, Brooks et al, 1992, Deacon et al, 1993
& Corbo et al, 1994). The role EBV plays in the development of malignant
conditions is highly controversial, since all are associated with cellular genetic /
chromosomal alterations, as well as inappropriate expression of cellular oncogenes.
1.4.6 The roles of EBV in malignancy development
The most common oncogenic alteration associated with BL cells is the deregulated,
constitutive expression of the cellular proto-oncogene c-myc. This is normally
achieved by translocation of the c-myc gene, from 8q24 to the immunoglobulin
heavy chain locus 14q32, although it also can get translocated to the Ig light chain
loci, 2pl3 or 22ql 1 (Klein et al, 1983). Although deregulated c-myc expression can
induce direct immortalisation in some experimental systems (Bernard et al, 1989), it
cannot directly transform lymphocytes. Being latently infected with EBV, may well
enhance progression to malignancy, in cells with deregulated c-myc. Deregulated c-
myc expression in transgenic mice has been shown to vastly increase the probability
of spontaneous B-cell lymphoma development (Leder et al, 1986) and EBV through
it's immortalising functions can prevent the cell undergoing apoptosis in response to
inappropriate proto-oncogene expression or chromosomal damage. Over expression
of c-myc in EBV positive LCL cells causes an increase in susceptibility to non-MHC
restricted NK and lyphokine activated killer (LAK) cells, in vitro (Cuomo et al,
1993). This could explain why eBL, associated with the malaria belts of sub-Saharan
Africa and New Guinea, and AIDS associated BL have a high association with EBV
but sBL, which affect healthy individuals, has a low association with EBV. It is
possible that EBV infected B-cells, in individuals immunocompromised through
persistent infection with the malaria parasite or HIV, can acquire oncogenic
mutations over a period of time and so go on to form BL (de The et al, 1982).
Although EBV gene BHRF1, does encode a viral proto-oncogene, which shows
limited sequence homology, but good functional homology, to the apoptosis inhibitor
Bcl-2 (Henderson et al, 1993), it is not believed to be expressed during latency.
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Other EBV genes, such as EB2, are also potentially transforming (Corbo et al, 1994)
but again do not seem to be appropriately expressed. This appears to only leave
LMPl, which is only expressed in a proportion ofEBV positive malignant conditions
(Brooks et al, 1992, Deacon et al, 1993). It remains controversial to whether EBV
plays a causative role in malignancy development or is merely a passenger. There is
evidence that EBV is one of the main causes of the malignant phenotype of the BL
Akata cell lines, since the EBV negative clonal cell lines derived from the same
tumour as EBV positive lines, lose their malignant phenotype as compared to EBV
positive clonal lines from the same origin (Shimizu et al, 1994).
The role of EBV may be very different during the early and late stages of
tumourogenesis. EBV infected CD21 transfected immortal epithelial cell lines take
on a more transformed phenotype. When injected subcutaneously into nude mice
with TPA the EBV cells developed into poorly differentiated carcinomas (Li et al,
1997). However, in NPC, EBV shows a highly restricted pattern of gene expression.
Similar patterns of EBV gene expression have been observed in sub populations of
EBV infected CD21 transfected epithelial cells which show a lower degree of
differentiation (Knox et al, 1996).
1.4.7 Herpesvirus saimiri
HVS is a member of a group of oncogenic, T-cell tropic y-2 herpesviruses, which
also includes HV ateles and HV aotus type 2, the natural hosts being new world
primates. HVS infection of its natural host, the squirrel monkey (Saimiri sciureus), is
asymptomatic (Falk et al, 1972) but infection of other new world monkey species
and cotton tailed rabbits leads to the rapid development of highly malignant T-cell
lymphomas (Fleckenstein et al, 1982 and Medveczky et al, 1989). Infection of PBLs
of non-host New World monkeys results in the out growth of virally infected,
transformed/immortalise T-cell lines (Schirm et al, 1984 & Biesinger et al, 1992).
The resultant T-cell lines can be either IL-2 dependant, but lack the need for
antigenic stimulation, or IL-2 independent, depending on the HVS strain used to
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transform (Szomolanyi et al, 1987). HVS isolates can be categorised into three
strains, A - C, which denotes their relative oncogenic virulence (Medveczky et al,
1984). HVS will transform/immortalise both a/(3 CD4 positive and CD8 positive T-
cells, in vitro (Berend et al, 1993 & De Carli et al, 1993), as well as y/8 T-cells
(Yasukawa et al, 1995 & PachecoCastro et al, 1996). Transformed T-cell lines
retain many of the untransformed phenotypes and specificity. CD4 positive T-cells
retain there Thl or Th2 cytokine production profiles after transformation (De Carli et
al, 1993) and CD8 positive T-cells retain their peptide specific cytotoxicity and
cytokine production profiles (Berend et al, 1993 & Mackewicz et al, 1997).
1.4.8 HVS genome and genetics
As with other y-2 herpesviruses, the HSV genome consists of a unique coding region
(UCR), with a low G+C content flanked at both ends by tandem repeats with a high
G+C content. The tandem repeats are each 1,444 bp and the UCR 112,930 bp. The
UCR codes for 75 ORFs, 38 of which code for the conserved herpesvirus "core"
genes (see Table 1.2). Of the remaining 37 ORFs, 22 are homologous to EBV genes,
7 are y-2 herpesvirus specific (ORFs -2, -4, & -71 to -74) and 8 are unique to FTVS
(ORFs -1, -3, -5, -12 to -15,& -51) (Albrecht et al, 1992).
1.4.9 Gammaherpesvirus specific genes encoded by HVS
Of the 22 non-core ORFs that HVS shares with EBV, 2 are common to both alpha
and gammaherpesviruses. These ORFs code for the small unit of ribonucleotide
reductase (HVS ORF60 & EBV BARF1) and the nucleotide scavenging enzyme
thymidine kinase (HVS ORF21 & EBV BXLF1). The HVS TK is predicted to
contain 527 residues, with the nucleotide binding domain motif located at residues
212 to 224. This region is highly conserved in the TK homologues coded by other
gammaherpesviruses such as EBV, alphaherpesviruses such as HVS, VZV, MDV,
HVT, the poxviruses and the cellular gene. Outside this motif the HVS nucleotide
sequence and predicted peptide amino-acid sequence is far more divergent, though
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retaining significant homology with the EBV gene (Honess et al, 1989). A further 4
genes are common to both gamma and betaherpesviruses, of which, 3 (HVS ORFs
24, 31 & 35 and EBV BcRFl, BDLF4 & BGLF3.5 respectively) are located in or
close to the conserved gene block VI and the last (HVS ORF18 & EBV BVRF1.5) in
block 4. The function of these genes is presently unknown (Compels, et al, 1995).
Of the remaining 16 ORFs, all ofwhich are unique to the gammaherpesviruses, only
5 code for a protein with a defined function. ORF16 (EBV BHRF1) codes for a Bcl-
2 homologue, ORF40 (EBV BBLF1) codes for a helicase / primase enzyme, ORF50
(EBV BRLF1) codes for a homologue of the EBV R-transactivator, ORF65 (EBV
BFRF3) codes for a capsid protein and ORF75 (EBV BNRF1) which codes for a
putative tegument protein. ORF75 has a high level of homology with the
Escherichia coli and Drosophila melanogaster purine biosynthesis enzyme N-
formylglycinamide ribotide amidotransferase (FGARAT). The Bcl-2 homologue
encoded by ORF16 is functionally active at inhibiting apoptosis. It contains a highly
conserved SHI and SH2 domain but not the SH3. The ORF16 product has been
shown to heterodimerise with other members of the Bcl-2 family, such as BAX and
BAK (Nava et al, 1997). ORF50 codes for two transcripts, the first has a
transcriptional initiation start site located in ORF49 and is spliced, the second has a
transcriptional initiation start located in the first exon of ORF50 and is unspliced.
The spliced transcript codes for a transactivator which is expressed early in the lytic
cycle. The unspliced transcript codes for a transactivator which is expressed much
later in the lytic cycle. The two transcripts, both homologous to the EBV R-
transactivator, produce products which have different affinities and transcriptional
activities and are expressed in different phases of the productive replicate cycle
(Nicholas et al, 1991 & Whitehouse et al, 1997).
1.5.1 Gamma-2 herpesvirus specific genes encoded by HVS
Of the seven y-2 herpesviruses specific genes encoded by HVS, most code for
homologues of cellular genes. ORF 2 and 70 code for enzymes involved in
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nucleotide metabolism, dihydrofolate reductase (DHFR) and thymidine synthase
(TS). They have an 83% and a 66% respective amino acid identity with their human
cellular counterparts (Trimble et al, 1988 & Bodemer et al, 1986) and are expressed
early in the lytic cycle (Nicholas et al, 1990). ORF4 codes for one of two CRPs
encoded by HVS. The sequence of ORF4 has a potential coding capacity for 360
amino acid protein with seven sites for N-linked glycosylations, a 20 amino acid
signalling domain and a C-terminal 23 amino acid transmembrane domain.
Sequence comparisons have shown it to have significant homology with known
members of the complement protein family that interact with C3b and C4b. These
include C4b-binding protein, membrane co-factor protein (CD46) decay-accelerating
factor (CD55), complement receptors CR1 (CD35) and CR2 (CD21), factor H and a
35-kDa secretory protein encoded by vaccinia virus, that has been shown to bind C4b
and down regulate both classical and alternative complement pathways (Kotwal et
al, 1988 & 1990 and Isaacs et al, 1992). ORF4 produces two mRNAs, the first, a
1.7kb, non-spliced mRNA that codes for a membrane glycoprotein and the second, a
1.5kb mRNA with the transmembrane coding domain removed by splicing. Both
forms have been shown to confer resistance to complement-mediated lysis and to
inhibited C3 convertase activity. The spliced form is probably a secretory version of
the unspliced form, which is probably a membrane protein. Both are expressed
during the lytic infection in vitro (Albrecht et al, 1992 & Fodor et al, 1995). The
final two y-2 herpesvirus specific ORFs (72 & 74) encode cell cycle regulatory
molecules. ORF72 encodes a homologue to a type D cyclin, exhibiting greatest
amino acid identity (25%) to the human cyclin D1 (Xiong et al, 1991). ORF74
encodes a GCR homologue with a 30% amino acid identity to the human interleukin
(IL)-8 receptor (Murphy et al, 1991 and Nicholas et al, 1992). GCR homologues are
also encoded by betaherpesviruses, such as HCMV and HHV6 (Gompels, et al,
1995). HVS ORF74 shares a 22% amino acid identity with HCMV US28. Both
cellular cyclin D and GCR family members have been directly linked with
oncogenicity and malignancy development (Jackson et al, 1988 & Motokura et al,
1991).
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1.5.2 Genes Unique to HVS
Of the 9 ORFs that are unique to HVS, two code for homologues of cellular genes
and a third for a homologue of the mouse mammary tumour virus 7 superantigen.
ORF13 encodes a homologue to cellular IL-17 which exhibits a 72% amino acid
identity with human IL-7 and 57% identity to the murine CTLA8. The ORF13
product, termed vIL-17 will stimulate NF-kB transcriptional activity and IL-6
secretion in fibroblasts, and co-stimulate T cell proliferation, in vitro (Yao et al,
1995a & Yao et al, 1995b). The ORF14 product is a secreted glycoprotein that will
bind to heterodimeric MHC class II HLA-DR molecules and will act as a
superantigen. ORF14 has a predicted 22% amino acid identity to the mouse
mammary tumour virus 7 superantigen and will induced the proliferation of human
PBMC and purifies blood T cells, in vitro (Yao et al, 1996). ORF 15 is the second of
the CRP like ORFs encoded by HVS. ORF 15 has a 69% amino acid identity to
squirrel monkey CD59 and a 48% identity to human CD59. Cellular CD59 is a
phosphatidyl-inositol-glycan-anchored glycoprotein involved in the restriction of
complement-mediated lysis and T-cell activation. The HVS-CD59 has been shown
to inhibit complement lysis, after C3b deposition, as effectively as its human and
squirrel monkey homologues but with a greater species diversity. ORF 15 expression
can be detected during lytic but not latent infections (Albrecht et al, 1992 and Rother
et al, 1994).
1.5.3 HVS latency and transformation
Cell lines derived from HVS (and HVateles) induced lymphomas, from both
marmosets and cotton tail rabbits, as well as in vitro transformed T-cell lines,
contain covalently closed circular viral genomic DNA (Kaschaka-Dierich et al 1982,
& Szomolanyi et al, 1987). The origin of plasmid replication (oriP) that allows stable
episomal replication is located within a 1.955-Kbp DNA fragment at the left hand
end of the UCR. The 1.955-kb viral fragment includes a dyad symmetry region
located between two small nuclear U-RNA (HSUR) genes and is located upstream of
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the DHFR gene homologue (ORF2). Episomal replication requires a HVS encoded
trans-acting factor(s), analogous in function to the EBV gene product EBNA-1 (Kung
et al, 1996). Viral gene expression in latently infected T-cells is restricted to the
HSURs, which do not code for proteins, tyrosine kinase interacting protein (Tip) and
the saimiri transformation-associated protein (Stp) (Medveczsky et al, 1993, Lund et
al, 1995 & Biesinger et al, 1995). All are encoded within the highly heterogeneous,
left hand terminal region of the HVS UCR. Genetic variation in this region accounts
for the differences in oncogenic virulence of the HVS isolates (Medveczky et al,
1984).
HVS encodes up to 7 small HSURs, which comprise the majority of viral specific
transcripts within latently infected T-cells. HSURs 1, 2 and 5, which exhibit repeat
sequences at their 5' ends, identical to the AUUUA motif that targets a number of
proto-oncogene, cytokine, and lymphokine mRNAs for rapid degradation, are
encoded between ORF1 and ORF2. The other HSURs (3, 4, 6 and 7) are encoded
between ORF2 and ORF3 (Albrecht et al, 1992). In transformed marmoset T-cell
lines HSURs 1, 2 and 5 have been shown to associate with a 32 kDa cellular protein
associated with RNA degradation. Similar observations have been reported in HVS
infected human T-cell lines (Myer et al, 1992 & Geek et al, 1994).
1.5.4 Expression of the HVS transformation associated protein Stp
Both subgroup A and C HVS strains are oncogenic in new world monkeys and will
transform marmoset T-cells, in an IL-2 independent manner, in vitro. Subgroup C
strains, having greater oncogenicity than subgroup A, will also transform human,
rhesus monkey and cotton-tailed rabbit T-cells (Medveczky et al, 1984 & Biesinger
et al, 1992). For both subgroups, A and C, expression of Stp is essential for both
transformation of T-cells and the development of T-cell malignancies (Desrosier et
al, 1985, Murphy et al, 1989, Jung et al, 1991 and Jung & Desrosier 1991). Stp is a
19-22kDa protein (Lund et al, 1996) with a 17 amino acid amino-terminal domain, a
central region containing 18 collagen-like repeats and a carboxyl terminal
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hydrophobic transmembrane domain. The N-terminal domain contains 3 glutamic
acid residues and has an overall negative charge which have been shown to be
essential for the transforming abilities of Stp. Disruption of the collagen-like repeats
also disrupts the transforming activity of Stp and the C-terminal hydrophobic domain
is essential for membrane localisation (Jung et al, 1994). Both Stp -A & -C have
been demonstrated as being oncogenic, independent of the viral genome. Transgenic
mice that constitutively expressed either Stp-A or Stp-C develop either T-cell
malignancies or epithelial malignancies, respectively (Murphy et al, 1994 &
Kretschmer et al, 1996). Further more Stp-C can transform rat-1 cells in vitro, so
they can grow in soft agar and form invasive tumours in nude mice (Jung et al,
1991). Although the sequence of Stp is quite variable between the different HVS
strains all contain a highly conserved YAEV/I motif preceded by a negatively
charged glutamic acid residue. This matches the consensus sequence for binding the
SH2 domain of the src family kinases. Stp-A has been shown to bind cellular src in
virally transformed T-cell lines and will act as an in vitro substrate for src kinase
activity. After phosphorylation by src, Stp will then go on to bind both P561ck and
Fyn in vitro {et al, 1997). Stp-C has also been shown to associate with the cellular
proto-oncogene ras in transformed T-cell lines. Expression of Stp-C has been to
activate the ras signalling pathway in cell lines, in vitro (Jung et al, 1995)
1.5.5 HVS expression of the tyrosine kinase interacting protein Tip
With the subgroup C HVS strains, Tip expression has also been shown to be essential
for transformation of T-cells and oncogenesis (Medveczky et al, 1993& Lund et al,
1997). Tip is a 32-40 kDa protein containing a C-terminal transmembrane domain
and is associated with the plasma membrane ofHVS transformed T-cells (Lund et al,
1995). The central region and N-terminal of Tip remains in the cytoplasm and
interacts with P561ck via a src family kinase regulatory domain, amino acids 106 -
113, and a SH3 binding motif, amino acids 132 -141 (Jung et al, 1995a, Biesinger et
al, 1995 & Lund et al, 1996). Tip, from HVS strain 488, expression in Jurkat-T-cell
lines and fibroblastoid cell lines has been shown to down regulate lck activity (Jung
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et al, 1995b). Tip, from HVS strain 484, expression in T-cells however, leads to a
several hundred fold increase in lck activity. Further more infection of peripheral
blood T-cells with HVS-484 lead to a 9 fold increase in cellular lck activity, as
compared to uninfected controls and infection with Tip knock out HVS-484 lead to a
significant decrease in lck activity (Lund et al, 1997). It has been hypothesised that
the lck constitutive activation by Tip is instrumental in converting PIVS infected IL-2
dependent T-cells to a IL-2 independent transformed state. This has been based on
the observations that P561ck is associated with T-cell receptor and IL-2 receptor
signalling (Hatakeyama et al, 1991 & Straus et al, 1992) and transgenic mice that
over express P561ck develop thymic tumours (Abraham et al, 1991).
1.5.6 Kaposi's sarcoma-associated herpesvirus
To date the closest genetically related human herpesvirus to MHV-68 is the newly
discovered KSFIV or HHV8 . The scientific world was first alerted to the possibility
of an eighth human herpesvirus when tissue samples from AIDS associated Kaposi's
sarcoma were found to harbour unique 'y-herpesvirus like' DNA sequences (Chang
et al, 1994). Since then KSHV DNA has also be found to be detectable in primary
effusion lymphomas (PEL), a specific subgroup of body cavity-based (BCBL) non-
Hodgkin's lymphoma (NHL) (Cesarman et al, 1995a) and the DNA of 2 simian
'KSHV-like' gammaherpesviruses have been discovered in two different macaque
species (Rose et al, 1997). Cell lines generated from PELs have shown to harbour
whole viral genomes in latent episomal form (Gaidano et al, 1996, Said et al, 1996 &
Cesarman et al, 1995b). The virus from a number of these cell lines has been
reactivated to produce whole virions (Renne et al, 1996 & Said et al, 1996) and the
viral DNA in one such line, apart from a 3kb region at the right hand side of the long
UCR of the viral genome, has been fully sequenced (Russo et al, 1996).
1.5.7 KSHV genome and genetics
The BC-1 cell line derived KSHV genome conforms to the 'C' type structural
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organisation, common to the y-2 herpesviruses. It consists of a 140.5Kb long UCR
containing 5 internal repeats, flanked by multiple copies of a G+C rich 801bp
terminal repeat sequence. 81 ORFs have so far been described within the UCR,
representing 79% of the 137.5 kb sequenced. 38 of which correspond to the core
herpesvirus genes which exist within the conserved gene blocks. 66 ORFs, including
the 39 core genes, are homologous to genes coded by FIVS, though 2 of which, ORFs
2 & 70 do not lie in the same co-linear order. The remaining ORFs that do not show
significant sequence homology to HVS, have been named K1 to K15. 2 of these,
ORFs K3 & K5, show significant homology to the BHV-4 encoded IE1 gene. The
remaining 13(K) ORFs do not show significant homology to any gene encoded by a
herpesvirus sequenced to date (Russo et al, 1996).
As is common to gammaherpesviruses KSHV encodes a functionally active Bcl-2
homologue (ORF16) (Russo et al, 1996 & Nicholas et al, 1997). ORF16 has a
conserved BH1 and BH2 domains but not the BH3 domain and will inhibit apoptosis
when expressed in vitro (Cheng et al, 1997). It has been shown to heterodimerise
with human Bcl-2 but not with either Bak and Bax, despite being capable of
suppressing Bax toxicity (Sarid et al, 1997).
1.5.8 Gamma-2 herpesvirus specific genes encoded by KSHV
KSF1V encodes a number of y2-herpesvirus specific genes, which are not found in
any sequenced yl-herpesviruses. Other than ORFs K3 and K5, KSHV also encodes
homologues to DHFR (ORF2), a CRP (ORF4), TS (ORF70), the HVS ORF71 (K13),
cyclin D (ORF72), an immunogenic latent nuclear antigen (ORF73) and a GCR
(ORF 74) (Russo et al, 1996, Cesarman et al, 1996 & Nicholas et al, 1997). The
ORF72 gene product has been shown to have D type cyclin functional activity in
vitro. As with the cellular homologue, it will complex with the cycle dependent
kinase cdk6 and phosphorylate the retinoblastoma tumour suppresser protein (Rb),
but unlike the cellular homologue, the ORF72/cdk6 complex will also phosphorylate
the histone FI1 (Li et al, 1997 & Goddenkent et al, 1997). The viral GCR homologue
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has also been shown to be functionally active. When transfected into cells in vitro it
acts as an antagonist independent signalling receptor, which drives proliferation via
constitutive activation of the phosphoinositide-inositol trisphosphate-protein kinase
C pathway (Arvanitakis et al, 1997).
1.5.9 Gene unique to KSHV
Unlike other sequenced herpesviruses, KSHV also encodes homologues to IL-6
(ORF K2), 2 macrophage inflammatory protein (vMIP I & II encoded by ORFs K6 &
K4 respectively), an interferon regulatory factor (IRF) (ORF K9) and a 'NCAM like'
adhesion molecule (ORF K14) (Russo et al, 1996 & Nicholas et al, 1997). The viral
IL-6 homologue has a 62% amino acid similarity to human IL-6 and can prevent
mouse myeloma cell undergoing IL-6 deprivation apoptosis (Moore et al, 1996).
1.6.1 Restricted patterns of KSHV gene expression
As is the case with EBV and HVS, KSHV gene expression both in tumours in vivo
and tumour derived in vitro cell lines, appears to be highly restricted. In both cases
the viral genome exists in a circular episomal form as opposed to linear (Decker et
al, 1996, Cesarman et al, 1995b) inferring that the viral infection is latent as opposed
to productive. In latently infected KS tissue, 2 virus specific transcripts were
detectable (Zhong et al, 1996). The first is predicted to encode a small membrane
protein; the other is an unusual polyadenylated RNA that accumulates in the nucleus
to high copy number. This pattern of viral gene expression is seen in the majority of
the KS cells and is believed to be synonymous with viral latency. Productive viral
replication is restricted to a much smaller sub population of cells in which two other
KSHV RNAs are also detectable (Staskus et al, 1997). These viral RNAs, one of
which encoded a major viral capsid protein, were expressed to relatively low levels
and believed to represent late gene expression. The unusual 1.2kb polyadenylated
nuclear localising RNA (PAN-RNA), is transcribed by RNA polymerase II, lacks a
trimethylguanosine cap and does not associate with polyribosomes (Sun et al, 1996).
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It contains internal regions of extremely high sequence homology to the HSURs
encoded by HSV and the 5' upstream region contained both proximal and distal
sequence elements characteristic of regulatory regions of the HSURs. The continual
transcription of untranslated RNA is common to herpesviruses during latent
infection, but a specific role in viral infection remains unproved. Both episomal and
linear viral DNA has also been associated with the viral infection of peripheral blood
mononuclear cells (PBMC) (Decker et al, 1996). This suggests that there is a latent
and a productive viral infection ofPBMCs. It has also been observed that the KSHV
IL-6 homologue is also specifically expressed in these cells in vivo (Moore et al,
1996).
1.6.2 KSHV association with Kaposi's sarcoma
KSHV is highly associated with a number of hyperplastic and neoplastic conditions,
the most common being KS. There are 3 forms of KS, sporadic KS, which is a rare
hyperplastic condition that occurs in Mediterranean men, AIDS-associated KS which
is a virulent neoplastic condition and a common cause of death in AIDS victims and
iatrogenic KS a virulent neoplastic condition that generally regresses on withdrawal
of immunosuppressive treatment (Beral et al, 1991, Schalz et al, 1995 and Schalling
et al, 1995) KSHV DNA can be commonly detected in the KS tissue in over 90% of
all 3 types (Chang et al, 1994, Chang et al, 1996, Cathomas et al, 1996a, Dictor et al,
1996, Kedda et al, 1996 and Aluigi et al, 1996). KSHV transcription and DNA is
detectable in both the spindle cell and the flattened neoplastic epithelial cells, but not
in the surrounding normal skin epithelium (Boshoff et al, 1995, Staskus et al, 1996
& Aluigi et al, 1996). Following reduction in immunosuppressive treatment,
elimination of KSHV DNA from both the iatrogenic KS lesion and the patients
blood, within the limits of detection, directly pre-empts tumour regression, leaving a
KSHV negative scar (Aluigi et al, 1996, Kedda et al, 1996 & Lock et al, 1997).
Together the evidence indicates that KSHV is directly involved in the development
of KS, and not merely an opportunistic, tumour tropic herpesvirus. The issue of
whether KSFIV is the only etiological agent in KS development remains
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controversial since a highly transforming human papovavirus called BK virus has
also been found in both sporadic and AIDS-associated KS lesions, as well as in KS
derived cell lines (Monini et al, 1996b).
1.6.3 KSHV association with primary effusion lymphomas
KSHV is also highly associated with AIDS-associated and non-AIDS-associated
PELs, a specific BCBL subgroup, of a mature B-cell origin (Cesarman et al, 1995a,
Cesarman et al, 1996, Said et al, 1996, Ansari et al, 1996 & Gessain et al, 1997).
The AIDS-associated are also generally co-infected with EBV (Cesarman et al,
1995a & Ansari et al, 1996), where as the non-AIDS-associated PELs tend to be
excessively infected with KSHV (Said et al, 1996). KSHV does not seem to be
associated with other AIDS-associated or non-AIDS-associated lymphomas of either
T or B-cell origin (Gessain et al, 1997) or other EBV infected BCBLs (Cesarman el
al, 1996). The cells from PELs can be cultured in vitro giving rise to a set ofKSHV
latently infected (Said et al, 1996) or KSHV / EBV latently infected, transformed
cell lines (Cesarman et al, 1995b, Gaidano et al, 1996 & Miller et al, 1997). Virions
reactivated from a latently infected cell line have been shown to infect CD19
positive B-cells (Mesri et al, 1996), thus confirming that KSHV is B-cell tropic as
well as epithelial cell tropic.
1.6.4 KSHV association with of multicentric Castleman's disease
KSHV has also been shown to be associated with the development of multicentric
Castleman's disease (MCD), an atypical lymphoproliferative disorder often
associated with KS development. KSHV DNA can be detected in the vast majority
(>90%) of AIDS-associated MCD tissue, both in patients with and without KS, but
much less frequently (40%) in non AIDS-associated MCD. (Soulier et al, 1995).
KSLIV has also been implicated in numerous endothelial proliferative disorders, all
be it at a reduced frequency of association. These include angiosarcoma in
immunocompetent individuals, (McDonagh et al, 1996) and various proliferative
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skin lesions in AIDS and immunosuppressed patients, including basal cell
carcinomas, squamous cell carcinomas, actinic keratoses, verruca vulgaris, atypical
squamous proliferations, and seborrhoeic keratosis (Rady et al, 1995, Chang et al,
1994 & Chang et al, 1996). However, the KSHV association with these conditions,
remains contentious (Dictor et al, 1996 & Cathomas et al, 1996a) and requires
further verification.
1.6.5 KSHV transmission and epidemiology
The epidemiology of the KSHV infection likewise, remains highly controversial and
to a large extent unresolved. It has been studied using essentially 4 different
parameters, KS incidence, sera conversion to latent viral antigens and the presence of
viral DNA in PBMCs and semen. It has long been observed that in Western
countries KS is far more prevalent in HIV positive homosexuals than in patients who
acquired HIV from blood products (Beral et al, 1991 & Schalz et al, 1995). This has
lead to the general theory that the disease causing agent for KS development, is
predominantly sexually transmitted in Western / Developed countries. This has been
further reinforced by the fact that in both HIV positive and KS patients, KSHV DNA
can be detected in both semen and prostate tissue but not, with the exception of
patients with pulmonary KS, in sputum or throat swabs (Lin et al, 1995, Monini et al,
1996a, Howard et al, 1997, Staskus et al 1997 & Cathomas, G., et al 1996b). There
have also been reports ofKSHV DNA being detectable in skin samples, especially in
immunosuppressed individuals (Rady et al, 1995, Cathomas et al, 1996b, Monini et
al, 1996a) though these findings have proved controversial (Dictor et al, 1996 &
Staskus et al, 1997).
As well as sexual transmission vertical transmission of KSHV also appears probable
since in sub-Saharan Africa there is a relative high incidence of childhood KS, where
the median age of development is 4 years. These cases generally arise from children
whose mothers are HIV positive and are often themselves HIV positive. In these
cases KSHV was probably transmitted vertically, and since the predominant tumour
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distribution suggests viral entry via the gastrointestinal mucosa, via breast milk
(Ziegler et al, 1996).
1.6.6 KSHV detection in human populations
Although the evidence provided by surveys looking at the incidence of KSHV
infection by sera conversion and nested-polymerase chain reaction (PCR) of both
blood and semen, are often highly conflicting, the overall trends are consistent with
sexual transmission being the principal means by which KSHV infection occurs {see
Table 1.5). The general incidence of KSHV with all three detection systems was
highest in AIDS patents with KS, then the KS negative AIDS patients, who were
predominantly homosexual (with the exception of Uganda), and lastly were the HIV
negative / KS negative controls. The serological studies (Gao et al, 1996 & Kedes et
al 1996) have divided populations with respect to relative promiscuity. There results
show that, with respect to KSHV incidence, HIV positive homosexuals > HIV
negative homosexuals > promiscuous heterosexuals > general heterosexuals. They
also show that Ugandans have a much greater general incidence that is seen in
Western countries. Both show that KSHV infection directly correlates to 'presumed'
promiscuity.
None of the detection systems used could detect the presence of KSHV, in
individuals with KS, to the same extent that KSHV can be routinely detected in the
KS lesions. Given that virus load and antibody responses are generally much higher
in individuals who have developed virus specific tumours, than in normal healthy
virus infected individuals, it is probably fair to assume that all the detection methods
under estimate the frequency ofKSHV infection in the general population. The viral
load in normal healthy people is probably very low since studies following the
regression of iatrogenic KS on withdrawal of immunosuppressive therapy, have
shown that KSHV levels in the blood decrease to undetectable levels, by PCR
(Aluigi et al, 1996 & Lock et al, 1997). Variation in detection sensitivity could
explain why some studies did not find KSHV in the general population at all (Whitby
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Table 1.5 * The KSHV prevalence in HIV positive and negative human
populations, as detected by serology and nested-PCR.
Sample HIY +ve HIV +ve HIV-ve Reference
Tested KS+ve KS-ve KS-ve
PBMC 52% (46) 8% (143) 0% (134)1
0% (26)2
Whitby etal, 1995
PBMC 35% (98) 19% (64) Humphrey et al,
1996
PBMC 60% (5) 60% (5)2
80% (5)3
Deckers al, 1996







Semen 91% (33) Monini et al,
1996a























Key: 1 General blood donor, 2Hospital control, 3 lmmunosuppressed, 41st round only
PGR, 5 heterosexual STD clinic visitors, 6 homosexual STD clinic visitors, 7
Haemophyliacs /IV drug users, 8 North America, 9 Italy & 10 Uganda. The % value
denotes the percentage of individuals KSHV positive by nested PCR / nuclear
immunostaining of latently infected cell lines, by patients sera at a 1/160 dilution.
The () value denotes sample size.
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et al 1995 & Howard et al 1997). Other studies have provided evidence that KSHV
may be ubiquitous in the general population (Monini et al, 1996a & Decker et al,
1996). It is however, hard to conceive how over 90% of the population of a western
country, could be infected by a virus completely reliant on sexual transmission.
HSV-2, a highly contagious sexually transmitted herpesvirus, has a prevalence,
amongst white heterosexuals, of approximately 20% in north America and as low as
8% and 20% in the British blood donor and sexually transmitted disease clinic
populations, respectively (Cowan et al, 1996 & Duncan et al, 1997).
Detection of KSHV may be unreliable at present as a method of determining the
prevalence of KSHV in the population at large, in terms of absolute numbers, but it
has proved effective as a means of predicting whether HIV positive patients go on to
develop KS. In studies carried out, 42-55% ofHIV sera positive who tested positive
for KSHV, went on to develop KS, as opposed to 0-9% of those who tested negative
(Lin et al 1995 & Whitby et al 1995). However, the initial detection level in the
latter of the 2 studies failed to diagnose 9/15 test subjects who went on to develop
KS. It seems unlikely that over half of them went on to contract KSHV after being
diagnoses HIV positive, if the predominant route of transmission is sexual.
1.6.7 Murine gammaherpesvirus 68
MHV-68 was originally isolated as 1 of 5 viral isolates, from 2 species of free living
rodent, the bank vole (clethrionomys glareolus) and the yellow tailed mouse
(.Apodemus flavicollis), during a field study in Czechoslovakia (Blaskovic et al,
1980). All 5 isolates were found to be antigenically related (Svobodova et al, 1982b)
and based of electron microscopy studies, they were classified as herpesviruses.
Based on their replication in epithelial and fibroblastoid cells lines, in vitro, the
isolates were further classified as belonging to the alphaherpesvirus subgroup
(Ciamper et al, 1981, Svobodova et al, 1982a & 1982b). This classification however
was called into doubt when pathogenesis studies carried out in young and new-born
out-bred inbred mice, demonstrated that following intranasal or oral inoculation,
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MHV-68 established latency in lymphoid tissue, predominately the spleen, as
opposed to in neuronal tissue (Rajcani et al, 1985, Sunil-Chandra et al, 1992b).
1.6.8 MHV-68 genomic architecture
MHV-68 was isolated from the brain of Clethrionomys glareolus. Doubts over the
correct classification ofMHV-68 led to the entire genome being cloned into a library
of restriction fragments. The library was then used to generate a complete restriction
map of MHV-68 (Efstathiou et al, 1990a). The cloning and characterisation of the
MHV-68 genome revealed a 118 kb central unique region, flanked by a variable
number of 1.2kbp repeat units. This conforms to a type 'B' genomic arrangement (as
specified by Roizman et al, 1990), an arrangement common to herpesviruses of the
y-2 sub-grouping. The overall size is also comparable to y-2 herpesviruses, such as
HVS and HVateles (Efstathiou et al, 1990a).
As well as having a type B genome arrangement, as opposed to a type C (type C
being common to the y-1 herpesviruses, such as EBV), MHV-68 also has a low G+C
content of 45% (Efstathiou et al, 1990b). The y-2 herpesviruses also have low G+C
content; HVS and HVateles have 46% and 48% respectively. The y-1 herpesviruses
have relatively high G+C content; EBV has 80% total genome. Having the low G+C
genomic content, distinguishes MHV-68 from the y-1 herpesviruses, but having a
low G+C content is by no means unique to the y-2 herpesviruses.
Alphaherpesviruses, such as VZV and MDV, and betaherpesviruses, such as HHV6
also have genomes with low G+C contents, 46%, 42% and 46% respectively
(Roizman et al, 1990).
1.6.9 MHV-68 genetics
Partial sequencing of 'core' genes and there relative order and orientation proved
beyond doubt that MHV-68 is a gammaherpesvirus (Efstathiou et al, 1990b). Since
then the entire genome has been sequenced (Virgin et al 1997). MHV-68 encodes 75
77
ORFs and a further 8 small 'tRNA-like' non polyadenylated RNA molecules. All the
core and semi-conserved herpesviruses genes are present, except for a gene
homologous to HVS ORF 41, in block VI (see Table 1.2 and 1.3). Of the semi-
conserved herpesvirus genes, the MHV-68 TK homologue, encoded by ORF 20, has
been characterised (Pepper et al, 1996). MHV-68 TK contains the six conserved
motifs found in all herpesvirus TK homologues and is a functionally active
pyrimidine kinase. Despite having greater genetic homology to the HVS TK, MHV-
68, unlike HVS, is inhibited by acyclovir (ACV) (Sunil-Chandra et al, 1993),
implying that functionally, the MHV-68 TK is more similar to the EBV TK.
1.7.1 Gammaherpesvirus specific genes encoded by MHV-68
MHV-68 encodes 16 genes which are considered to be gammaherpesvirus specific.
These include ORF 50, a homologue of the EBV R transactivator, and ORF Mil,
which codes for a Bcl-2 homologue. MHV-68 however does not appear to encode
genes homologous to the HVS ORFs 28 and 65, EBV genes BDLF3 and BFRF3
respectively. The HVS ORF65 / EBV BFRF3 gene is believed to encode a capsid
protein.
MHV-68 encodes 5 genes which are unique to the y-2 herpesviruses, ORFs 4, 72, 73,
74 and K3. As is the case with HVS and KSHV, ORFs 4, 72, 73 and 74 code for a
CRP homologue, a cyclin D homologue, the y-2 specific immediate early
transactivator and a GCR homologue, respectively. The MHV-68 ORF K3, as with
KSHV, but unlike HVS, codes for a homologue to the BHV IE1 protein. However,
MHV-68 does not code for either a TS or a DHFR homologue. This is unusual for a
y-2 herpesvirus since both HVS and KSHV encode homologues to these proteins,
encoded by ORFs 2 and 70 respectively.
1.7.2 Genes unique to MHV-68
The remaining 13 MHV-68 ORFs, Ml to 10 and M12 to 14, with the exception of
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ORF M7, do not have significant homology to any known genes encoded by
herpesviruses. ORF M7 encodes a glycoprotein (gpl50) of molecular weight 150
kDa, which is present in the envelope of virions. ORF M7 does not show significant
homology to any known y-2 herpesvirus gene, but has limited homology with EBV
gp340/220 (Stewart et al, 1996). The EBV gp340/220 is situated in the EBV virion
envelope and mediates attachment and entry into B-lymphocytes (Nemerow et al,
1989). MHV-68 gpl50 may well have a similar role as EBV gp340 since gpl50-
specific antibodies neutralise the infectivity ofMHV-68 virions. Of the remaining
genes unique to MHV-68, ORF Ml has been partially characterised. ORF Ml shows
homology to a family of serine protease inhibitors encoded by the poxviruses. ORF
Ml has highest homology to the same 4 regions found to be conserved between the
different poxvirus serpin homologues (Bowden et al, 1997, Boursnell et al, 1988 and
Ali etal, 1994).
1.7.3 MHV-68 gene expression
The gene expression of MHV-68 following in vitro infection of tissue culture cell
lines has been partially characterised and appears to follow a similar pattern to that
observed in EBV (Mackett et al, 1989). It is presently unclear which viral ORFs are
expressed during latency however there are eight small viral RNA species which are
expressed at high levels during latent infection of splenic B-cells in vivo. These
small RNA species are coded at the left terminal of the MHV-68 UCR. The RNA
species have a sequence similar to tRNA and are theoretically capable of forming a
clover structure. They contain RNA polymerase promoters, but do not appear to
load with amino acids (Bowden et al, 1997). Other herpesviruses code for latency
associated non-translated RNA species, the function of which remains unproved.
Herpesvirus gB homologues (typified by HSV-1 gB) are one of the most conserved
genes within the Herpesviridae. MHV-68 gB shows sequence homology to the gB
homologues of all sequenced herpesviruses but with special regard to the
gammaherpesviruses. MHV-68 gB is also expressed, in cells infected in vitro, in a
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gammaherpesvirus specific manner (Stewart et al, 1994). Unlike with the other sub¬
families, MHV-68 gB, HVS gB and EBV gB (gpllO) exists only in the immature
glycosylated form, i.e. containing, only high manose N-linked glycosylations. MHV-
68 gB (with a Mr of 105,000) is analogous to the precursor form ofHSV-1 gB and is
present only associated with the ER and nuclear membrane, not with the Golgi
apparatus or plasma membrane. MHV-68 gB is also not detectable in virus particles
(Stewart et al, 1994) demonstrating both in terms of sequence and expression how
highly related it is to the gB of other gammaherpesviruses (Gong et al, 1990).
1.7.4 The pathogenesis ofMHV-68 infection in inbred mice
As an example of a gammaherpesvirus, which naturally infects small rodents, MHV-
68 makes an ideal model for the study of gammaherpesvirus pathology in, what is
presently, the most versatile experimental host species. Intra-nasal (in) inoculation
ofMHV-68 into 3 to 4 week old BALB/c mice, results in an acute viral infection of
the lungs. During the acute infection, viral antigen can be detected, by
immunostaining, in alveoli epithelial cells and mononuclear cells. The acute lung
infection is resolved by 10 days post infection, by which time a latent infection of the
spleen is established. Latent virus can first be detected in the spleen as early as 7
days post infection. Latent viral titres exponentially increase, peaking at 15 days
post infection, then decrease to a low level (Sunil-Chandra et al, 1992a). Peak viral
latency is generally associated with a pronounced splenomegaly. Numbers of splenic
B-cells, CD4 T-cells and CD8 T-cells, all dramatically increase during the
splenomegaly. The CD8 T-cell expansion is dominated by CD8 T-cells with V(34 T-
cell receptors. This strongly suggests that MHV-68 expresses a superantigen (Tripp
et al, 1997). The splenomegaly resolves only after viral latency has been reduced to
its base level, (for review onMHV-68 infection of inbred mice see Nash et al, 1994).
1.7.5 Viral latency in the spleen
Viral latency established in the spleen predominately localises to the germinal
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centres (Bowden et al, 1997). The splenocytes harbouring latent MHV-68 appear to
be exclusively B-lymphocytes since virus can be reactivated from B-cells, but not T-
cells from the spleen of infected mice (Sunil-Chandra et al, 1992b). Furthermore,
virus cannot be detected in the spleens of intra-nasally infected, B-cell knock-out
(jliMT) mice by both reactivation assay and by PCR (Usherwood et al, 1996a). As
well as being B-cell tropic in vivo, MFIV-68 will persistently infect transformed cell
lines of B cell but not T-cell origin, in vitro (Sunil-Chandra 1993). The NSO B-cell
line, when persistently infected with MHV-68, harbours both linear and episomal
viral DNA. When these lines were cultured in the presence of acyclovir, a potent
inhibitor of productive herpesvirus replication, the proportion of linear viral DNA
was greatly reduced, but the episomal DNA was unaffected. These results strongly
suggest the establishment of viral latency.
1.7.6 Cellular and humoral immune responses to MHV-68 infection
CD8 T-cells play a critical role in controlling the acute lung infection. Depletion of
CD8 T-cells prior to intra-nasal infection with MHV-68, results in the development
of a lethal infection in BALB/c mice. The CD8 depleted mice experienced both an
acute lung infection of greater severity than the undepleted controls, and a
disseminated infection in which the virus spread to other organs, such as the spleen,
liver, kidneys and adrenal glands (Ehtisham et al, 1993). The mechanism by which
the CD8 T-cells exert their effect is at present, not well understood. Mice lacking in
perforin, one of the main mechanisms by which CTLs and NK cells kill infected
cells, efficiently control the MHV-68 infection indicating a redundant role for this
mechanism of cytotoxicity (Usherwood et al, 1997).
CD4 T-cells also play a critical role in both the elevated levels of latently infected B-
cells seen in the spleen around day 15 post infection and the development of
splenomegaly. CD4 T-cells do not however appear to play a major role in controlling
the acute lung infection (Ehtisham et al, 1993 & Usherwood et al, 1995). The
development of splenomegaly appears to be dependant on both CD4 T-cells and
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virally infected B-cells since intra-nasal infection of pMT mice as well as CD4 T-
cell deficient mice fail to develop splenomegaly (Usherwood 1995 & 1996a). CD4
T-cells may have a role in the control of viral persistence in the lungs of infected
animals, since MHC class II knock-out mice develop a low level chronic infection of
the lungs at late times post infection (Cardin et al, 1996). Host antibody responses
appear to play little or no role in controlling the acute lung infection. The humoral
response of BALB/c mice to MHV-68, does not become detectable until after the
acute lung infection has been resolved. MHV-68 antibodies only become detectable,
by ELISA, in mice sera 10 to 15 days post infection, though once established remain
at high titres though out the life of the mouse (Usherwood et al, 1996a).
1.7.7 Cytokine responses to MHV-68 infection
Alpha and beta interferon (INF-a/p) appear to be important in controlling the acute
lung infection. Mice lacking INF-a/p receptors are killed by MHV-68, inoculated
(in), in a dose dependant manner. The acute infection in these mice is more severe
both in terms of longevity and lung viral titres (Nash and Dutia personal
communication). The cytokine response to MHV-68 infection appears to be
predominantly IL-6 and INF-y (Sarawar et al, 1996). INF-y knock out mice, do not
have an obvious phenotype in response to MHV-68 infection (Sarawar et al, 1997).
However, mice deficient in the INF-y receptor develop chronic splenic atrophy,
though show no obvious signs of disease (Dutia et al, 1997) (for review on the
immunological features of the MHV-68 infection see Nash et al, 1996).
1.7.8 Alternative routes of MHV-68 infection
MHV-68 infections can be initiated by both intra-peritoneal (ip) and intra-venous (iv)
routes of inoculation. The infections that result from these less-natural routes are
different from the infection initiated by intra-nasal route. Intra-peritoneal and intra¬
venous inoculations result in a more severe systemic infection. A transient acute
infection of the spleen occurs and the splenomegaly occurs earlier and is more
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pronounced. High titres of MHV-68 inoculated (ip) into INF-y receptor knock-out
mice and p.MT mice results in a lethal infection and splenic persistence, respectively
(Week et al, 1996). The nature of the viral persistence in the spleens of the intra-
peritoneally infected INF-y receptor knock-out mice has not been characterised.
1.7.9 MHV-68 association with malignancies
As with EBV, MHV-68 is associated with LPD development. Nine percent of
BALB/c mice infected long-term with MHV68 (between 9 months pi to 3 years pi)
go on to develop lymphoproliferative disorders. Fifty percent of these were high
grade lymphomas. The lymphomas were mainly associated with the spleen and
other lymphoid organs such as the mesenteric lymph node. The LPD incidence went
up from 9% to 65%, over the same time scale, when the mice were
immunosuppressed with cyclosporin A (CsA) early on in the course of the infection
and then allowed to fully recover (Sunil-Chandra et al, 1984a). The lymphomas
were comprised of B-cell, showing light chain restriction and CD3 positive
infiltrating T lymphocytes. One such tumour gave rise to a transformed in vitro B-
cell cell called SI 1. The Sll line contains both linear and episomal MHV-68
genomes and appears to harbour both lytic and latent virus (Usherwood et al, 1996b)
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Chapter 2: Materials and Methods
2.1.1 Ceil lines used
Baby hamster kidney (BHK) cells clone 21 is an immortal fibroblastoid cell line
(previously described by Sunil-Chandra 1992a).
NSO cells are a transformed B-cell myeloma cell line (previously described by Sunil-
Chandra et al, 1993).
Mixed glial culture clone 7 (MGC7) were derived from retrovirus transformed
mouse mixed glial cells. The mouse retrovirus used contained a temperature
sensitive SV40 large T antigen, which transforms at permissive temperatures (35°C)
but does not at non-permissive temperatures (39°C) (previously described by Terry et
al, 1997).
Primary splenocyte cultures were derived from the spleens of BALB/c mice and
comprise ofmixed splenic leucocytes.
Murine lymphoma lines - Basal lymph node derived (BLN), mesenteric lymph node
derived (MLN) and splenic derived (SP-) lymphoma cell lines. All were derived
from mice infected with MHV-68 and immunosuppressed with CsA (Sunil-Chandra
1994a).
2.1.2 Culture reagents
Glasgow modified Eagle medium (GMEM) (GibCo BRL).
Dulbecco's modified Eagle medium (DMEM) (GibCo BRL).
RPMI 1640 (GibCo BRL)
Foetal calf serum (FCS) - (Globepharm).
New-born Calf serum (NCS) - (Harlan Sera lab).
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Tryptose phosphate broth (TPB) - (Life Technologies, Paisley)
Fungizone (100X) - (Squibb) - 200pg/ml in SDW.
L-Glutamine (100X) - (Merck - BDH) - 200mM in sterile distilled water (SDW)
Penicillin (100X) - (Merck - BDH) / - 7mg/ml dissolved in SDW and filter sterilised.
Streptomycin (100X) - (Sigma) - Img/ml dissolved in SDW and filter sterilised,
p-mercapto-ethanol (Sigma) (100X) - 5mM in STD and filter sterilised
Trypsin / EDTA solution tissue culture grade (Life Technologies, Paisley).
Dimethyl sulfoxide (DMSO) (Merck - BDH)
Essential amino acids (50X) (Dulbecco).
Non-essential amino-acids (Dulbecco).
Trypan blue (stock) -1% (WW) trypan blue (Gurr) in PBS and filter sterilised.
Trypan blue (working stocks) - 1/10 dilution ofworking stock with sterile PBS.
Lymphoprep (Ficoll).
Phosphate buffered saline (PBS) - 80 mg/ml sodium chloride (NaCl), 2mg/ml
potassium chloride (KC1), 2 mg/ml mono-potassium orthophosphate (KH2P04),
11.05 mg/ml mono-sodium orthophosphate (Na2HP04) (pH 7.2), sterilisation by
autoclaving.
Filter sterilising was done using sterile syringes (Becton Dickinson) and a 0.2p.
sterilising filters (Sartorius).
2.1.3 Anti-virals
ACV stock solution (GlaxoWellcome) - 2 mg/ml suspention was made up using
SDW and heated to 60°C for 1 hour, under-constant agitation. The soluble ACV was
then filter sterilised whilst still hot.
4'-s-EtdU stock solution (GlaxoWellcome) - 2mg/ml suspention was made up using
SDW and heated to 60°C for 1 hour, under-constant agitation. The soluble ACV was
then filter sterilised whilst still hot.
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2.1.4 Tissue culture growth medium
BHK growth medium (ECT10) - GMEM with 10% NCS, 10% TPB,
Penicillin/Streptomycin (70pg/ml / lOpg/ml respective final concentrations),
Fungizone (2pg/ml final concentration) and L-Glutamine (2mM final concentration).
Lymphoma cell lines culture (LCLC) medium - RPMI 1640 + 10% FCS,
Penicillin/Streptomycin (70pg/ml / lOpg/ml respective final concentrations),
Fungizone (2p.g/ml final concentration) and L-Glutamine (2mM final
concentration).
NSO cloning medium - LCLC medium with 20% filter sterilised, exhausted
uninfected NSO LCLC medium.
MGC7 growth medium - DMEM with 10% FCS, 2% (V/V) non-essential amino-
acids, Penicillin/Streptomycin (70pg/ml / 10p.g/ml respective final concentrations)
and L-Glutamine (2mM final concentration).
2.1.5 In vitro cell line culture procedures
Cell numbers were evaluated by counting dilutions of the cell suspention mixed 1:1
with 0.1% trypan blue, using a haemacytometer. Viability was determined by the
proportion of cells that do not stain after a five minute incubation with the trypan
blue.
BHK cells were grown up in T175 flasks (Nunc), at 37°C, with 50ml of ECT10
medium. Flasks were seeded with 5xl06 cells and cultured for 3 to 4 days, or until
confluent. Confluent monolayers had the spent medium removed, washed once with
PBS and incubated for 1 to 2 minutes with 5ml of trypsin/EDTA, pre-warmed to
37°C. The monolayers were separated from the bottom of the flasks by external
agitation and then the trypsin quenched with 15ml ECT10. The cells were dispersed
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by vigorous pipetting and pelleted by centrifugation at 1800 RPM for 5 minutes in a
Beckman TJ-6 centrifuge. The supernatant was removed and the cells resuspended
in 10ml of fresh medium. The cells were pelleted and resuspended in fresh medium
a further two times to remove all traces of the trypsin, (previously described by
Sunil-Chandra 1992a).
The NSO, MLN, BLN and SP- lymphoma cell lines were grown up in T75 (Nunc)
flasks at 37°C, with 20 ml of LCLC medium. Flasks were seeded with 5xl06 cells
and cultured for 3 to 4 days. The cell lines grow as a single cell, partial suspention
culture. Weakly adherent cells were put into suspention by the vigorous use of a
pasteur pipette. The cells were pelleted (1600 RPM for 5 minutes in a Beckman TJ-
6 centrifuge) and resuspended in 10ml of fresh LCLC medium twice (previously
described by Sunil-Chandra et al, 1993).
MGC7 cells were grown up in Nunc T175 flasks, at 34°C, with 50ml of culture
medium. Flasks were seeded with 5xl06 cells and cultured for 3 to 4 days, or until
confluent. Confluent monolayers had the spent medium removed, washed once with
PBS and incubated for 1 to 2 minutes with 5ml of trypsin/EDTA, pre-warmed to
37°C. The monolayers were separated from the bottom of the flasks by external
agitation and then the trypsin quenched with 15ml ECT10. The cells were dispersed
by vigorous pipetting and pelleted by centrifugation at 1600 RPM for 5 minutes in a
Beckman TJ-6 centrifuge. The supernatant was removed and the cells resuspended
in 10ml of fresh medium. The cells were pelleted and resuspended in fresh medium
a further two times to remove all traces of the trypsin (previously described by Terry
etal, 1997).
2.1.6 Storage and retrieval of cell lines from liquid nitrogen.
Cell lines were stored frozen in liquid nitrogen. Cells were pelleted by
centrifugation and resuspended in FCS, 2xl05 cells/ml. The cell suspention then had
an equal volume of 20% (V/V) DMSO dissolved in cooled FCS and mixed. The cell
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suspention was then dispensed into cryovial (Nunc) in 1.8 ml aliquots and frozen at -
85°C for 24 hours. The vials were then placed in liquid nitrogen for indefinite
storage.
Cell retrieved from liquid nitrogen were thawed rapidly and cold growth medium
was added gradually with constant swirling. After 10ml of medium was added the
cells were pelleted by centrifugation and the medium discarded. The cells were then
resuspended in 10ml of fresh medium and repelleted a further two times to remove
all traces of DMSO. The cells were then added with 7 ml of medium to a T25
(Nunc) flask and incubated at an appropriate temperature (37°C or 34°C) until
confluent. The cells were then passaged and transferred to either a T75 or T175
depending on cell numbers or cell line used.
2.1.7 Splenocyte preparation
Whole spleens were mashed in a sterile stainless-steel tea strainer (John Lewis Ltd),
with 4 ml of cold LCLC medium, in a 60mm petri-dish (Sterilin). The strainer was
rinsed with a further 3ml of cold lymphoma cell line culture medium. Cell clumps
were dissociated using a pasteur pipette and the cell suspension transferred to a
universal (Sterilin). Cells were pelleted by centrifugation at 1600 RPM for 5
minutes in a Beckman TJ-6 centrifuge, set to 4°C. The supernatant was removed and
the cells resuspended by external agitation and placed on ice. The red cells were
removed by water lysis, 1ml of sterile distilled water added to the dissociated cell
pellet and incubated for 10 seconds at room temperature, followed by 10 ml cold
LCLC medium. The cells were pelleted by centrifugation at 1600 RPM for 5
minutes in a Beckman TJ-6 centrifuge, set to 4°C. The supernatant was removed and
the cells resuspended by external agitation and replaced with 5ml cold LCLC
medium. The cells were put into suspention using a 5ml pipette, the clumps of lysed
red cells allowed to settle out, and the white cell suspention removed, put into a
bijoux (Sterilin) and then placed on ice.
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2.1.8 Ficoll purification of splenic lymphocytes
Whole spleens were mashed in a sterile stainless-steel tea strainer (John Lewis), with
4 ml of cold LCLC medium, in a 60mm petri-dish (Sterilin). The strainer was rinsed
with a further 4ml of cold lymphoma cell line culture medium. Cell clumps were
dissociated using a pasteur pipette and the cell suspension was overlaid onto 10ml of
lymphoprep, in a universal. The lymphoprep overlays were centrifuged at 2500
RPM for 20 minutes in a Beckman TJ-6 centrifuge, set to 4°C. The lymphocytes are
then removed from the medium-lymphoprep interface with a pasteur pipette and
mixed with fresh medium, made up to 20ml, in a fresh universal. The cells were
then pelleted by centrifugation at 2000 RPM for 10 minutes in a Beckman TJ-6
centrifuge, set to 4°C. The supernatant was removed and the cells resuspended by
external agitation. The cells were resuspended in 10ml fresh LCLC medium and
were repelleted and resuspended twice more, by centrifugation at 1600 RPM for 5
minutes in a Beckman TJ-6 centrifuge, set to 4°C. The cells were finally resuspended
at a density of 107 cells perml and put on ice.
2.1.9 Virus stocks
MHV-68 was originally obtained from the late Professor J. Lesso, Institute of
Virology, Academy of science, Slovakia (Blaskovic et al, 1990). The virus stocks
used though out this study were generated from the sub-master stock of clone G2.4
(Estathiou et al, 1990). To generate the initial MHV-68 stocks, BHK cells, 5xl06 per
T175 flask, were infected at a multiplicity of infection (MOI) of 0.1 plaque forming
units (pfu) MHV-68 per cell. The later MHV-68 working stocks were generated by
infecting BHK cells at an MOI of 0.01. To allow the virus to adsorb to the cells, the
inoculated BHK cells were suspension in 5ml ECT10 and then incubated for 1 hour
at 37°C, on a shaker. The cells were then transferred to T175 flasks containing 50ml
ECT10 and cultured for 3-4 days at 37°C. The monolayers were then removed from
the flasks using a plastic cell scraper (Sterilin) and pelleted by centrifugation at 1800
RPM for 5 minutes in a Beckman TJ-6 centrifuge, set at 4°C. The cells were dance
89
homogenised in 2 ml / monolayer of cold ECT10 and the debris pelleted by
centrifugation at 3000 RPM for 15 minutes in a Beckman TJ-6 centrifuge, set to 4°C.
The supernatants were dispensed in 0.2 ml aliquots and stored at -80°C (see Table
2.1).
2.2.1 4'-s-EtdlJ resistant virus cloning
The polyclonal resistant virus stock was derived from the crude lysate of a
persistently infected MGC7 culture, grown in medium supplemented with 2p.g/ml 4'-
s-EtdU. The titrc of the polyclonal virus stock was established by infectious virus
assay. BHK cells were infected with halving dilutions of the resistant virus from 4
pfu/105 cells to 0.125 pfu/105 cells in ECT10 supplemented with 4'-s-EtdU 2pg/ml.
After a 1 hour absorption at 37°C the cells were then pipetted into 24-well plates, lO3
cells per well. After 4 days culture, the medium from each well was removed and
stored separately at -80°C. The monolayers were fixed with formyl-saline and
stained with toluidine blue. The medium from the selected wells (MHV-68 positive
from the dilution 0.25 pfu/well) were then used to infect cell in a similar manner, for
a second and then a third round of cloning. Following the third round of cloning, six
cloned isolates selected, termed mixed glial culture clone 7 derived 4'-s-EtdU
resistant virus (MERV) for further characterisation (see Table 2.1).
2.2.2 Infectious virus assay
Regents
Formyl-saline - (Surgipath Europe Ltd) - 10% neutral buffered formaldehyde
solution.
Toludine blue (stock)- (Merck BDFI) -1% (W/V) in distilled water.
90
Table 2.1 The titres of the MHV-68 virus stocks used in this study.
MHV-68 virus stock Virus titre
'Working stock 1 107 pfu/ml
1
Working stock 2 3.5xl07 pfu/ml
'Working stock 3 108 pfu/ml
'Working stock 4 3.5xl08 pfu/ml
2MERV (34/22/41) 2.2 xlO7 pfu/ml
2MERV (34/22/44) 3.0 xlO7 pfu/ml
2MERV (43/62/67) 3.6 xlO7 pfu/ml
2MERV (43/62/72) 3.2 xlO7 pfu/ml
2MERV (43/68/89) 2.8 xlO7 pfu/ml
2MERV (43/68/96) 2.5 xlO7 pfu/ml
Key: 1 Wild type MHV-68. 2 4'-s-EtdU resistant MHV-68 variants.
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Protocol
Tissue homogenates or virus samples were serially diluted and 0.2 ml was added to a
bijoux containing lxlO6 BHK cells in 2ml ECT10. The virus was then incubated
with the cells at 37°C for one hour on a shaker. A further 4 ml ECT10 was added to
each bijoux and the contents of each added to a 60mm petri-dish and incubated at
37°C for 4 days. The medium was then removed and the monolayers fixed with
formyl-saline and stained with toludine blue. The plaque counts were established by
microscopic (Wild Heerbrugg 1274) examination of the stained monolayer. Virus
titre was evaluated by multiplying the plaque counts by the dilution factors (as
previously described by Sunil-Chandra et al, 1992b).
2.2.3 Infectious centre assay
Splenocyte preparations were serially diluted in lymphoma medium and 0.5ml of the
resultant cell suspensions added to a bijoux containing lxlO6 BHK cells in 6ml
LCLC medium. The contents of each bijoux was then added to a 60mm petri-dish
and incubated at 37°C for 5 days. The medium was then removed and the
monolayers fixed with formyl-saline and stained with trypan blue. The infectious
centre counts was established by microscopic examination of the stained monolayer.
The infectious centre titre was determined by multiplying the infectious centre
counts by the dilution factors (as previously described by Ehtisham et al, 1993).
2.2.4 Lung co-cultivation assay
Half a mouse lung was dissected into 8 pieces and placed in a 60mm petri-dish with
lxl06 BHK cells and 6ml LCLC medium. The lung tissue is the cultured at 37°C for
5 days. The lung tissue is then homogenised along with the monolayer in the spent
medium and titred for reactivated virus by infectious virus assay.
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2.2.5 Effective concentration 50% (EC50) assay
Serial dilutions are made using ECT10 and 4'-s-EtdU or ACV, pre-warmed to 37°C.
5 ml of each dilution is added to a bijoux containing lxlO6 BHK cells, which have
been pre-incubated with 200 pfu ofMHV-68, at 37°C for 1 hour. The contents of the
bijouxs were then emptied into 60mm petri-dishes and incubated at 37°C for 4 days.
The medium was then removed and the monolayers fixed with formyl-saline and
stained with trypan blue. The plaque counts were established by microscopic
examination of the stained monolayer. The EC50 value defined the anti-viral
concentration that inhibited 50% of plaque formation.
2.2.6 Establishment of cell lines persistently infected with MHV-68
One million NS0 cells were infected with MHV-68 at a MOI of 5, in 2ml of LCLC
medium. The inoculated cells were incubated at 37°C for 1 hour on a shaker and
then transferred to a T75 flask containing 20ml LCLC medium. The cells were
cultured at 37°C for 3 passages and then frozen in liquid nitrogen. All experiments
were carried out on infected NS0 cells retrieved from N2(l).
2xl07 MGC7 cells were infected with MHV-68 at a MOI of 1, in 5ml of the MHC7-
growth medium. The inoculated cells were incubated at 37°C for 1 hour on a shaker
and then transferred to 4 T175 flasks containing 50ml growth medium supplemented
with 4'-s-EtdU, at either 2pg/ml or 0.2pg/ml (final concentration). The cell lines
were then cultured as per normal using 4'-s-EtdU supplemented medium.
BHK cells were inoculated with serial dilutions of MHV-68 resulting in a MOI
ranging from 4 to 4x10"6 pfu per cell. After a one hour incubation at 37°C on a
shaker, 1.25xl06 cells, from each MOI were cultured at 37°C, in T25 flasks with 7ml
of ECT10 supplemented with 4'-s-EtdU (2pg/ml final concentration). On reaching
confluence the cells were passaged and transferred to T75 flasks containing 20ml 4'-
s-EtdU supplemented medium. The cells were then further passaged, on reaching
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confluence, and transferred to T175 flasks containing 50ml of 4'-s-EtdU
supplemented medium. The cells were then maintained in T175 flasks.
2.2.7 Cloning infected NSO cultures
Persistently infected NSO cultures were diluted using NSO cloning medium, to 1.5
cells/ml. 200pl was then pipetted in each well of 5 round bottomed 96-well plates
(Nunc). When the cloning medium became exhausted 20 well per original culture
were selected to be transferred to 24 well plates (Nunc) containing 1ml NSO cloning
medium per well. Each clonal NSO culture was further expanded into 1 well of a 6-
well plate (Nunc) containing 6ml of normal LCLC medium. The clones were then
expanded into T25 flasks and frozen in liquid nitrogen.
2.2.8 Mice used for in vivo experiments
C57BL/6 females 3-4 weeks of age on arrival (Bantin and Kingman, Grimston,
Aldbrough, Hull, UK).
BALB/c females 3-4 weeks of age on arrival (Bantin and Kingman, Grimston,
Aldbrough, Hull, UK).
SCID females (on a BALB/c background) 4-5 weeks of age on arrival (Olac ).
2.2.9 Experimental infection of mice
Both the intra-nasal and the intra-peritoneal routes of infection were used to
experimentally introduce MHV-68 into mice. Mice were lightly anaesthetised with
halothane (Rhone Merieux Ltd, Harlow, Essex) and inoculated (in) with 4x1 (T pfu
MHV-68, in 40pi, using a Gilson automatic pipette. Viral inoculum was derived
from the viral stock, diluted to the right concentration with PBS (as previously
described by Sunil-Chandra et al, 1992a). Alternatively, mice were injected intra-
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peritoneally (ip), with 4xl05 pfu MHV-68, in 0.2 ml, using a 1ml sterile syringe
(Becton and Dickinson) and a 27G hypodermic needle (Sherwood Medical). Viral
inoculum was derived from the viral stock, diluted to the right concentration with
PBS.
2.3.1 Anti-viral administration
For short term administration, lightly anaesthetised mice were orally injected with
0.2ml of a 0.5% (W/V) 4'-s-EtdU suspention (was made up with sterile distilled
water) using a gavarge needle. For long-term administration, sterile 4'-s-EtdU stock
solution was diluted with tap water (1/6) to give a final concentration of 0.33mg/ml.
The 4'-s-EtdU solution was then filter sterilised and administered as drinking water
for the long-term treatment of mice.
2.3.2 Immune suppression ofmice
Cyclosporin A powder (lg) was mixed with 50ml ultra-pure olive oil (Sigma) and
heating to 60°C and devolved under constant agitation, via a magnetic stirrer. The
resultant 20mg/ml stock was stored at room temperature (RT). The CsA stock was
injected into mice (ip) at 0.1ml per mouse twice weekly.
2.3.3 Adoptive transfer of splenocytes
Splenocytes were adoptively transferred into mice following 2 different protocols.
For the pilot adoptive transfer of splenocytes, from infected mice, into SCID mice,
spleens were removed from BALB/c donors 12 days post intra-pcritoncal inoculation
with 4xl05 pfu MHV-68. The donor mice had been place on 4'-s-EtdU drinking
from day 6 post infection so as to prevent there being any infectious virions being
present at the time of adoptive transfer. Lymphocytes were purified on a ficoll
gradient and pooled. Half the splenocytes were mixed with YTS169 derived anti-
CD8 monoclonal (lmg/7x!07 cells). 7xl07 cells were then injected (ip) into the four
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groups of SCID mice. Groups 1 and 3 got whole lymphocytes and groups 2 and 4 got
lymphocytes mixed with anti-CD8 antibody. Groups 3 and 4 were put on 4'-s-EtdU
drinking water from 2 days prior to adoptive transfer of splenocytes. Two days after
adoptive transfer groups 2 and 4 were injected (ip) with lmg/mouse, in 0.1ml, of the
YTS169 derived anti-CD8 monoclonal antibody.
For the main adoptive transfer of splenocytes into SCID mice, spleens were removed
from uninfected BALB/c and infected BALB/c donors 12 days post intra-peritoneal
inoculation with 4x105 pfu MHV-68. The resultant whole splenocyte preparation
were injected (ip) into the different groups of SCID mice, 4x107 white cells per
mouse. Groups 1 and 2 received uninfected splenocytes and groups 3 and 4 received
uninfected splenocytes mixed with anti-CD8 antibody. Groups 5 received
splenocytes from infected donors and groups 6 and 7 received splenocytes from
infected donors mixed with anti-CD 8 antibody. Group 10 consisted of normal
BALB/c mice, which received splenocytes from the infected donors.. The day after
adoptive transfer groups 2, 3, 4, and 7 were injected ip with 4x104 pfu MHV-68, as
were groups 8 and 9 SCID mice, which did not receive an adoptive transfer. Two
days after adoptive transfer groups 3, 4, 6 and 7 were given a second injection ip
with anti-CD8 antibody, lmg per mouse in 0.1ml. The mice from groups 4, 7 and 9
were put on 4'-s-EtdU drinking water from 5 days post adoptive transfer and until
the experiment ended.
2.3.4 Sampling of mice
Mice were killed by cranial dislocation and the relevant organs removed by
dissection. Organs, on removal, were placed in a bijoux containing 4ml of cold





Long-term MHV-68 infected BALB/c mouse serum.
Rabbit (A) anti-MHV-68 hyper-immune serum.
YTS 191 rat anti-mouse CD4 ascites (NH4S04 precipitated)
YTS 169 rat anti-mouse CD8 ascites (NH4S04 precipitated)
Biotin conjugated goat anti-mouse IgM (Sera lab)
Biotin conjugated Sheep anti-mouse IgG heavy chain (Serotec)
Horseradish peroxidase (HRP) conjugated rabbit anti-mouse (DAKO)
Flouroscene (FITC) conjugated swine anti-rabbit IgG heavy chain (DAKO)
FITC conjugated Strepavidin (Serotec)
FITC conjugated anti-mouse CD45R (Pharminogen)
FITC conjugated star 49 goat anti-rabbit (Serotec)
Rat ascites were carried out, using LOUxDA F1 hybrids (as described by Cobbold et
al, 1994)
2.3 .6 Collection ofmouse sera
Blood, including clots, was collected from the thorax of killed mice, using a sterile
pasteur pipette, placed in a cryovial, and put on ice. The heart ventricles were
snipped with dissection scissors of newly dead animals to maximise yield. Blood
collection from live animals was achieved by tail bleeds. Mice were placed in a
bucket positioned under a heating lamp for 2 minutes. The tail veins of the mice cut
with a sterile scalpel. The blood drops were collected in a cryovial and put on ice.
After approximately 10 minutes on ice, the clots in the blood samples were broken
up by external agitation and then placed back on ice for a further 2 to 3 hours. The
clots were then pelleted by centrifugation at 1800 RPM for 10 minutes in a Beckman
TJ-6 centrifuge, set to 4°C. The serum was removed, placed in a sterile 1.5ml
eppendorf tube and stored at -30°C (as previously described by Sunil-Chandra et al,
1992b).
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2.3.7 Cytosmear preparation and staining for MHV-68 antigens
Reagents
Wash buffer - PBS with 0.2% (W/V) bovine serum albumin faction V (Sigma) and
0.02% (V/V) Tween 20 (Sigma).
Using a diamond tipped pen, six circles were drawn onto a bio-bonded slide. The
circles were the traced around using a water repellent pen. Cell were suspended in
10% formyl-saline at a density of 107 cells per ml. 10pl were then pipetted onto a
slide, using a 20pl Gilson, in the centre of a circle. The cells were spread though out
the well using the tip of the Gilson and allowed to air dry in a fume hood. When dry
the cells were rapped in aluminium foil and stored at -80°C.
Protocol
The cytosmears were removed from the -80°C and allowed to reach RT before the
foil was removed. Before staining the slides were placed in rack and washed once
with wash buffer. Each wash consisted of the rack, containing the slides, into a glass
jar containing a magnetic stirrer. The jar was filled with wash buffer, stirred for 5
minutes at RT and then the wash buffer removed. The slides was then place face up
across the two parallel plastic tubes within a damp box. The damp box comprised of
a foil rapped plastic box containing 2 parallel plastic tubes of equal height attached
to the bottom, surrounded by two pieces of damp cotton wool.
Two methods for staining for MHV-68 antigen expression was used. The first used
rabbit anti-MHV-68 hyper immune sera as the primary detection antibody. To each
cytosmear containing well, 50j.il of normal swine blocking serum, (diluted 1/10) was
added. With both methods the blocking serum used was the normal serum of the
species from which the secondary antibody was derived and the different anti-bodies
diluted with wash buffer. The lid was placed on the damp box and the cells were
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incubated at 37°C for 30 minutes. The normal swine serum was removed and
replaced with 50pl of rabbit anti-MHV-68 hyper immune serum (diluted 1/1000).
The cells were then incubated, as before, for 30 minutes at 37°C. The primary
antibody was then removed and the slides washed three times with wash buffer. The
slide then had 50pl FITC-conjugated swine anti-rabbit serum (diluted 1/1000) added
and the slides incubated as before. The secondary antibody was then removed and
the slides washed a further three times.
The second of the 2 methods, used sera from long-term MHV-68 infected mice as
the primary detection antibody. To each cytosmear containing well, 50pi of normal
sheep blocking serum (diluted 1/10) was added. The lid was placed on the damp box
and the cells were incubated at 37°C for 30 minutes. The normal sheep serum was
removed and replaced with 50pl of sera from long-term infected mice, (diluted
1/50). The cells were then incubated, as before, for 30 minutes at 37°C. The
primary antibody was then removed and the slides washed three times with wash
buffer. The slide then had 50pl of biotin conjugated sheep anti-mouse (diluted
1/1000).added and the slides incubated as before. The secondary antibody was then
removed and the slides washed a further three times and 50pl of streptavidin FITC
(diluted 1/1000). The were then slides incubated as before, the streptavidin FITC
removed and washed a further three times. The slides containing antibody bound
cytosmears were mounted using aqueous mountant and a cover-slip. The cover-slip
was sealed to the slide using nail-varnish and observed using a UV microscope.
2.3.8 FACS analysis of splenocytes
Reagents
1% formyl saline - 10% formyl-saline solution diluted 1/10 (V/V) with sterile PBS.
FACS buffer - Cytosmear wash buffer (see section 2.3.8) with 0.02% (W/V) sodium
azide in PBS (all antibody working stocks were diluted in FACS buffer).
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Procedure
FACS analysis of splenic lymphocytes was carried out (in accordance with Ehtisham
et al, 1993) using splenocytes preparations, as previously described. lxlO6 cells
were added to a FACS tube and the cells pelleted at 1400 RPM for 3 minutes in a
Beckman TJ-6 centrifuge, set to 4°C. The cells were resuspended by external
agitation, 50pl of primary antibody added and the tubes incubated for 20 minutes on
ice. T-cells were stained with rat anti-mouse CD4 (1/1000) and rat anti-mouse CD8
(1/1000) monoclonal antibodies. B-cell were stained for using either FITC-
conjugated anti-mouse CD45R (1/500) or biotin conjugated sheep anti-mouse IgM
antibodies (1/200). The cells were then pelleted by centrifugation and the
supernatants removed by aspiration. Each tube then underwent 3 washes with cold
FACS buffer. Each wash consisted of adding 200pl of cold FACS buffer to a
resuspended cell pellet and then repelleting the cells by centrifugation. 5Op] of
secondary antibody was then add and incubated on ice, for 20 minutes. The
secondary antibodies for the anti-CD4 and anti-CD8 monoclonal antibodies was Star
49 (1/1000) and the secondary antibody for the anti-IgM was streptavidin labelled
FITC (1/1000). The cells were then peletted by centrifugation, the supernatant
removed and washed a further 3 times. The cells were finally fixed using 1%
formyl-saline. The cells were counted using a FACStar (Becton Dickinson) FACS
scanner.
2.3.9 MHV-68 Enzyme-Linked Immunosorbent Assay (ELISA).
Reagents
Borate buffered saline (BBS) - Boric acid (Sigma) 61.85g, disodium tetraborate
(Sigma) 95.4g and NaCl (Sigma) 43.85g, made up to 10 litres with distilled water
(pH 8.2).
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BBS/Tween 20 - Tween 20 (Sigma) was added to BBS to make final concentration
of 0.05% (V/V).
Carbonate/bicarbonate buffer (pH 9.8) - 22ml of sodium carbonate solution (0.2M)
added to 28ml sodium bicarbonate solution (0.2M).
Citrate phosphate buffer (pH 5.0) - 0.1M citric acid (Sigma) solution was added to
0.2M disodium orthophosphate (Sigma) solution until pH reaches 5.0.
HRP substrate solution - 0.4ml O-phenylenediamine dihydrochloride (OPD) stock
solution and 25pl of hydrogen peroxide solution (20 volumes) was added to 25ml
citrate phosphate buffer (pH 5.0).
OPD stock solution - OPD lg dissolved in 40ml of citrate phosphate buffer (pH 5.0).
Store as frozen 0.4ml aliquots.
PBS/Tween 20 - Tween 20 (Sigma) was added to PBS to make final concentration of
0.05% (V/V).
Protocol
The mouse MHV-68 sera conversion ELISA was carried out (in accordance with
Usherwood et al, 1996) on mouse sera diluted 1/20. To each well of an Immulon 4
plate (Dynatech), 100pi of Rabbit A anti-MHV-68 hyper-immune sera diluted
1/1000 in carbonate/bicarbonate buffer (pH 9.8), was added and incubated over night
at 4°C. The wells were then blocked for 1 hour at 37°C with lOOpl of 2% (V/V)
normal rabbit serum, diluted in BBS/Tween 20. The plates were then washed 6
times with BBS/Tween 20, lOOpl per well. MHV-68 stock (3.8xl08 pfu/ml) was UV
irradiated for 30 minutes. The irradiated MHV-68 was diluted 1/64 in PBS and then
added to the plate (lOOpl per well) and incubated for 1 hour at 37°C. The plates were
then washed 6 times with BBS/Tween 20 (100pi per well). 200pl of the test and
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control sera, diluted in 1% normal rabbit sera in PBS/Tween 20, was added to each
well and incubated over night at 37°C. The test mouse sera samples were diluted
1/20. Hyper-immune mouse sera, diluted 1/400, was used as a positive control and
pre-bleed mouse sera, diluted 1/20, were used as negative controls. The plates were
then washed 6 times with BBS/Tween 20 (lOOpl per well). lOOpl of HRP
conjugated rabbit anti-mouse (diluted 1/2000 in 1% normal rabbit serum dissolved in
BBS/Tween 20) was then added to each well and incubated for 1 hour at 37°C. . The
plates were then washed 6 times with BBS/Tween 20 (100pl per well). lOOpl of
HRP substrate solution was then added to each well and incubated at room
temperature. After 15 minutes the reaction was stopped with lOOpl of 12.5% (V/V)
sulphuric acid. The sample OD value was taken at 490nm using an ELISA plate
reader (DYNATECH MR5000).
2.4.1 DMA extraction and purification
OlAamp tissue kits (Qiagen) reagents (50 preparations)
AL buffer - Add the contents of reagent AL1 (Qiagen) to the reagent AL2 (Qiagen)
solution and mix thoroughly by shaking. The buffer was store at RT in the dark.
ATL buffer (Qiagen) - Stored at RT.
AW solution - 40ml of 99.7-100% Ethanol (BDH) was added to the AW stock bottle,
mixed by shaking and then stored at RT.
Proteinase K stock - 1.4ml of distilled water was added to the lyophilised proteinase
K (Qiagen) powder and stored at -20°C in lOOpl aliquots.
Protocol
DNA extraction from both tissues and in vitro cell lines was achieved using QIAamp
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tissue kits (Qiagen) in accordance with the manufactures instructions.
Approximately 5xl06 cells, 25mg of tissue or 80pl of tissue homogenate was placed
in a 1.5ml microfuge tube and made up to 1 80li1 with ATL buffer. 20pl of
proteinase K stock solution was added to each tube and incubated at 55°C, vortexing
frequently, until sample was completely digested. 200pl of AL buffer was then
added, the tubes vortexed and then incubated for 10 minutes at 70°C. 21 Ogil of 99.7-
100% ethanol (BDH) was then added and the tubes and vortexed. A QIAamp spin
columns were placed in 2ml collection tube and the cell / tissue lysates pipetted into
the columns. The columns were centrifuged in a Micro centaur (MSE) microfuge at
7500 RPM for one minute. The columns were placed in fresh collection tubes and
500pl of AW buffer added to each column. The columns were re-centrifuged as
before for one minute and place in a fresh collection tube. A further 500pl of AW
buffer was added to each column and the columns were centrifuged as before for 3
minutes. lOOpl of distilled water pre-heated to 70°C was added to each tube,
incubated for 1 minute and then centrifuged as before for 1 minute into a 1.5ml
eppendorf.
2.4.2 DNA quantification
Reagents (Hoefer Pharmacia Biotech Inc.)
Hoechst (H) 33258 stock - 10ml of SDW was added to lOmg H 33258 powder to
make a lmg/ml stock solution. The solution was stored in the dark at 4°C.
Tris normal saline EDTA (TNE) buffer (10X) stock solution - lOOmM Tris (Sigma),
lOmM EDTA and 2M NaCl made up in distilled water and adjusted to pH 7.4 using
10M Hydrochloric acid (HC1). The solution was then autoclaved and stored at RT.
Solution A - 10ml of TNE (10X) and 10p.l ofH33258 was added to 90 ml SDW and
stored in the dark at 4°C.
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Standardising DNA stock - lOOpl calf thymus DNA (lmg/ml) standard was mixed
with lOOjul of TNE (10X) and 800jo.l of SDW. The resultant DNA solution
(lOOjag/ml) was stored at 4°C.
Protocol
DNA samples were quantified using a DyNA Quant 200 Fluorometer (Hoefer
Pharmacia Biotech Inc.), in accordance with the manufacturer's instructions. 2ml of
Solution A and placed in a quartz cuvette and used to blank the fluorometer. 2jul of
Standardising DNA was added to the cuvette, mixed thoroughly and re-read to
calibrate. The unknown DNA samples were read in the same manner as with the
calibration of the apparatus.
2.4.3 MHV-68 detection by Polymerase Chain reaction
Tag DNA polymerase kit (Boehringer Mannheim Ltd).
Taq stock - Recombinant Taq DNA polymerase (5units/pl) in 20mM Tris-HCl (pH
8.0), O.lmM EDTA, ImM DTT and 50%(V/V) glycerol.
PCR buffer (10X) - 200mM Tris-HCl (pH 8.4) and 500mM KC1.
Magnesium solution - 50mM MgCl.
dNTP Set (Pharmacia Biotech) - 2'-Deoxyadenosine 5'-triphosphate (dATP)
lOOmM, 2'-Deoxycytidine 5'-triphosphate (dCTP) lOOmM, 2'-Deoxyguanosine 5'-
triphosphate (dGTP) lOOmM, and 2'-Deoxythymidine 5'-triphosphate (dTTP)
lOOmM.
Primers - PAG 1 and 2 were diluted 1/30 and PAG 11 and 12 diluted with 1/5, both























Figure 2.1 The nucleotide sequence ofORFM7 (BPRF1) that is amplified by the PCR
primers PAG 1 and 2 (red) and PAG 11 and 12 (blue). The arrows denote the
direction ofextension from the primers. The sequence is numberedfrom the upstream
BamHI site which is the boundary between the BamHI P2 and Nfragments according
to the map ofEfstathiou et al, 1990b. Thefigure was adaptedfrom Stuart et al, 1996.
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PAG1 - 5' GTA GGA TCC GTG AGA GTG TAC ACA AAG ACG C 3' (sense)
PAG2 - 5' GGA GAA TTC TCC TTT GGT TCA GC 3' (anti-sense)
PAG11-5' CAC CTC AGA ACC AAC TTC 3' (sense)
PAG12 - 5' GTA TCT GAT GTG TCA GCA G 3' (anti-sense)
2.4.4 First round PCR
The first round of PCR was carried out as previously described (Stewart et al, 1996).
The PCR cocktail mix was made up with 77pl Ultra pure de-ionised water (Sigma),
lOpl PCR buffer (Boehringer Mannheim), 3pi magnesium solution (Boehringer
Mannheim), lpl dNTP stock (Pharmacia Biotech) and lpl of both PAG1 and PAG2
(the volumes were multiplied up depending on the number of tubes taking part).
93pi was then added to each tube and 5pi of sample DNA (lOOng/pl 1) was added
and the samples put in the PCR machine (Hybaid OmniGene - with heated lid). The
Taq was added after a hot start. For the first cycle, the blocks were set, using tube
control, at 45°C for 1 minute to bring the tube contents up to temperature, then 95°C
for 5 minutes, to melt the DNA, and finally 1 minute at 56°C to allow primer
annealing. The temperature was held at 56°C while the Taq was added, 2pl diluted
1/5 with IX reaction buffer. The second cycle consisted of a 72°C elongation step,
for 1 minute, a 94°C re-melting step, for 1 minute and a 56°C re-annealing step for
one minute. This was repeated 40 times and then finally there was a 5 minute final
extension at 72°C.
2.4.5 Second round (nested) PCR
The second round of PCR was carried out as previously described (Usherwood et al,
1996). The PCR cocktail mix for the second round ofPCR was made up the same as
the first but lpl of PAG11 and PAG12 was added instead of PAG1 and PAG2. 5pi
of first round PCR product was added to 93pl of the second round cocktail mix in a
fresh 750pl eppendorf and placed in the PCR machine. For the first cycle, the blocks
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were set, using tube control, at 45°C for 1 minute to bring the tube contents up to
temperature, then 95°C for 5 minutes, to melt the DNA, and finally 1 minute at 49°C
to allow primer annealing. The temperature was held at 49°C while the Taq was
added, 2pi diluted 1/5 with IX reaction buffer. The second cycle consisted of a 72°C
elongation step, for 1 minute, a 94°C re-melting step, for 1 minute and a 49°C re-
annealing step for one minute. This was repeated 25 times and then finally there was
a 5 minute final extension at 72°C.
2.4.6 Visualising PCR products
Reagents
Agarose (Flowgen) - SeaKem LE agarose.
Ethidium bromide stock (Sigma)- 5mg/ml. Stored in the dark at 4°C.
Tris acetate EDTA (TAE) buffer (50X) - 24.2% (W/V) Tris base (Sigma), 5.71%
(V/V) concentrated acetic acid (Sigma) and 10% (V/V) 0.5M EDTA (pH 8.0).
Loading buffer (10X) - 15% (W/V) Ficoll type 400 and 0.25% bromophenol blue in
SDW.
1Kb ladder (GibCo BRL) - 200 to 1200 mg/ml in lOmM Tris-HCl (pH 7.5), 50mM
NaCLand O.lmMEDTA.
Protocol
PCR products were visualised by agarose gel electrophoresis. Gels were made by
adding 2% (W/V) agarose powder to distilled water containing 2% (V/V) TAE(50X).
The mixture was boiled in a microwave and swirled until the agarose was completely
melted and had gone into solution. The solution was then cooled in a 60°C water
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bath. The agarose solution was then poured in the assembled gel apparatus (GibCo
BRL Horizon™ and allowed to solidify for approximately 2 hours. TAE Buffer (IX)
was made by diluting the TAE stock solution 1/50 with distilled water and pour into
the gel apparatus so the gel was immersed. The PCR samples were mixed with
loading buffer (9:1 respectively) and loaded onto the gel. The gels were run at 60
volts (rate limiting step), using a power pack (Pharmacia LKB) for approximately 3
hours. The gels were then placed in a plastic container containing approximately
300ml of ethidium bromide solution (250ng/ml diluted in distilled water) and
incubated for 20 minutes on a shaker (set to low speed). The ethidium bromide was
then removed and replaced with 1 litre of distilled water and allowed to de-stain for
20 minutes on the shaker. The DNA was visualised using a UV transilluminator
(UVP Inc.) and an image analyser (Mitsubishi).
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Chapter 3: The inhibitory properties of 2'-deoxy-5-ethyi-|3-4'-thiouridine on
MHV-68 infection of in vitro cell lines.
3.1.1 Summary
The inhibitory properties of 2'-deoxy-5-ethyl-(3-4'-thiouridine (4'-s-EtdU) on the
replication ofMHV-68 was studied in a number of different in vitro cell lines. The
potency of 4'-s-EtdU was determined to be 35 ng/ml, by EC50 assay and was shown
to be over 10 fold more potent than ACV. 4'-s-EtdU treatment of persistently MHV-
68 infected NSO cells, effectively eliminated productive virus replication but failed
to significantly effect the number of latent virus infected cells in the culture. At
2p.g/ml, 4'-s-EtdU long-term treatment of persistently infected NSO cells suppressed
the reactivation of latent virus for up to 3 weeks after withdrawal. However, 4'-s-
EtdU treatment at 0.2pg/ml failed to have any long-term effects on viral reactivation
after withdrawal of 4'-s-EtdU. Interestingly, MHV-68 could not be eliminated from
cell lines which ordinarily support only lytic virus replication. 4'-s-EtdU treatment
protected MGC7 cells, a transformed glial cell line, from the cytolytic effects of
infection with MHV-68 and eliminated viral antigen expression. However, treatment
could not eliminate MHV-68 from the cells. BHK cells were less readily protected
from the cytotoxic effects ofMHV-68 infection by 4'-s-EtdU. Cultures infected at a
MOI of 4 or 0.4 pfu per cell were either not protected or only partially protected. 4'-
s-EtdU however did protect cultures infected at a MOI of 0.04 pfu per cell or less.
Long-term treatment of MGC7 cells and BHK cells lead to the spontaneous
generation of 4'-s-EtdU-resistant viruses. However, infected BHK cells gave rise to
4'-s-EtdU resistant virus variants over shorter periods of time than the MGC-7 cells.
Six 4'-s-EtdU resistant virus isolates were cloned from persistently infected MGC-7
cells and the 4'-s-EtdU resistance was found to be independent of ACV resistance.
No reduction in ACV sensitivity was observed in any of the six cloned 4'-s-EtdU
resistant isolates and therefore resistance was unlikely to be due to the functional




There are a great number of compounds and reagents that have anti-viral properties,
both in vitro and in vivo. They act either on the target cells, (i.e. interferon) or
directly on the virus, by disrupting replication at different stages of the infectious
cycle. Anti-viral reagents have been generated to disrupt cellular attachment (i.e.
antibodies), fusion/uncoating (i.e. antibodies and amantadine), viral DNA and RNA
polymerase activity (i.e. pyrophosphate analogues and non-nucleoside reverse
transcriptase inhibitors) and post translational modification (i.e. viral protease and
glycosylation inhibitors). However, the most effective inhibitors of herpesvirus
replication are the nucleoside analogues (for general reviews, see Hirsch et al, 1990
and Bean 1992). Nucleoside analogues are generally good at combating lytic viral
infections but appear ineffective at controlling latent virus infections, either in vivo
(Field et al, 1979, Yao et al, 1989 & Sunil-Chandra et al, 1994c) or in vitro (Lin et
al, 1985, Lin et al, 1991 & Sunil-Chandra et al, 1993). As with all anti-viral
therapies, there are a number of disadvantages with nucleoside analogue treatments.
The two main disadvantages are toxicity and restricted virus range. All nucleoside
analogues, with perhaps the exception of ACV, tend to be toxic and therefore have
narrow therapeutic windows. They also tend to be effective at inhibiting only a
narrow range of different viruses. Nucleoside analogues that are effective on a large
range of viruses tend to have high toxicity. Other problems associated with
nucleoside analogues arise through their mode of action. Nucleosides once
phosphorylated become 'activated'. In this active form, they become recognised by
viral nucleic acid polymerases, in preference to cellular DNA polymerases, and get
incorporated into replicating viral genomes. This interferes with replication,
generally during elongation, either by inducing chain termination or by less well
defined mechanisms. Because cellular DNA polymerases can also incorporate
activated nucleoside analogues and because there is always, with the exception of
ACV, a certain amount of "read through", this can induce mutations which have
110
potential carcinogenicity or embryo toxicity in the patients.
3.1.3 Virus activated anti-virals
Nucleoside analogues can be split into 2 groups, those that are preferentially
phosphorylated by viral kinases and those that are phosphorylated by cellular
kinases. However, all anti-viral nucleoside analogues are believed to work in a
similar manner. The nucleoside analogue, once phosphorylated at the 5' position,
mimics one of the 4 naturally occurring dNTPs and is incorporated into replicating
viral genomic DNA (or RNA). The effect of incorporation brings about a premature
termination of DNA (or RNA) polymerisation. This occurs either by direct
termination of elongation or by inducing structural aberrations in the expanding
duplex and so destabilising the viral polymerase complex.
Examples of nucleoside analogues which appear exclusively phosphorylated by viral
TK are ACV (9-[2 hydroxy ethoxymethyl guanine]), 9-(4-hydroxyl-3-hydroxy
methylbut-l-Y) Guanine, termed penciclovir (PCV), (E)-5-(2-bromovinyl)-2'-deoxy-
uridine (BVdU), and l-p-D-arabinofuranosyl-(E)-5-(2-bromovinyl) uracil (BVaraU).
As previously described, viral TK is encoded by a partially conserved gene found
throughout the alpha and gammaherpesviruses (see Table 1.3). ACV is an acyclic
guanosine analogue, which contains a positional equivalent of a 5' hyroxyl group but
not a positional equivalent to the 3' carbon. ACV will not therefore act as a
substrate for 5' phosphorylation, by cellular TK. However, due to the promiscuous
nature of the enzymes encoded by herpesviruses for nucleotide metabolism, ACV
will act as a substrate for the TK homologue encoded by many herpesviruses. ACV
is phosphorylated efficiently by alphaherpesviruses, such as HSV-1, HSV-2 and VZV
but less efficiently by gammaherpesviruses, such as EBV and HVS (Boon et al,
1997). ACV will inhibit the productive replication of EBV but not HVS.
Betaherpesviruses, such as HCMV, do not code for a TK homologue and so fail to
significantly activate ACV above background levels.
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PCV is chemically similar to ACV, though unlike ACV, PCV does have a positional
equivalent of a 3' hydroxyl group. The 3' hydroxyl group allows 'read through' to
occur after incorporation into elongating DNA and so making PCV a non-obligate
chain terminator. Despite this, the anti-viral activity associated with PCV appears
due to incomplete synthesis ofDNA during elongation. In vitro PCV inhibits HSV I,
HSV II, VZV and EBV at similar concentrations as ACV (Ertl et al, 1995, Bacon
1995, 1996a & b). PCV is activated by HSV I TK more efficiently than AVC but
HSV I polymerase has a higher affinity for ACV triphosphate (TP) than PCV-TP
(Bacon et al, 1996b). PCV has intracellular half life of 10, 20 and 9 to 14 hours in
HSV I, HSDV II and VZV infected cells respectively. This compares to 0.7, 1 and
0.8 hours respectively for ACV, giving PCV the far superior intracellular half life
(Crumpacker et al, 1996 and Bacon et al, 1996b & c). Unlike ACV and PCV, BVdU
and BVaraU are both pyrimidine analogues and are both highly potent at inhibiting
VZV.
Other nucleotide analogues that are preferentially activated by viral kinases are 9-
[l,3-dihydroxy-2-propoxyl] methylguanine, known as ganciclovir (GCV), 5'-iodo-2'-
deoxyuridine (IDU) and triflurothymidine (TFT). GCV can be activated by both TK
and a second herpesvirus specific kinase, encoded by homologues of the HCMV
UL97 gene. The HCMV UL97 gene is a core herpesvirus gene {see Table 1.2)
making GCV a highly potent anti-viral, with a broad herpesvirus range. As well as
inhibiting the replication of HCMV, GCV is also able to inhibit HSV-1, HSV-2,
VZV and EBV. However, because GCV along with IDU and TFT can be in part
activated by cellular enzymes they have a greater toxicity than either ACV or PCV
(Thust et al, 1996 and Lalezari et al, 1996).
3.1.4 Non virus activated anti-virals
The second group of nucleoside analogues, rely on cellular kinases for activation.
Their specific anti-viral properties are due to the viral DNA (or RNA) polymerase
having a higher substrate affinity for the activated nucleoside analogue, than cellular
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DNA polymerases. In this way the anti-viral dose is set to be too low to be
recognised by host cell polymerase, but high enough to inhibit viral replication. In
general these nucleoside analogues will inhibit the replication of a broad range of
different viruses, including both DNA and RNA viruses, but are highly toxic. 9-b-D-
arabinofuranosyl adenine, known as vidarabine (ara A), has broad anti-herpesvirus
specificity, though shows reduced effects against EBV and CMV. As with other
analogues in this group, such as l-D-ribofuranosyl-l,2,4-triazole-3-carboxamide,
known as ribavirin, and 3[-azido-3'-deoxythymidine], known as zidovudine (AZT),
ara A has anti-viral activity against a number of RNA viruses. Ribavirin is used to
treat lassar fever and AZT to treat HIV infection. The requirement for virus
activation of an anti-viral can be a disadvantage. The anti-viral nucleotide analogue
cidofovir (HPMPC or GS 504) is an acyclic analogue of cytodine-monophosphate.
Cellular kinases convert HPMPC to the triphosphate form and so anti-viral activity
does not require viral TK. HPMPC has activity against alpha, beta and
gammaherpesviruses, including TK negative isolates, as well as papillomaviruses.
The cellular half life for HPHPC is also greatly in excess of normal nucleoside
analogues (Alrabiah et al, 1996 and Freeman et al, 1996).
3.1.5 2'-deoxy-5-ethyl-P-4'-thiouridine
2'-deoxy-5-ethyl-p-4'-thiouridine (4'-s-EtdU) is a new nucleoside analogue,
developed by GlaxoWellcome, as one of a large batch of different 5'-substituted 2'-
deoxy-4'-thiouridine analogues. Unlike ACV, PCV or GCV, which are acyclic
purine analogues, 4'-s-EtdU, as with BVdU and BVaraU, is a cyclic pyrimidine
analogue. Along with the addition of an ethyl group in the purine ring, 4'-s-EtdU also
has a sulphur atom substituted for the 4' oxygen in the deoxyribose chain (see figure
3.1.1). Substitution of the 4' oxygen atom reduces the susceptibility of 2'-
deoxynucleosides to degradation by nucleoside phophorylases. Although 4'-
thioribonucleosides have been shown to have anticancer properties, little is known
about their potential anti-viral effects (Secrist et al, 1991). A study into 4'- oxygen
substituted, thio-analogues has shown that the thio-analogue of BVdU (4'-s-BVdU)
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Figure 3.1.1
Figure 3.1.1 The structural formula of 2'-deoxy-5-ethyl-f3-4'-thiouridine (4's-EtdU).
4 '-s-EtdU is a cyclic pyrimidine nucleoside analogue with a sulphur atom substituted
for the 4' oxygen atom in the deoxyribose chain. Activation (5' phosphorylation) is
required for incorporation into elongating DNA, however the exact mechanism of
inhibition of viral replication is unclear, since 4'-s-EtdU is not an obligatory chain
terminator.
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remains highly active against HSV-1, HSV-2 and VZV. However, the 4'-thio
analogue of AZT (4'-s-AZT) is rendered inactive against HIV infection (Eltorgman
et al, 1992, Rahim et al, 1996 and Basnak et al, 1998).
4'-s-EtdU is specifically activated by herpesvirus TK, and appears to have a low
toxicity, both in vivo and in vitro. 4'-s-EtdU is activated, via phosphorylation of the
5' hydroxyl group and it has a greater combined over all potency against
alphaherpesviruses, such as HSV-1, HSV-2 and VZV, than either BVdU, ACV or
PCV (Rahim et al, 1996). 4'-s-EtdU appears to be active against a similar range of
viruses as is ACV and hence does not inhibit the replication of HCMV (see Table
3.1). Prior to this study the potency of 4'-s-EtdU against gammaherpesviruses, such
as MHV-68, had not been investigated. However a preliminary study had shown that
4'-s-EtdU is a potent inhibitor of MHV-68 productive replication both in vitro and in
vivo, and has a low toxicity in mice (Barnes et al, unpublished data). The precise
mechanism by which 4'-s-EtdU inhibits the productive replication of susceptible
herpesviruses is at present unclear, since in activated form, unlike ACV, it is not an
obligate chain terminator (GlaxoWellcome personal communication).
3.1.6 The effect of ACV on the productive replication of MHV-68 in vitro
MHV-68 will readily form plaques, due to lytic replication, in fibroblastoid and
epithelial in vitro cell lines. It is therefore possible to determine, by plaque reduction
(EC50) assays, the concentration of an anti-viral necessary to inhibit 50% of a fixed
number of viral pfu. Previous studies testing the potency of ACV at inhibiting the
lytic replication of MHV-68 have reported the EC50 of ACV to be 200ng/ml (Sunil-
Chandra et al, 1994). Since MHV-68 is sensitive to ACV it was considered likely
that MHV-68 would also be sensitive to 4'-s-EtdU.
3.1.7 The effect of ACV on the latent replication of MHV-68 in vitro
EBV does not readily form plaques in in vitro cell lines and hence it is not possible
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Table 3.1* The comparative inhibitory effect of 4'-s-EtdU as compared to 3
leading anti-herpesvirus drugs.
EC50a (pM)
Compound HSV-1 HSV-2 VZV HCMV
4'-s-EtdU 0.17-0.5 b 2-5 b 0.99 138
ACVcf 1.8 1.7 46.8 85
PCVdf 3.9 12.8 78.7 >100
BVdUe 1.4 10 <1 >100
* Table adaptedfrom Rahim et al, 1996.
Key: a The micromolar concentration of the drug required to inhibit viral plaque
formation by 50% over a 4 day period. The ECso assay for HSV-1 and HSV-2 were
carried out using Vero cells lines and for VZV and HCMV, MRC-5 cell lines. b
Concentration depending on the specific strain used. c Acyclovir. dPenciclovir. e (E)-
5-(2-bromovinyl)-2 '-deoxy-uridine. ' The mean EC50 concentration for a variety of
strains.
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to determine the potency of an anti-viral by performing EC50 assays. An alternative
to the EC50 assay is to super-infect RAJI cells with EBV in the presence of a test
anti-viral. RAJI cells are an EBV positive, BL derived, in vitro cell line. Super¬
infection of RAJI cells induces an abortive productive infection, elevating the viral
copy number from approximately 50 to between 300-600 viral genome copies per
cell. In the presence of an effective EBV replication inhibitor, the copy number
decreases to approximately 30 copies per cell. The rate at which this occurs and the
converse after withdrawal of treatment, denotes the potency of the anti-viral. This
method has been used to compare different anti-herpesvirus nucleoside analogues,
including BvdU and ACV (Lin et al, 1984, 1985 & 1991 and Vanderhorst et al,
1987).
A similar, if not directly parallel, in vitro model has been established with MHV-68,
in the form ofMHV-68 infected B-cell myoloma derived, in vitro cell lines, such as
NS0 cells. MHV-68 will persistently infect NS0 cells, giving rise to a chronically
infected population, that persistently shed virus, as well as appearing to establish
latency. Persistently infected lines contain both circular as well as linear viral
genomic DNA, as determined by Gardella gel. After 2 weeks of culturing in the
presence of 25 pg/ml of ACV, the linear genome cell content was greatly reduced,
but the circular content was not. ACV was shown to eliminate productive virus from
the cultures, but not latent, measured by infectious virus and co-cultivation assay,
respectively (Sunil-Chandra et al, 1993). Persistently infected NS0 cultures provides
a useful model for the study of the effects of an anti-viral on the dynamic state
between viral latency and productive replication, over variable periods of time. The
model also provides a system by which the relative concentration of an anti-viral,
necessaiy for the complete elimination of productive viral replication in a culture,
can be determined. This concentration tends to be greater than the minimal
concentration required to prevent plaque formation, the EC100 value, since limited
viral productive replication can potentially occur in the absence of plaque formation.
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3.1.8 Mixed glial clone 7 (MGC7)
Cell lines other than epithelial and fibroblastoid cell lines are also susceptible to lytic
infection by MHV-68. One such line is the in vitro transformed monoclonal glial
cell line MGC7. MGC7 were derived from mixed glial cell cultures derived from the
brains of 2 day old neonatal CBA mice. The glial cells were then infected with the
tsa 58.3 recombinant retrovirus (Jat et al, 1989), allowing the stable expression of a
temperature sensitive mutant of the SV40 large T antigen, in the infected cells. At
the permissive temperature, 33°C to 34°C, the large T antigen expression
transformed the cells allowing for the cloning out of 8 different lines. MGC7 are a
monoclonal cell line of astrocytic lineage, expressing the astrocyte markers A2B5
and GFAP, but not oligodendrocyte markers, such as glactocerebroside, MOG and
CNPase. The cells are a rapidly dividing, adherent cell line when cultured at 34°C




3.1.9 The inhibition of MHV-68 lytic replication in BHK cells
To determine the relative concentration of 4'-s-EtdU required to inhibit the lytic
replication ofMHV-68 in vitro, 4'-s-EtdU and ACV EC50 assays were carried out, in
parallel, on MHV-68 working stocks. The EC50 for ACV was found to be 450 ng/ml
(2pM) and for 4'-s-EtdU 35ng/ml (0.13|uM) (see figure 3.1.2). From this result not
only does 4'-s-EtdU inhibit the productive replication ofMHV-68 but does so at a 15
fold lower molar concentration than ACV. The minimum concentration of 4'-s-
EtdU required to prevent 100% plaque formation over a 4 day period was 200 ng/ml
(0.73pM).
3.2.1 The establishment of MHV-68 persistently infected NS0 cells
To further characterise the anti-viral effects of 4'-s-EtdU, a persistently infected NS0
cell line was established. NS0 cells were infected at a MOI of 4 and cultured for 3
passages, to dilute out any input infectious virus, before being frozen in liquid
nitrogen. NS0 cells were then retrieved from the N2(l) store and cultured for a
further 3 passages prior to being treated with 4'-s-EtdU. The culture was split into 3
sub-cultures. The first remained untreated, the second and third were cultured in
medium containing 0.2 jug/ml and 2 pg/ml 4'-s-EtdU respectively. These
concentrations were chosen because 0.2 jug/ml 4'-s-EtdU represented the IC10o
concentration, where as 2 jug/ml 4'-s-EtdU represented a biologically saturating dose.
The persistently infected NS0 cells were cultured for 6 weeks with their respective
doses of 4'-s-EtdU. After 3 weeks of culture the 4'-s-EtdU treatment was withdrawn
from a flask of each of the treated cultures and then cultured for a further 3 weeks in
the absence of 4'-s-EtdU. The cultures were passaged every 3 to 4 days and cells




Figure 3.1.2 A typical plaque reduction profile for MHV-68 against ACV (red) and 4
s-EtdU (blue), as determined by EC50 assay. The assay was performed in parallel, for
both ACV and 4'-s-EtdU. The dotted lines represent the 100%, 75%, 50% and 25%>
plaguing values, as determined by the mean number ofplaques observed in the absence
ofeitherACVor 4 '-s-EtdU.
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3.2.2 The inhibitory effects of 4'-s-EtdU on the productive replication ofMHV-
68 in persistently infected NSO cells
Treatment of infected cultures with 0.2 pg/ml 4'-s-EtdU did not completely
eliminate cell associated infectious virus, although a 1000 fold decrease in titre was
observed (see figure 3.2.1A). The amount of cell associated infectious virus
produced by the cultures steadily declined for the first 3 weeks of treatment then
levelled off at approximately 20 pfu per 2.5xl06 cells, from 24 days post treatment.
On withdrawal of the 4'-s-EtdU treatment, the cell associated infectious virus titres
remained constant for the first week, then gradually increased, reaching the original
pre-treatment level by 18 to 22 days post withdrawal.
Treatment of the infected cultures with 2 pg/ml 4'-s-EtdU completely eliminated
productive virus replication, as determined by both infectious virus assay (see figure
3.2. IB) and by immunostaining for late viral antigens (see figure 3.2.2). After 7 days
of treatment, the cell associated infectious virus titre was reduced to 25 pfu per
2.5xl06 cells. After 14 days of treatment the cell associated infectious virus titres
became undetectable and remained undetectable for the duration of treatment. After
withdrawal of the 4'-s-EtdU medium supplement, a low level of cell associated
infectious virus was detected in the cultures. However, the titres remained low (160
+/- 48 pfu per 2.5xl06 cells) and did not return to the original pre-treatment level.
This compares with the mean infectious virus titre for the untreated culture of
2.2xl04 (+/- 4.8xl03) pfu per 2.5xl06 cells, over the entire time course.
Despite being cultured with 4'-s-EtdU for over 3 months, no evidence for the
spontaneous generation of 4'-s-EtdU resistant virus variants was found in the
persistently infected cultures. EC50 assays were carried out on virus preparations,
generated from cells that were continuously cultured with 4'-s-EtdU at both 0.2 and
2pg/ml, for 47 days. These were compared with both the virus preparation generated
from untreated NSO cells and the original virus working stock, used to establish the
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Figure 3.2.1 The levels of productive virus replication that occurred in persistently
infected NSO cultures which had been cultured in the presence of 4'-s-EtdU at 0.2pg/ml
(A) and 2pg/ml (B). The persistently infected NSO cells were either left untreated,
continually treated with 4 '-s-EtdU (bluej or withdrawn from 4 '-s-EtdU after 21 days oj




Figure 3.2.2 The abundance ofviral antigen in NSO cultures, persistently infectedMHV-68,
after 4 '-s-EtdU treatment, as determined by immunoflorescent antibody staining. The cells
were fixed onto bio-bonded slides and then stained with rabbit anti-MHV-68 hyper-immune
sera and pig anti-rabbit FITC. Persistently infected NSO cells were either treated with
2pg/ml 4'-s-EtdU 10 days (B) or left untreatedfor the same length of time (A). The cells
were viewed by light microscope, usingphase contrast (i) and by UV (ii). The viral antigen
positive cells show up as white or light grey patches by UV microscopy. The cells these




Figure 3.2.3 The plaque reduction profileforMHV-68 isolates derivedfrom persistently
infected NSO cells, as determined by EC50 assay. The isolates were derivedfrom either
untreated cultures (blue lines and open circles), cultures treated with 0.2 pg/ml 4'-s-
EtdUfor 47 days (green lines and open triangles), cultures treated with 2 pg/ml 4'-s-
EtdU for 47 days (red lines and open diamonds) or the wild type virus stock used
originally to generate the persistently infected NSO line (black lines and solid squares).
The dotted lines represent the 100%, 75%, 50% and 25% plaquing values, as
determined by the mean number ofplaques that occurred in the absence of4 '-s-EtdU.
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sensitivity to 4'-s-EtdU were observed between the different virus preparations.
3.2.3 The inhibitory effects of 4'-s-EtdU on viral persistence in MHV-68
infected NSO cells
Neither the higher or lower concentration of 4'-s-EtdU could eliminate the virus
from the NSO cultures. At every time point tested, virus could be reactivated from
cells by infectious centre assay (see figure 3.2.4). However, 4'-s-EtdU treatment of
the cultures did significantly reduce the ability of the virus, harboured in the infected
cells, to reactivate.
The mean infectious centre titre of the untreated cultures, over the entire experiment
was 1.55x10s (+/- 3.4xl04) infectious centres per 2.5xl06 NSO cells (On average,
6.2% of the untreated NSO cells gave rise to infectious centres). Treatment of the
persistently infected NSO cultures with 0.2 pg/ml 4'-s-EtdU reduced the number of
infectious centres over the entire time course (see figure 3.2.4A). The infectious
centre titre decreased 10 fold after 21 days of treatment and over 100 fold after 43
days (0.03% of 2pg/'ml 4'-s-EtdU treated NSO cells gave rise to infectious centres at
day 43). On withdrawal of the treatment after 21 days, the infectious centre titre
remained at a suppressed level for a week then gradually increased back to the
original pre-treatment level. Treatment of the NSO cultures with 2 pg/ml 4'-s-EtdU
likewise suppressed the ability of infected cells to reactivate (see figure 3.2.4B). The
infectious centre level decreased approximately 10 fold after 7 days of treatment and
1000 fold after 43 days of treatment (0.006% of 2pg/ml 4'-s-EtdU treated NSO cells
gave rise to infectious centres at day 43). After withdrawal of the 2pg/ml 4'-s-EtdU
treatment (at day 21) the infectious centre titre remained largely constant and did not
return to the pre-treatment titre. The average number of infectious centres observed
in the cultures withdrawn from the 2pg/ml 4'-s-EtdU treatment was 3300 (+/- 700)
per 2.5xl06 NSO cells (on average 0.13% of cells gave rise to infectious centres).
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Figure 3.2.4 The levels of virus positive cells, by infectious centre assay, that occurred
in persistently infected NSO cells cultured in the presence of 4'-s-Etd.U at 0.2pg/ml (A)
and 2pg/ml (B). Persistently infected NSO cells were either left untreated, continually
treated with 4'-s-EtdU (blue) or withdrawn from 4's-EtdU after 21 days of treatment
(red). The assay limit ofdetection was 25 infectious centres per 2.5x106 cells.
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was not due to a reduced number of cells harbouring viral DNA. There was no
significant difference in the proportion of virus positive NSO cells within the 2 pg/'ml
4'-s-EtdU treated culture (at day 21 post treatment) than from the untreated cultures
(taken at the same time point). Twenty clonal NSO cell lines were established from
the persistently infected NSO culture, treated with 2 pg/ml 4'-s-EtdU for 21 days. Of
these, 11 harboured viral DNA as determined by first round MHV-68 specific PCR.
PCR carried out on the 23 clonal NSO cell lines were derived from the parallel
untreated culture, revealed 15 to be virus DNA positive (see figure 3.2.5 and 3.2.6).
The decrease in the number of virus positive cell in the treated culture was not
significant (using the binomial probability distribution, P=0.23). To determine
whether viral DNA present in the clonal cell lines represented viable virus genomes,
6 monoclonal cell lines, all derived from the 4'-s-EtdU treated infected NSO culture,
were retrieved from N2(l) storage. The cell numbers were expanded over 3 passages
and then tested by infectious centre assay. The 2 clonal cell lines which were MHV-
68 PCR negative, 10D4 and 13D4, failed to produce infectious centres. The
remaining 4 clonal NSO cell lines, which were all MHV-68 specific PCR positive,
10E9, 11D6, 12E6 and 13E6, all gave rise to approximately 10 infectious centres per
106 cells (see Table 3.3).
3.2.4 Protection of MHV-68 infected MGC7 cells with 4'-s-EtdU
To determine the long-term effects of 4'-s-EtdU on the MHV-68 infection of cell
lines which normally only support lytic viral replication, two cell lines, MGC7 and
BHK, were chosen. MGC7 cells support relatively slow productive replication of
MHV-68, one pfu ofMHV-68 takes approximately 6 days to form a visible plaque in
a MGC7 monolayer. 4'-s-EtdU pre-treated MGC7 cultures were infected with
MHV-68 at a MOI of 1. Initial infection ofMGC7 cells, at high multiplicity, lead to
cytotoxicity in both the 4'-s-EtdU treated and untreated controls. However, the 4'-s-
EtdU treated cells recovered after 3 to 4 days and then assumed normal growth in the
4'-s-EtdU supplemented medium. The infected MGC7 cells treated with a 2pg/ml
4'-s-EtdU medium supplement, could be cultured for over of 2 months. However,
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Figure 3.2.5
Figure 3.2.5 The first round PCR products amplifiedfrom DNA, 250ng, extractedfrom
23 cloned NSO cell lines, derived from untreated, persistently MHV-68 infected NSO
cultures (gel A - lanes 5 to 16 and gel B - lanes 5 to 15). PCR was also carried out on
250 ng ofDNA extracted from persistently MHV-68 infected (lane 3) and uninfected
(lane 4) polyclonal NSO cultures and distilled water (lane 2) as PCR positive, negative
and blank controls, respectively. The Products were visualised using 2% agarose gel
electrophoresis (and ethidium bromide staining) and their size determined by
comparison to 1 Kb ladder (lane 1). MHV-68 specific PCR bands, at 500 bp, is
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Figure 3.2.6 The first round PCR products amplifiedfrom 250ng DNA extractedfrom
the 20 cloned NSO cell lines, derived from persistently MHV-68 infected NSO cell
cultures after 21 days of 4 '-s-EtdU (2 p g/ml) treatment (lanes 5 to 14 for both gels A
and B). PCR was also carried out on 250 ng ofDNA extractedfrom persistently MHV-
68 infected (lane 3) and uninfected (lane 4) polyclonal NSO cultures and distilled water
(lane 2) as PCR positive, negative and blank controls, respectively. The products were
visualised using 2% agarose gel electrophoresis (and ethidium bromide staining) and
their size determined by comparison to 1 Kb ladder (lane 1). MHV-68 specific PCR
bands, at 500 bp, is indicated with black arrows. See table 3.2 for a description of
each lane.
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Table 3.2 The different cloned NSO cell lines derived from 4'-s-EtdU treated
and untreated MHV-68 infected cultures that underwent the PCR
analysis shown in Figures 3.2.5 and 3.2.6.
Lane
Number
Figure 3.2.5 Figure 3.2.6
Gel A Gel B Gel A Gel B
1 1 KB Ladder 1 KB Ladder 1 KB Ladder 1 KB Ladder
2 Blank Blank Blank Blank
3 NSO (+) NSO (+) NSO (+) NSO (+)
4 NSO (-) NSO (-) NSO (-) NSO (-)
5 1E4 2B11 10D4 12E7
6 1D2 3C11 10E7 12E5
7 1E2 3H3 10F6 12E6
8 1D5 3A6 10E9 12D7
9 1E5 3D7 11F4 13D8
10 1G5 3H10 11E6 13D4
11 1G8 3B11 11E5 13E6
12 2F1 4G5 11D6 13D8
13 2G5 4D7 11E7 13C9
14 2G7 4A12 11E8 13E9
15 3C3 4D12 - -
16 2C11 - - -
Key: The 'blank' controls contained no Target DNA. The NSO (+) and (-) controls
refer to PCR carried out on 250 ng of DNA extracted from MHV-68 persistently
infected and uninfected NSO cultures, respectively. The different cloned NSO lines
were named according to the individual well of the 96 well plate they originally
grew in. The first digit refers to the plate number. The 96 well plates used to clone
the NSO cells derived from untreated persistently infected NSO cells were numbered
1 to 4 and those used to clone the 21 day 2/j.g/ml 4 '-s-EtdU treated cultures were
labelled 10 to 13. The rows of each 96 well plate were labelled A to H and the
columns 1 to 12. Lanes 5 onwards refer to PCR carried out on 250 ng of DNA




















Figure 3.2.7 The possible proportions ofvirus positive cells that could theoretically be
present within the cell populations ofpersistently MHV-68 infected NSO cultures, at
their relative probability ofoccurrence. The NSO cells were either left untreated (red)
and treated with 4'-s-EtdU (2pg/ml) for 21 days (Blue). The relative probabilities were
determined using the binomial theorem, based on the number of cloned NSO cell lines
that were virus positive byfirst round, 40 cycle PCR.
—
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Table 3.3 The relative number of infectious centres produced by different
monoclonal cell lines (derived from persistently infected NSO cultures
that had been treated with 4'-s-EtdU at 2jag/ml for 21 days).
The number of infectious centres per petri-dish containing
106 cells 105 Ceiis 10-* cells 103 cells 102 cells 101 cells
NSO(+) « >100 >100 >100 57 5 0
NSO(-) b 0 0 0 0 0 0
10E9 c 9 1 0 0 0 0
11D6 c 12 1 0 0 0 0
12E6 c 11 1 0 0 0 0
13E6C 8 1 0 0 0 0
10D4 d 0 0 0 0 0 0
13D4 d 0 0 0 0 0 0
Key: a Untreated, persistently MHV-68 infected polyclonal NSO cell line. b
Uninfectedpolyclonal NSO cell line. c MHV-68 PGR positive monoclonal NSO cell
line. dMHV-68 PCR negative NSO cell line.
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the infected MGC7 cells treated with a 0.2pg/ml 4'-s-EtdU medium supplement died
after 2 to 3 weeks.
3.2.5 The effect of 4'-s-EtdU on viral persistence in MGC7 cells
MGC7 cells have a doubling time of under 24 hours. To determine whether the
input virus was diluted out in the apparent inhibition of productive virus replication,
a number of cloned cell lines were derived from an MHV-68 infected MGC7 culture
(MOI of 1). The parental culture was infected at an MOI of 1 and cultured in the
presence of 2pg/ml 4'-s-EtdU for 32 days. Cells from the culture were then cloned
by limiting dilution and cultured in the presents of 2pg/ml 4'-s-EtdU. After 2 weeks,
the cloned MGC7 cell outgrowths were withdrawn from the 4'-s-EtdU treatment and
cultured for a further 7 days with unsupplemented medium. The medium was then
tested for the presence of infectious virus by plaque assay. Of the 12 monoclonal
cultures tested, 4 (1/3) gave rise to MHV-68 pfu.
After 2 months, the 2pg/ml 4'-s-EtdU treatment was withdrawn from persistently
infected MGC7 cultures and productive replication allowed to reinitiate. The treated
cultures were virus antigen negative at the point of withdrawal, as determined by
fluorescent immunocytochemistry. The staining of the MGC-7 cells, was carried out
in parallel, using 2 different seras, rabbit anti-MHV-68 hyper-immune serum and late
time point (day 60 post infection) mouse scrum. Two days after the 4,-s-EtdU was
withdrawn, a small proportion of the MGC7 cells (3.5%) became viral antigen
positive. This increased to approximately 40% by 4 days and was over 95% by day
6. Up to day 6, the fluorescent signal observed in the stained cells was predominately
of low intensity. However, by day 8, the staining was predominately of high
intensity. All the cells were virus antigen positive by this time and the cells were
starting to form large clumps. All the cells were dead by day 10 (see figure 3.3.1).
No significant differences were observed using the 2 different sera.
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Figure 3.3.1
Figure 3.3.1 shows persistently MHV-68 infected MGC7 cells 0 days (A), 2 days (B), 4
days (C), 6 days (D), 8 days (E) and 10 days (F) after withdrawal of 2pg/ml 4'-s-EtdU
treatment. The cells were fixed onto bio-bonded slides and stained with rabbit anti-MHV-
68 hyper-immune serum and FITC conjugated swine anti-rabbit serum. The slides were
viewed under phase contrast light microscopy (i) and UV microscopy (ii). Cells positive
forproductive viral antigen appear fluorescent green by UVmicroscopy.
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3.2.6 The cloning and characterisation of 4'-s-EtdU resistant virus generated
spontaneously from 4'-s-EtdU treated, MHV-68 infected, MGC7 cells
Persistently infected MGC7 cultures, cultured for long periods of time (in excess of 2
months) spontaneously went into crisis. Culture medium from one such flask was
shown, by plaque assay to contain infectious virus that would form plaques in the
presence of 2pg/ml 4'-s-EtdU (data not shown). The 4'-s-EtdU resistant virus,
contained within the culture medium underwent three consecutive rounds of limiting
dilution plaque purification. This gave rise to 6 cloned 4'-s-EtdU resistant virus
isolates. The isolates were named MGC7 derived 4'-s-EtdU resistant virus (MERV)
34/22/41, 34/22/44, 43/62/67, 43/62/72, 43/68/89 and 43/68/92 (the numerical suffix
denotes the well numbers selected during the cloning). All six MERV clones were
unaffected, with respect to in vitro plaquing efficiency, by 4'-s-EtdU up to lOpg/ml.
However, all remained sensitive to the inhibitory effects of ACV (for plaque
reduction profiles see figure 3.3.2).
3.2.7 The effect of 4'-s-EtdU on the MHV-68 infection ofBHK cells
BHK cells support rapid productive viral replication. One pfu of MHV-68 takes
approximately 4 days to form a visible plaque (by light microscopy) in a BHK
monolayer. Infection of 4'-s-EtdU pre-treated BHK cells, at a MOI of 4, resulted in
all the cells in the culture dying. However, BHK cells could clearly be protected for
short periods of time (4 days) at low MOI, as demonstrated by EC50 assay (see figure
3.2). An experiment was therefore set up test the ability of 4'-s-EtdU, at 2pg/ml, to
protect BHK cultures infected at varied MOI. The 4'-s-EtdU treatment did not
protect the BHK cultures at 4 pfu per cell (see figure 3.4.1) and only partially
protected cultures at 0.4 pfu per cell (see figure 3.4.2). Surviving BHK cells,
infected at a 0.4 pfu per cell, underwent limited expansion, with respect to the
number of viable cells in the culture. However, the cultures did not fully recover,
with respect to both viability and growth rate. The 4'-s-EtdU treatment protected






Figure 3.3.2 The plaque reduction profiles for the 4'-s-EtdU resistant MHV-68 clones
MERV 34/22/41 (open diamonds with pink lines), 34/22/44 (open triangles with yellow
lines),43/62/67 (diagonal crosses with brown lines), 43/62/72 (asterisks with green
lines), 43/68/89 (open circles with red lines) and 43/68/92 (horizontal/vertical crosses
with blue lines) against both 4 '-s-EtdU (A) and ACV (B). These were compared with
wild type MHV-68 (solid squares with black lines). The assays were all done in parallel
and the percentage plaque values derived from the plaquing efficiency of untreated
controls. The dotted lines represent the 100%, 75%, 50% and 25% plaquing efficiency
values.
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3.4.5). BHK cells infected with 4x10~2 to 4xl0"6 pfu per cell and cultured with
2jug/ml 4'-s-EtdU, were indistinguishable from uninfected BHK cells, derived from
the same parental culture, with respect to both viability and growth rates (see figure
3.4.6). However, protection mediated by the 4'-s-EtdU treatment tended to be
transient, since spontaneous lytic replication of 4'-s-EtdU resistant virus generally
occurred after approximately 12 days, except for the cultures infected at 4x10~5 to
4xl0"6 pfu per cell. Virus resistant to 4'-s-EtdU first became detectable by the
appearance of discrete plaques in an otherwise healthy monolayer. Over a period of
2 to 3 days the plaques spread though out the monolayer, resulting in the death of all
BHK cell present. MHV-68 was not lost from any of the infected cultures even
those infected with the lowest MOI. BHK cells infected at a MOI of 4x10"5 and
4X10"6 were withdrawn from treatment after 20 days of culture. Viral plaques
became detectable, by light microscopy, after 4 to 6 days, respectively and the
monolayers completely destroyed by 10 days {data not shown).
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Figure 3.4.1
Figure 3.4.1 The effects ofMHV-68 infection, MOl 4, on BHK cells, grown using
F.CTJO groM'th medium which was either left unsupplemcntcd (i) or supplemented with
4 '-s-EtdUat 2pg/ml (ii). The cells were initially seeded at 5x106 cells per T40 flask and
were passaged as and when required. The cultures were photographed in situ, on day 1




Figure 3.4.2 The effects ofMHV-68 infection, MOI of 0.4, on BHK cells, grown using
ECT10 growth medium which was either left unsupplemcnted (i) or supplemented with
4 '-s-EtdUat 2pg/ml (ii). The cells were initially seeded at 5x106 cells per T40 flask and
were passageas and when required. The cultures were photographed in situ, on day 1




Figure 3.4.3 The effects ofMHV-68 infection, MOI of 4x10 ~2 on BHK cells, grown
using ECT10 growth medium which was either left unsupplemented (i) or supplemented
with 4'-s-EtdU at 2pg/ml (ii). The cells were initially seeded at 5xl06 cells per T40
flask and were passageas and when required. The cultures were photographed in situ,




Figure 3.4.4 The effects ofMHV-68 infection, MOI of 4x10 ~3 on BHK cells, grown
using ECT10 growth medium which was either left unsupplemented (i) or supplemented
with 4'-s-EtdU at 2pg/ml (ii). The cells were initially seeded at 5x106 cells per T40
flask and were passageas and when required. The cultures were photographed in situ,




Figure 3.4.5 The effects ofMHV-68 infection, MOI of 4x10 ~4 on BHK cells, grown
using ECT10 growth medium which was either left unsupplemcnted (i) or supplemented
with 4'-s-EtdU at 2pg/ml (ii). The cells were initially seeded at 5xl06 cells per T40
flask and were passageas and when required. The cultures were photographed in situ,




Figure 3.4.6 Uninfected control BHK cells grown on ECT10 growth medium which was
either left unsupplemented (i) or supplemented with 4 '-s-EtdU at 2pg/ml (ii). The cells
were initially seeded at 5xl06 cells per T40 flask and were passageas and when
required. The cultures were photographed in situ, on day 1 (A), 3 (B), 5 (C) and 10 (D)
post mock infection, using a light microscope, under phase contrast (x20).
Discussion
3.2.8 The effectiveness of 4'-s-EtdU as an inhibitor of MHV-68 in vitro.
In vitro, 4'-s-EtdU was shown to be at least 10 times more potent at inhibiting the
lytic replication of MHV-68 than ACV, in BHK cells. The EC50 of 4'-s-EtdU was
evaluated to be 35 ng/ml, which is equivalent to a 0.13 pM solution. This compares
to ACV, which had an EC50, under parallel conditions, of 450ng/ml (2pM). The
ACV value is higher than has been previously reported (Sunil-chandra, et al, 1993)
but is within 1 order of magnitude. A possible explanation for the difference
between the two EC50 values is that with the study carried out by Sunil-Chandra, the
EC50 assays were carry out using ACV kept in suspension. In this study, the anti-
virals were dissolved, by heating to 60°C, and then filter-sterilised, prior to use.
Although this may account for the difference between the 2 different ACV EC50
values, it is unlikely to have affected the relative difference in potency between ACV
and 4'-s-EtdU, since both were tested and treated in exactly the same manner.
3.2.9 Viral persistence in NSO cells
MHV-68 is B-cell tropic and establishes latency in these cells. NSO cells are a
transformed myeloid cell of B-cell origin. The persistent infection established by
MHV-68 in NSO cells is believed to be an in vitro model for viral latency coupled
with spontaneous reactivation. The evidence for the establishment of viral latency
comes from the fact that the cultures contain episomal DNA as detected by Gardella
gel electrophoresis. Virus can be reactivated from the cells be co-cultivation assay,
despite the majority of the cells being virus antigen negative, as detected by
polyclonal anti-MHV-68 hyper-immune serum (Sunil-Chandra et al, 1993). By
studying the effects of anti-virals on infected cell lines which supports both latent as
well as limited productive viral replication, it is possible to gain insights into how
long-term treatment can affect viral persistence and the balance between viral
latency and reactivation.
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Previous studies have shown that after the initial infection of NSO cells, high tires of
cell free virus are present in the culture medium for the first 2 to 3 days post
infection. The cell free virus titres then decrease to below the cell associated vims
levels, which remained largely constant (Sunil-Chandra et al, 1993). So as to allow
the persistently infected NSO cells to achieve equilibrium, with respect to virus load
and reactivation levels, 4'-s-EtdU treatment did not start at day 0 post infection.
Instead the MHV-68 infected NSO cells were passage 3 times, frozen in liquid
nitrogen, retrieved and then passaged a further 3 time prior to treatment initiation.
Thr.ough out the experimental time-course, the non-4'-s-EtdU treated MHV-68
infected cultures remained largely constant with respect to numbers of cells
undergoing reactivation, as determined by both co-cultivation and infectious virus.
The levels of cell associated infectious virus present within the culture at any one
instant, was generally at least 10 times less, than the amount of infectious centres
that could be generated by 5 day co-cultivation assay. The levels of infectious virus
present in the NSO cultures ranged from 1 - 2 xlO4 pfu per 106 cells and the numbers
of cells virus antigen positive by immunocytochemistry rarely exceeded 2%. These
results are indicative of a persistently infected culture undergoing a low level of
continual, but constant, virus reactivation.
3.3.1 The effects of 4'-s-EtdU on productive virus replication in NSO cells
Treatment of the persistently infected NSO cell cultures with 2jug/ml 4'-s-EtdU,
readily eliminated productive viral replication and late gene expression, from the
cells. By 14 days post treatment, no infectious vims could be detected by direct
plaque assay and no virus antigen could be detected by immunocytochemistry.
However, 4'-s-EtdU treatment did not eliminate the vims from the cultures, since
vims could always be reactivated from cells by co-cultivation assay. This is largely
consistent with the findings from a previous study, determining the effects of ACV
treatment on persistently infected NSO cells (Sunil-Chandra et al, 1993). Treatment
of persistently infected NSO cells with ACV at 25jug/ml, resulted in the elimination
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of detectable infectious virus from the cells, by day 32 post treatment. The ACV
treatment also failed to eliminate latent virus from the culture since infectious
centres remained detectable. After 10 days of treatment the level of linear viral
genome harboured within the cells was significantly reduced, as determined by
Gardella gel electrophoresis, in line with the decrease in productive virus replication,
as determined by infectious virus assay. The Gardella gel electrophoresis also
showed the level of episomal DNA contained within the cells was only minimally
decreased by treatment (Sunil-Chandra, et al, 1993). The relative potency of ACV,
as compared to 4'-s-EtdU, in the elimination of infectious virus from the persistently
infected NSO cultures, is in agreement with the differences in potency observed by
EC50 assay. ACV at 25 pg/ml, took longer to eliminate the productive MHV-68
replication occurring in the NSO cultures than 4'-s-EtdU at over a 10 times lower
concentration.
Further key differences exist between the reported effects of ACV treatment of
infected NSO cells and the effects of 4'-s-EtdU, reported in the study. The ACV
treatment failed to eliminate virus antigen expression, as determined by
immunohistochemistry. Where as 4'-s-EtdU treatment at 2pg/ml eliminated virus
antigen expression from both weekly and strongly staining infected cell populations.
This is again indicative of the greater potency of 4'-s-EtdU in the inhibition ofMHV-
68. Although a FITC conjugated secondary antibody was used in this study, instead
of a horseradish peroxidase based detection system, the primary antibody was the
same for both studies. Therefore the detection levels for both immunostaining
approaches should have been similar.
The overall pattern, with respect to productive virus replication and latency
reactivation, was similar with both 0.2jug/ml and 2pg/ml 4'-s-EtdU treatments of
persistently infected NSO cells. Both concentrations of 4'-s-EtdU reduced the levels
of cell associated infectious virus, present within the cultures. Further more, on
withdrawal, after 21 days, the levels of productive virus replication in the cell
cultures, once more increased. Although treatment of the cultures with 0.2pg/ml 4'-
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s-EtdU reduce the levels of cell associated infectious virus 1000 fold, unlike the 4'-s-
EtdU treatment at 2p.g/ml, it failed to eliminate all productive virus replication. By
EC50 assay, 0.2pg/ml 4'-s-EtdU was sufficient to prevent MHV-68 forming plaques
in BHK cells. However, the concentration was clearly insufficient to inhibit the
productive replication ofMHV-68 entirely.
3.3.2 The effect of 4'-s-EtdU on viral reactivation from persistently infected
NSO cells
At both concentrations of 4'-s-EtdU, there was a suppression of the ability of latently
infected cells to reactivate, as determined by infectious centre assay. The
suppression was more marked with the higher dose of 4'-s-EtdU but remained
significant with the lower dose. The apparent suppressed latency phenotype was not
due to the carry over of 4'-s-EtdU into the infectious centre assay, since it was a
phenotype that was acquired gradually over a period of weeks. The suppression was
only partial since neither treatment dose could entirely eliminate cells capable of
reactivation.
In part, the suppressed latency phenotype could be due to inhibition of productive
virus replication prior to the infectious centre assay taking place. Immunostaining of
the persistently infected NSO cells revealed 2% of the cells to be virus antigen
positive. Cloning the cells revealed approximately 65% of the total cells contained
viral DNA, as determined by PCR. On the assumption that all viral DNA containing
cells harbour viable virus genomes, (an assumption based on the fact that virus could
be reactivated from all the PCR positive NSO clones tested) only a small proportion,
approximately 3%, of the virus infected cells expressed detectable levels of virus
antigen. It is therefore not unreasonable to assume that the rabbit anti-MHV-68
hyper-immune serum, could not pick up latently infected cells. Of the 2% of cells
that did stain, approximately 30% stained brightly and hence probably contained
cell-associated infectious virus. The remaining cells, approximately 70%, of the 2%
that stained, stained only weakly. These cells may not have contained viable
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progeny but were clearly already in the process of reactivation. This would mean
between 30 to 40% of the cells that would have given rise to an infectious centre by
co-cultivation assay, would have already started to reactivate prior to the assay being
performed. It is therefore reasonable to assume that inhibition or reduction of
productive replication prior to the assay being performed, would reduce the number
of resultant infectious centres by up to 40%.
Reduction or elimination of productive virus replication within the NSO cell cultures,
even if the virus pfu were spread optimally though out the culture, could only
account for a small proportion of the decrease in infectious centre titre. This is due
to the total infectious virus titre always being a fraction of the total infectious
centres, observed per culture. There were also fundamental differences in the
dynamics of the rates of decrease, seen in the infectious virus and infectious centre
titres. This was particularly apparent with the infected NSO cell cultures treated with
2ug/ml 4'-s-EtdU. The cell associated infectious virus titre was virtually eliminated
after 7 days of treatment, and undetectable from day 14. In contrast, the infectious
centre titre decreased at a relatively constant rate, over the entire course of the
treatment.
A more likely explanation for the decreased levels of virus reactivation would be that
the infected cells with a transcriptional environment less suited for stable virus
latency, are selectively growth inhibited or killed in the presence of 4'-s-EtdU. This
could have been to the reactivation associated up regulation of viral TK which would
activates the 4'-s-EtdU present in the cell and inhibit cellular DNA synthesis. Virus
reactivation is a sporadic event that occurs in only a small proportion of infected
NSO cells, at any one time. The gradual depletion of the cells less capable of
harbouring 'tightly' latent virus, would probably go undetected by trypan blue
viability testing of the cell culture. This explanation fits well with the dynamics of
the suppression of virus reactivation, observed over the time course. The decrease in
infectious centres, followed the general pattern of exponential decay. This is
indicative of a large number of individual entities, all capable of under going a low
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probability spontaneous event. The event then results in the individual entity being
taken out of the system, as typified by the emission decay of radioactive isotopes.
The decrease in infectious centre titre observed with the 2jug/ml and 0.2pg/ml 4'-s-
EtdU treatments, corresponded to a half-life of approximately 4 and 6 days,
respectively. The difference between the 2 values was presumably due to the lower
concentration of 4'-s-EtdU having a decreased inhibitory effect on cellular DNA
synthesis.
3.3.3 The effect of 4'-s-EtdU on viral persistence and latency in NSO cells
The suppressed levels of virus reactivation, was not due to a reduction in the number
of cells infected with MHV-68. There was no significant difference in the number of
cloned cell lines that harboured virus DNA, generated from either the persistently
infected NSO cell cultures 21 days after treatment with 2]ag/ml 4'-s-EtdU, or the
untreated infected cell cultures, cloned at the same time. The proportion of clones
derived from the untreated culture, that were MHV-68 DNA PCR positive, was
higher (15/23) than with the treated culture (11/20). However, the ratios were
sufficiently similar, to give an acceptable probability (P = 0.23) that the difference
occurred though chance (i.e. getting only 11 positives from 20 randomly selected
individuals, each with an individual probability of 15/23 of being positive).
Since the exact proportion of virus positive cells in either the treated or untreated
cultures was unknown, it is possible, by application of the binomial theorem, to
determine the relative probability of achieving the PCR results for all possible ratios
of virus positive cells (see figure 3.2.7). The area of overlap between the two curves
accounts for approximately 60 to 70% of the total area under either of the two curves
and approximately 47% of the total combined area. The area under the curves
representing all possible proportions of cells harbouring virus, within the cultures as
a whole. This further confirms that the ratio of virus positive cells, within the treated
and untreated cultures, was unlikely to be of significant difference.
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Virus could reactivated from all 4 of the virus genome positive NSO clones derived
from the 2pg/ml 4'-s-EtdU treated cultures, that were retrieved from liquid nitrogen
storage, as determined by infectious centre assay. The frequency of infectious
centres for all 4 cells lines was approximately 1/105 cells. These results indicate that
the MHV-68 DNA harbouring cells, in the 4'-s-EtdU treated cultures, contained
viable virus genomes but spontaneous reactivation events occurred at a very low
efficiency. All the clones will have under gone over 20 rounds of cell division in the
absence of 4'-s-EtdU during the cloning process alone. Despite this, the number of
cell undergoing reactivation was lower than the average number from the parental
culture, which at the point of cloning was 1/103 cells. This implies that the cell lines
were derived from infected cells in the parental culture, which were not prone to
reactivation or 'tightly' latent. Therefore the implication is that it would be
impossible to completely eliminate cells capable of reactivation, since even cells
which are 'tightly' latent, will reactivate at a low level.
3.3.4 The effect of 4'-s-EtdT on viral persistence in NSO cells after treatment
withdrawal
On withdrawal of treatment after 21 days, there were marked differences between
the cultures treated with 0.2pg/ml 4'-s-EtdU and those treated with 2pg/ml 4'-s-
EtdU. The cell associated infectious virus titres in the cultures treated with 0.2 jug/ml
4'-s-EtdU, remained at the withdrawal level, between 100 to 200 pfu per 106 cells,
for the first week then slowly increased until reaching the original pre-treatment
level by 18 days post withdrawal. Likewise, the infectious centre titre slowly
increased reaching comparable levels to the pre-treatment cultures by approximately
2 weeks post withdrawal.
Neither the cell associated infectious virus titres or the infectious centre titres of the
2pg/ml 4'-s-EtdU treated cultures returned to the original pre-treatment level. Cell
associated infectious virus became detectable from the first time point after
withdrawal of 4'-s-EtdU. However, the levels remained stable over the latter 3
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weeks of the experiment, being between 100 to 500 times lower than was observed
with the untreated culture. This supports the argument that the number of latently
infected cells that would readily reactivate had been permanently reduced by the
presence of the 4'-s-EtdU. Likewise, the infectious centres also remained at a
relatively suppressed level, comparable with the observed titres at the point of 4'-s-
EtdU withdrawal. The fact that the cultures treated with 0.2pg/ml 4'-s-EtdU did
return to the pre-treatment levels is hard to rectify. However, the fact that the lower
dose 4'-s-EtdU treatment at the time of withdrawal, had not yet achieved maximal
inhibition of the productive replication of the virus, may have had a bearing on the
final outcome, within the persistently infected culture.
3.3.5 The effect of 4'-s-EtdU on cell lines that do not normally harbour
persistent virus
Little is known about the effects of anti-virals on gammaherpesvirus infections of
cell lines that do not normally support viral persistence. This is because the most
commonly studied gammaherpesvirus, EBV does not readily undergo productive
replication in vitro and then only in BL and LCL cell lines. However, productive
viral replication plays an important role in any virus infection, with respect to
transmission and often disease.
Infection of both BHK and MGC7 cells induces cell death. Neither cell line could be
protected for any length of time with 0.2pg/ml 4'-s-EtdU. The MGC7 cell cultures
went into crisis after approximately 2 to 3 weeks post infection. Similar results were
achieved using BHK cells infected at 0.04 pfu per cell, where the cultures died after
six to 7 days. This was presumably due to an incomplete inhibition of productive
viral replication. 0.2pg/ml inhibits plaque formation in BHK cells over a 4 day
period, but could not entirely eliminate infectious virus from NS0 cell lines, which
are predominately latently infected.
At a concentration of 2 jug/ml, 4'-s-EtdU protected MGC7 cultures from undergoing
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total crisis after being infected at a MOI of 1. Once established, the MHV-68
infected MGC7 cells could be grown in the presents of 2pg/ml 4'-s-EtdU for over 2
months without any obvious cytopathic effects. The virus was however not
eliminated since on withdrawal of the treatment after 2 months, productive virus
replication re-initiated, killing every cell in the culture. No virus antigens were
detectable in the 4'-s-EtdU treated controls, by fluorescent immunostaining at this
time. Limiting dilution analysis carried out at 32 days post infection, in the presence
of 2pg/ml 4'-s-EtdU, revealed that MHV-68 could be reactivated from 1/3 of the
clonal cell lines, after 7 days 4'-s-EtdU withdrawal. This clearly showed that at least
1/3 of the cells in the culture were still infected. These results further suggest that
successful productive replication had been entirely inhibited. If limited productive
replication had occurred within the culture, then one might expect the number of
uninfected cells to be far lower since all proved infectable on withdrawal of
treatment and 4'-s-EtdU does not prevent the establishment of infection. However,
some viral gene expression was likely to have occurred in the infected cells, since
viral TK is believed necessary for the inhibitory properties of 4'-s-EtdU.
3.3.6 Viral persistence in 4'-s-EtdU treated MGC7 cells
The cultures were originally infected, in suspension, at a MOI of 1. On the
assumption that the infection of cells is a random process, determined by random
collision events, then using the Poisson distribution it is to be expected that 63% of
the cells would become infected. Being able to reactivate virus from only 4/12
cloned cultures, shows a significant decrease in the number of infected cells present
in the cultured, compared to the predicted number (P = 0.036 using the binomial
analysis, assuming each had a 63% probability of being virus positive). Clearly this
analysis assumed that all infected cells were able to reactivate, however it was
considered a reasonable assumption. Based on the reactivation studies carried out by
myself and others (Dr L. Terry personal communication), the time of 4'-s-EtdU
treatment had no obvious effect on the virus harboured in MGC7 cells, with respect
to reactivation efficiency, as was the case for the persistently infected NSO cell lines.
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The decrease in the number of infected cells was probably due to the cell death that
occurred after initial infection. The cell death occurred in the presence of 2pg/ml 4'-
s-EtdU and resulted in approximately 40% to 50% of the cells dying. On the
assumption that only the infected cells died, presumably from either toxic build up of
virus specific products or, as is quite likely, high level expression of virus encoded
TK, inducing activated 4'-s-EtdU cellular toxicity, then the number of infected cells
would be reduced to approximately 13% to 23% of the original cells. Of the original
cells, 37% should have remained uninfected, so giving rise to the persistently
infected culture in which the infected cells comprise only approximately 26% to
38%.
The fact that MHV-68 was not eliminated from the cultures, implies that the virus
can maintain it's genome in rapidly dividing cells that would normally be the target
for productive replication in the apparent absence of productive virus replication.
The culture doubling time for MGC7 cells is under 24 hours (Dr L. Terry personal
communication) and therefore after 32 days of culture all the cells should have
divided over 32 times. If the virus was incapable of replication the dilution effect
after this time would have been approximately 1 in 4.3xl09, equating to there being
only 1 infected cell in every 4.3xl09. In the absence of closer scrutiny, it is
impossible to determine the exact mechanism by which the viral genome maintains
itself, however a number of possible scenarios can be speculated upon. Upon
infection herpesvirus genomes circularise. The virus can then undergo productive
replication and synthesis of linear concatemeric daughter strands or establish latency.
HSV-1 that has the VP16 gene made dysfunctional and hence can not undergo
productive replication, can infect cells, however, the genome becomes gradually
diluted over successive rounds of cell replication (Jamieson et al, 1995 and Dr C M
Preston personal communication). This is presumably due to the fact that HSV
establishes latency in neurones and so lacks an Ori P. MHV-68 as with other
gammaherpesviruses establishes latency in cells that can replicate and hence will
code for an Ori P. In this manner, the circularised replicative intermediate could be
replicated by the cell, during S phase of cell division. The replicative intermediate
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however, is continuously attempting to undergo productive replication and so early
genes, such as TK are expressed, which activates cellular 4'-s-EtdU which in turn,
prevents the synthesis of linear daughter strands and hence late gene expression.
An alternative, although similar mechanism, might be that, as with the persistently
infected NSO cells, the cells can potentially support both latent and productive virus
replication. However, unlike the persistently infected NSO cells, the balance in
MGC7 cells is heavily in favour of productive and hence lytic replication. The 4'-s-
EtdU prevents the lytic replication from taking place and so the culture establishes a
highly unstable form of latency. Attempts to reactivate cause the sporadic
production of TK which activates 4'-s-EtdU and prevents it from happening. There
is evidence from HSV research that ACV can cause HSV-1 to go latent in primary
neuronal cultures, in vitro, which would otherwise be productively infected (Wilcox
et al, 1988 and 1990). A third possible mechanism might involve the synthesis of
sufficient linear genomes to allow the re-circularisation of virus genomes and so
prevent the virus from becoming diluted out. However, if this was occurring one
might expect these daughter strands to be packaged into virions and so go on to
infect other cells. 4'-s-EtdU does not prevent the establishment of infection in either
BHK, MGC7 or NSO cells. In this manner over a period of time, one might expect
the culture to either go into crisis, as was the case with the 0.2pg/ml 4'-s-EtdU
treatment, or the number of infected cells to gradually increase. However, neither of
these phenomena were observed.
3.3.7 The of effect of MOl on the ability of 4'-s-Etdli to protect BHK cells
from MHV-68 infection
The anti-viral effects of 4'-s-EtdU was less able to protect BHK cells from the MHV-
68 induced cytopathic effects, than it was MGC7 cells. 4'-s-EtdU resistant virus
mutants also arose far more readily from infected BHK cells than with either
infected NSO or MGC7 cells. 4'-s-EtdU at 2pg/ml protected the BEIK cell cultures at
a MOI of 0.04 but did not protect at a MOI of 4 and only partially protected at an
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MOI of 0.4. This was presumably due to the fact that MHV-68 infection is more
cytotoxic in BHK cells than in MGC7 cells. MGC7 cells have constitutive
expression of the SV40 large T antigen at the permissive temperature. Expression of
large T antigen is known to bind tumour suppresser genes such as P53 and Rb and
has the effect of driving cells into continuous proliferation and inhibiting apoptosis
(Schaffhausen 1982 and Mole et al, 1987). This would probably make the cells
more tolerant to the toxicity virus encoded products, as well as activated 4'-s-EtdU.
Expression of large T antigen could therefore account for the fact that 4'-s-EtdU
protects MGC7 cells but not BHK cells, at high MOI, and that MHV-68 takes 6 days
to produce a plaque in MGC7 cells and only 4 days with BHK. However, it is also
possible that MHV-68 replicates faster in BHK cells, since BHK cells may provide a
more conducive environment for productive viral replication than the MGC7 cells.
Despite not being able to protect BHK cells at high MOI, 4'-s-EtdU at 2pg/ml could
protect BHK cells at low MOI. The virus was not lost from these cultures for at least
10 days of continual treatment. The doubling time of BHK cells is approximately 24
hours therefore the dilution effect in the absence of viral replication would have been
over 1000 fold. The numbers of infected cells, however was not quantified to
determine whether the levels had decreased or not. Studies could not be carried out
much further than 2 weeks since the infected BHK cell cultures were highly prone to
the spontaneous generation and outgrowth of 4'-s-EtdU resistant virus mutants.
3.3.8 The spontaneous generation of 4'-s-EtdU resistant virus
No evidence for the spontaneous generation 4'-s-EtdU resistant virus mutants was
found with the long-term 4'-s-EtdU treated persistently infected NSO cell cultures, at
either 0.2 or 2jug/ml. This was perhaps surprising since 4'-s-EtdU treatment at
0.2p.g/m1 allowed low level chronic replication of the virus within the culture.
However, NSO cells support predominately a latent infection and so the level of
productive virus replication, as compared to either BHK or MGC7 cells, was very
low. 4'-s-EtdU resistant mutants spontaneously arose from persistently infected
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MGC7 cells only after 10 weeks of 4'-s-EtdU treatment at 2jag/ml. The fact that 4'-
s-EtdU resistant mutants arose from BHK cells far more readily than from either NSO
or MGC7 cells could be due to the cellular environment being more conducive to
productive replication.
3.3.9 4'-s-EtdE resistant MHV-68 isolates
The 4'-s-EtdU resistant mutants that spontaneously arose from the persistently
infected MGC7 cells were cloned and partially characterised. Six resistant isolates,
MERV 1 to 6, were cloned by 3 rounds of limiting dilution plaque purification. 4'-
s-EtdU at concentration up to lOpg/ml had no effect on the plaque forming ability of
any of the resistant virus clones, however all remained sensitive to the anti-viral
effects of ACV. Since 4'-s-EtdU has a similar viral range similar to ACV, being
effective at inhibiting the productive replication of HSV and VZV but not HCMV
{see Table 3.1), it was assumed to be activated and incorporated in a similar manner.
ACV resistant HSV-1 mutants can be isolated from immunosuppressed, transplant
patients or AIDS patients after long-term treatment with ACV. Similarly, mutants
can be generated in vitro, by propagating polyclonal virus stocks, in the presence of
ACV and selecting for resistant virus. The most common mutations responsible for
conferring ACV resistance, result in the functional deficiency of the viral encoded
TK (Smith et al, 1980, Martin et al, 1985 and Hill et al, 1991). This is commonly
caused by the insertion or deletion of a single nucleotide resulting in a frame shift
mutation and so resulting in the complete loss of viral TK activity (Sasadeusz et al,
1997). Although TK deficient mutants replicate efficiently in vitro, they appear
greatly attenuated in vivo (Efstathiou et al, 1989 and Coen et at, 1989). Less
common mutations that result in ACV resistance, are caused by base pair
substitution in either the TK encoding gene (Darby et al, 1981, Martin et al, 1985
and Hill et al, 1991) or the viral polymerase encoding gene (Field et al, 1980 and
Collins et al, 1989). Base pair substitutions can give rise to TK alteration mutations,
where amino acid alterations in the viral TK, change the substrate specificity,
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resulting in the failure to recognise and phosphorylate ACV. Similarly amino acid
alterations in the viral DNA polymerase can result in failure to recognise ACV
triphosphate as a nucleotide so fails to incorporate the anti-viral into the viral DNA
during synthesis. Mutant polymerase strains of HSV often have reduced sensitivity
to the anti-viral pyrophosphate analogues, such as foscarnet (PFA) and
phosphonoacetic acid (PAA) (Morfin et al, 1996).
The fact that the MERV clones remained sensitive to ACV suggests that they are not
TK deficient mutants, since TK is required for ACV sensitivity. Mutations that alter
the ability of HSV TK to convert a specific nucleoside analogues to the
monophosphate derivative, tend to confer resistance to most other TK-dependant
anti-virals. However, only the pyrimidine analogues, such as BVdU and BVaraU,
require virus encoded TK to convert the nucleoside monophosphate to the
diphosphate form. Mutations that affect the TK conversion of nucleoside
monophosphates to the diphosphate form generally do not affect the conversion of
nucleosides to their monophosphate forms. The selective resistance of the MERV
clones therefore suggests that resistance was achieved via TK mutations that
specifically affect the phosphorylation of 4'-s-EtdU monophosphate to 4'-s-EtdU
diphosphate. Alterations to the MHV-68 TK, which affect the conversion of 4'-s-
EtdU to 4'-s-EtdU monophosphate, or to the viral polymerase are less likely. Studies
carried out on HSV resistance to anti-viral pyrimidine analogues such as BVdU and
BVaraU have shown that selection with either BVdU or BVaraU alone did not give
rise to mutants that lost sensitivity PAA and PFA. To achieve this, BVdU or BVaraU
had to be combined with either pyrophosphate analogues or ACV (Morfm et al,
1996). However, neither TK or polymerase mutations can be ruled out since MHV-
68 is not HSV and BVdU / PAA double resistant HSV mutants, can remain sensitive
to ACV. To determine the exact mechanism by which the 4'-s-EtdU resistance was
acquired, both the MERV TK encoding gene (ORF 21) and the viral polymerase
gene (ORF 9) would have to be genetically sequenced.
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Chapter 4: The effect of 4'-s-EtdC treatment on the pathology of the MHV-68
infection of BALB/c mice.
4.1.1 Summary
Experiments were carried out to determine the long-term effect of 4'-s-EtdU
treatment from day 3 post infection and the effect of prophylactic 4'-s-EtdU
treatment on the pathology of the MHV-68 infection of BALB/c mice 3 to 4 weeks of
age. Treatment from day 3 post infection, significantly shortened the acute lung
infection and had a pronounced inhibitory effect on viral persistence in the lung.
However, the treatment failed to prevent both the post acute splenomegaly and the
establishment (and maintenance) of viral latency in splenocytes. Prophylactic 4'-s-
EtdU treatment, prevented any detectable productive viral replication in the lungs of
mice infected via the intra nasal route. Furthermore, the mice failed to sera convert
to late viral antigens, undergo splenomegaly or establishment of viral latency in
splenocytes. However, the treatment did not prevent the establishment of a
persistent infection in the lung tissue, which was maintained up to day 54 post
infection, in the apparent absence of both productive viral replication and latently
infected circulating B-cells. On withdrawal, the mice sera converted to late viral
antigens and the virus was shown to seed to the spleen. Surprisingly, prophylactic
4'-s-EtdU treatment on mice infected via the intra peritoneal route, also resulted in
mice failing to develop splenomegaly and half the mice failing to establish splenic
latency. The lungs were not the predominant site for viral persistence outside
lymphoid organs in the 4'-s-EtdU treated mice, infected via the intra-peritoneal
route, pointing to a third site of viral persistence. The study clearly demonstrates the
importance of productive viral replication in the dissemination from the site of acute
infection to other cellular compartments. The study also provides clear evidence for
both chronic and latent viral persistence in the lungs of mice infected via the intra¬
nasal route. The evidence highlights the potential importance of the site of primary




4.1.2 Advances in the clinical use of nucleoside analogues to combat
herpesvirus infections
Over the previous 40 years, there have been major advances in the development of
anti-herpesvirus compounds. The first anti-herpesvirus agents used clinically were
IdU, TFT and vidaravine. All 3 had significant toxicity and have been largely
superseded by ACV. ACV is specifically activated by herpesvirus encoded TK to the
active form and hence has very low toxicity. Despite the low level of adverse side
effects associated with AVC treatment, ACV has a low solubility, low bioavailability
and a short intracellular half-life. Recently a new generation of highly soluble anti¬
viral pro-drugs which have greatly increased bioavailibility but equally low toxicity.
Valiciclovir (VACV) is a L-valyl ester derivative of ACV. VACV is highly soluble
and converted to AVC by first pass metabolism in the liver (Demiranda et al, 1994
and Burnette et al, 1994). The conversion of VACV to ACV is carried out by an
atypical esterase, termed valaciclovir hydrolase (Burnette et al, 1995). The oral
bioavailability ofACV following oral administration ofVACV is 54% (Murray et al,
1995 and Soullawton et al, 1995). This compares with only 12 to 20% for oral
administration of ACV (Acosta et al, 1997). VACV has proven effective in the
treatment of both clinical HSV I, HSV II and VZV infections (Patel et al, and 1997,
Fife et al, 1997, Bodsworth et al, 1997, Marley et al, 1997 and Tyring et al, 1998).
VACV also has been shown to be effective at preventing CMV recurrent infections
in immunocompromised patients (Feinberg et al, 1998 & Griffiths et al, 1998).
However, recurrence of HSV replication has been observed following cessation of
VACV treatment in animal models (Field et al, 1995a & 1995b, Thackray et al,
1996a&b& 1997).
Famcyclovir (FCV) is a diacetyl 6-deoxy derivative of PCV. As with ACV, PCV is
an acyclic guanosine analogue specifically activated by herpesvirus TK. The oral
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bioavailabilty of PCV following oral administration of FCV is 77% and similarly to
VACV is converted, to PCV, by first pass metabolism in the liver (Gill et al, 1996,
Crumpacker et al, 1996, Luber et al, 1996 and Borg et al, 1997). The conversion of
FCV to PCV involves di-deacetylation to 6 deoxcy PCV and then 6' oxydation to
PCV by the liver molyddemum hydroxylase, aldehyde oxydase (Clarke et al, 1995
and Rashidi et al, 1997). Oral FCV is affective in the treatment ofHSV I, HSVII and
VZV recurrent infections (Sack et al, 1996, Tyring, et al, 1995 & 1996, Mertz et al,
1997 and Schacker et al, 1998). FCV appears to be able to suppress the
establishment of latency by HSV (Thackray et al, 1996a & b & 1997 and Field et al,
1997) and recurrence of HSV replication following cessation of treatment has not
been observed in animal models (Field et al, 1995a & b, Thackray et al, 1996a & b
& 1997). Oral FCV as well as topical PCV, IdU and PFA have proven effective in
the treatment ofHSV labalis (Spruance et al, 1997a and b and Bernstein et al, 1997).
FCV has also been shown to be and effective treatment of hepatitis B virus infections
(Piqueras et al, 1997 and Lau 1998) due to the ability of PCV-TP to inhibit
hepadnavirus reverse transcriptase (Zoulin et al, 1995 and Dannaoui et al, 1997).
4.1.3 The clinical use of anti-virals that are virus non-exclusively virus
activated
Betaherpes viruses do not encode a homologue to the HSV I TK gene and therefore
ACV and PCV have proven ineffective at treating CMV disease in
immunocompromised patients. The main treatment for which, along with foscarnet,
has been a further acyclic guanosine analogue, GCV (Drew et al, 1995 and Balfour
et al, 1996). GCV has a higher level of toxicity than either ACV, PCV or their pro¬
drug derivatives (Thust et al, 1996). As with ACV and PCV, GCV has a low
bioavailability, which has led to the development of an oral GCV pro-drug similar to
FCV (Krasny et al, 1995). The monophosphate nucleotide analogue HPMPC has also
proved highly effective against ocular CMV disease, as well as the treatment ofACV
resistant HSV labelis in AIDS patients. HPMPC has a very long intracellular half life
and can inhibit a wide variety of herpesviruses (Alrabiah et al, 1996 and Freeman et
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al, 1996).
The non-virus activated nucleoside analogues in clinical use are a relatively
biochemically diverse group. The dideoxynucleosides, such as didanosine (ddl) and
dideoxycytodine (ddC), and the dideoxynucleoside derivatives, such as zidovudine
(AZT), stavadin (d4T) and 2'-deoxy-3'-thiacytidine (3CT), are all obligate chain
terminators (St. Clair et al, 1972 and 1991). All are used in the treatment of HIV
infection and AIDS, and have a range of side effects that include bone marrow
toxicity and neuropathy. HPMPC is a nucleotide mono-phosphate analogue and
hence does not require activation by viral kinases. HPMPC has anti-viral activity
against a broad range of herpesviruses and papillomaviruses. HPMPC has a very
long intracellular half life and is used in the treatment of ACV resistant HSV-2 and
HCMV retinitis in AIDS patients (Cundy et al, 1995, Lalezari et al, 1995 and Polis et
al, 1995). The main side effect of HPMPC is nephrotoxicity. Ribavirin is a
ribonucleoside analogue and has anti-viral properties against a variety of RNA
viruses (Eriksson et al, 1977 and Toltzis et al, 1988). Ribavirin is used in the
treatment of respiratory syncytial virus infections, Lassa fever and Hantaan virus
haemorrhagic fever (Hall et al, 1983, Andrei et al, 1993). Ribavirin is both
mutagenic and has side effects that include conjunctivitis, reticulocytosis and bone
marrow suppression.
4.1.4 The role of productive replication in EBV pathology
Productive virus replication plays a critical role in the transmission of virtually all
viruses. It is also commonly associated with viral disease pathology. Transmission
of EBV is generally achieved by the shedding of infectious virions in saliva. The
source of which, and probably the site of initial infection, are the epithelial cells of
the oro-pharynx. Productively infected epithelial cells have been observed in
association with (Lemon et al, 1977 ). The role of the epithelial cell infection in vivo,
is contentious since the treatment of IM patients with ACV has proved ineffective
and B-lymphocytes can also support limited productive replication in vivo (Pang et
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al, 1997 and Niedobitek et al, 1997).
The only disease directly associated with productive replication of EBV in the
epithelial cells of the oro-pharynx, is known as hairy oral leukoplakia (HOL). HOL
is a complication associated with AIDS patients and can be successfully treated with
anti-virals such as ACV and ACV derivatives (Resnick et al, 1988 and Greenspan et
al, 1990). Productive replication in the oro-pharynx may also play an important role
in IM since EBV transformation ofB-lymphocytes, both in vitro and in vivo, requires
the addition of exogenous virus or the reactivation of latent virus (Pope et al, 1968,
Rickenson et al, 1986, Morgan et al, 1988 and Dosch et al, 1991). It has also been
observed that the prevalence of EBV associated post-transplantation LPD is far
higher in children who are EBV sera-negative prior to immunosuppression, and then
become primarily infected (Cox et al, 1995 and Newell et al, 1996). The deciding
factor in whether a post-pubescent develops IM after primary infection, may well
depend on the number of B-lymphocytes initially infected. This is going to depend
on 2 factors; the titre of the initial infecting dose or the severity of the acute infection
of the oro-pharynx.
4.1.5 The MHV-68 in vivo gammaherpesvirus model for anti-viral testing
It is difficult to determine the potential therapeutic benefits of nucleoside analogues
in the treatment of EBV primary infection, because humans are the only natural host
for the virus and infection only becomes apparent after the onset of IM symptoms.
Although MHV-68 is genetically divergent from EBV, the 2 viruses appear to have
similar patterns of infection and cellular tropism, in their respective natural hosts.
MHV-68 also has similar anti-viral susceptibilities to EBV and so makes a good
model for the study of potential therapeutic treatments, under controlled
experimental conditions (for review see Sunil-Chandra 1994b). Previous studies
have shown that ACV taken orally from day 3 post intra-nasal infection, significantly
reduced the virus titres in the lung during acute infection. However, the treatment
failed to shorten the length of time of the acute infection or greatly affect the shape
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of the lung infectious virus titre profile. From the anti-virals previously tested on
MHV-68 in vivo, only cidofovir has been shown to effectively combat virus
replication in infected mice (Neyts et al, 1998). Anti-viral treatment ofMHV-68 has
also been shown to be ineffective at preventing the establishment of virus latency in
splenocytes, although the appearance of splenic infectious centres was delayed in
treated animals (Sunil-Chandra et al, 1994c and Barnes et al, unpublished data).
4.1.6 The effect of 4'-s-EtdU treatment on the MHV-68 infection of mice.
Experiments have been carried out comparing the potency of 4'-s-EtdU to ACV in
vivo. Treatment ofmice with 4'-s-EtdU (lmg/mouse per day) from day 3 post intra¬
nasal infection resulted in all detectable infectious virus being eliminated from the
lungs of the treated mice within 4 days of treatment. The ACV treatment, carried out
in parallel at the same dose (lmg/mouse/day), other than slightly reducing the lung
virus titres, had little affect on the acute lung infection. This data clearly
demonstrated the increased potency of 4'-s-EtdU over ACV in vivo. Despite this, the
4'-s-EtdU treatment failed to prevent the establishment of viral latency in
splenocytes. As with ACV treatment, 4'-s-EtdU treatment resulted in a significant
delay in the appearance of splenic infectious centres, with virus latency levels
remaining suppressed up till experimental termination (day 13 post infection). The
study did not therefore established whether the 4'-s-EtdU treatment would affect
viral latency levels long-term, in the spleen (Barnes et al, unpublished data).
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Results
4.1.7 The treatment of intra-nasally MHV-68 infected mice, with 4'-s-EtdU
from day 3 post infection.
To determine the long-term effects of 4'-s-EtdU treatment on the MHV-68 infection
in vivo, 61 female BALB/c mice, aged 3 to 4 weeks, were infected with 4xl05 pfu
MHV-68, via the intra-nasal route. For long-term drug treatment of mice, the 4'-s-
EtdU was to be administered via drinking water (containing soluble 4'-s-EtdU). To
explore the feasibility of this approach, a further group of 6 mice were infected with
4xl05 pfu MHV-68, via the intra-nasal route. The group of 6 infected mice were
split into 2 groups of three mice, one of which remained on normal drinking water,
the second were put on drinking water containing 0.3mg/ml 4'-s-EtdU. At day 3 post
infection, 3 mice from the group of 65 MHV-68 infected mice, were killed and lungs
removed, to assess the establishment of the acute lung infection. To assess the
effectiveness of 4'-s-EtdU administration, via drinking water, the 3 drinking water
control mice, and the 3 mice on 4'-s-EtdU supplemented drinking water, were also
killed and lungs removed. Of the remaining 58 infected mice, 40 were administered
0.2 ml of a 0.5% (W/V) 4'-s-EtdU suspension orally, under mild anaesthesia, using a
gavage needle. The remaining 18 mice were administered 0.2 ml water, in a similar
manner. The oral administration of the 4'-s-EtdU (or water) was repeated once a
day, until day 12 post infection.
Infectious virus assays carried out on the lungs of the drinking water control and the
4'-s-EtdU supplemented drinking water mice, clearly showed that administration of
4'-s-EtdU via drinking water was an effective way of inhibiting the replication of
MHV-68 (see figure 4.1.1). The drinking water control mice had infectious virus
titres between 2xl03 and 2xl05 pfu per lung, where as none of the treated mice had
any detectable infectious virus present. On day 12 post infection, half the treated
mice were withdrawn from 4'-s-EtdU treatment, the other half carried on treatment




Time (days post infection)
Figure 4.1.1 The infectious virus titres (as measured by direct plaque assay) detected in
the lungs ofmice infected intra-nasally with 4x10s pfu MHV-68, at day 3 post infection.
The mice were either left untreated (black) or treated, via drinking water supplemented
with 4'-s-EtdU (0.3mg/ml) from day 0 post infection (blue). Three mice were sampled
from both the treated and untreated groups. The assay limit ofdetection was 10 pfu per
lung.
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and 4 treated mice were sampled at days 7 and 12 post in b fection. A further 3
mock-treated, 4 continually treated and 4 treatment withdrawn mice were sampled at
days 26, 38, 48 and 61 post infection. At each time point lungs and spleens were
removed for analysis.
4.1.8 The effects of 4'-s-EtdU treatment (from day 3 post infection) on the
MHV-68 infection of the lung.
High titres of infectious virus could be detected in the lungs of mice at day 3 post
infection. Infectious virus titres remained high in the mock-treated mice up to day 7
post infection. However, by day 7 post infection, the lungs of the treated mice
contained no detectable infectious virus, by direct plaque assay. By day 12 post
infection, infectious virus was not detected in the lungs of any of the mice, as was
the case for all subsequent time points, (see figure 4.1.2). Despite the absence of
detectable infectious virus in the lungs, virus could be reactivated, by a lung co-
cultivation assay, from all the untreated mice (9/9), sampled at the later 3 time points
(days 38, 48 and 61 post infection). Virus could also be reactivated from lung tissue
of all the mice withdrawn from treatment (10/10), again sampled at the later 3 time
points. However, virus could only be reactivated from the lung tissue of 1/12 mice
not withdrawn from treatment (see figure 4.1.3).
4.1.9 The effects of 4'-s-EtdLi treatment (from day 3 post infection) on MHV-
68 induction of splenomegaly
Splenomegaly occurred in all the groups of infected mice (see figure 4.1.4). At day 7
post infection, the number of splenocytes observed in both the treated and untreated
mice was between 6xl07 and 7xl07 leukocytes per spleen. By day 12 post infection,
the number of splenocytes observed in both the untreated and treated mice, increased
significantly (P= 0.001 and 0.022 respectively, by student T test). The increase was
7 7
greater in the untreated than in the treated mice (1.48x10 as opposed to 1.25x10
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Figure 4.1.2 The infectious virus titres (as measured by direct plaque assay) detected in
the lungs ofmice infected intra-nasally with 4x105 pfu MHV-68. The mice were either
left untreated (black), 4 '-s-EtdU treated from day 3 post infection and not withdrawn
(blue) or treated from day 3 post infection and withdrawn day 12 post infection (red).
Four mice were sampledfrom the 4 '-s-EtdU treated groups at every time point (days 3,
7, 12 26, 38, 48 and 61 post infection). Three mice were sampled from the untreated
group at every time point. The values are represented by geometric means and the
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Figure 4.1.3 The levels of infectious virus reactivated (by co-cultivation assay) from the
lung tissue ofmice infected intra-nasally with 4x105 pfu MHV-68. The mice were either
left untreated (black), 4 '-s-EtdU treated from day 3 post infection and not withdrawn
(blue) or treated from day 3 post infection and withdrawn day 12 post infection (red).
Four mice were assayed from the 4 '-s-EtdU treated groups at every time point tested
(days 38, 48 and 61 post infection), exceptfor day 48 post infection where only 2 of the
treatment withdrawn mice were assayed. Three mice were assayedfrom the untreated




Figure 4.1.4 The number of splenocytes observed in mice infected intra-nasally with
4xl05 pfu MHV-68. The mice were either left untreated (black), 4'-s-EtdU treatedfrom
day 3 post infection and not withdrawn (blue) or treatedfrom day 3 post infection and
withdrawn day 12 post infection (red). Four mice were sampled from the 4'-s-EtdU
treated groups at every time point tested (days 7, 12 26, 38, 48 and 61 post infection).
Three mice were sampled from the untreated group at every time point tested. The
values are represented by arithmetic means and the error bars represent the standard
deviation.
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student T-test). At day 26 post infection, the number of splenocytes observed in the
mock-treated mice and in the mice withdrawn and non-withdrawn from treatment,
remained elevated showing no significant differences from the significantly elevated
values observed at day 12 post infection (P=0.65, 0.42 and 0.19 respectively, by
student T-test). However, by day 38 post infection, the number of splenocytes
observed in the mock-treated mice and in the mice withdrawn and non-withdrawn
from treatment, had significantly decreased with respect to the numbers observed at
the previous time point (P=0.031, 0.0026 and 0.046 respectively, by student T-test).
After day 38 post infection, no significant changes in the number of splenocytes was
observed in any of the groups of mice, with the numbers remaining significantly
lower than observed at day 26 post infection. There was no significant difference in
the number of splenocytes observed in any of the groups of mice, at any specific time
point.
4.2.1 The effect of 4'-s-EtdU treatment (from day 3 post infection) on viral
latency in the spleen.
At the first time point tested (day 7 post infection), all the mock-treated mice (3/3)
had detectable levels of latently infected splenocytes, as determined by infectious
centre assay. By day 12 post infection, the splenic infectious centre titres had
peaked, increasing from an average of 7 per spleen to 1767 per spleen (P=0.009 by
student T-test). From day 12 post infection, the splenic infectious centre titres
decreased, becoming significantly lower (than day 12 post infection) by day 38 post
infection. The infectious centre titres remained significantly lower for all subsequent
time points (P=0.032, 0.045 and 0.038 respectively, by student T-test). By day 48
post infection, the latent virus titres had reached a base line level, averaging between
5 and 15 infectious centres per spleen (see figure 4.1.5).
No latent virus was detectable in the splenocytes of any of the 4'-s-EtdU treated mice
at day 7 post infection (0/4), as detected by infectious centre assay. Although




Figure 4.1.5 The latent virus titres (as measured by infectious centre assay) detected in
the spleens ofmice infected intra-nasally with 4x103 pfu MHV-68. The mice were either
left untreated (black), 4 '-s-EtdU treated from day 3 post infection and not withdrawn
(blue) or treated from day 3 post infection and withdrawn day 12 post infection (red).
Four mice were assayed from the 4 '-s-EtdU treated groups at every time point tested
(days 7, 12 26, 38, 48 and 61 post infection), except on days 26 and 38 post infection
where only 3 mice from the treatment withdrawn group were assayed. Three mice were
sampled from the untreated group at every time point tested. The values are
represented by geometric means and the error bars represent the standard deviation.
The dotted line represents the assay limit ofdetection.
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the titres were signifu
(P=0.047). By day 2^
; seen in the untreated mice at that time
11 subsequent time points), the infectious
centre titres seen in both the mice withdrawn and non-withdrawn from treatment,
were indistinguishable from the mock-treated mice.
4.2.2 The effect of 4'-s-EtdU treatment (from day 3 post infection) on the
sensitivity of lung and splenocyte derived MHV-68 isolates
To determine whether the 4'-s-EtdU treatment of infected mice lead to the
generation and selection of 4'-s-EtdU resistant virus variants, a number of virus
isolates were generated from splenocytes and lung tissues of the infected mice. EC50
assays were carried out on virus preparations derived from the lung tissue (by co-
cultivation assay) of the mock-treated mice and the mice withdrawn from treatment,
sampled at days 38 and 61 post infection (see figure 4.1.6A & B). No difference in
4'-s-EtdU sensitivity was observed in the virus reactivated from the lungs of the mice
withdrawn from treatment as compared with either the virus reactivated from the
lungs of untreated mice or the virus working stock originally used to infect the mice.
EC50 assays were also carried out on virus preparations derived from splenocytes
from the mock-treated mice and in the mice withdrawn and non-withdrawn from
treatment, sampled on day 61 post infection {see figure 4.1.6C, D and E). Again no
difference in 4'-s-EtdU sensitivity was observed between the three groups of mice
and the virus working stock used to infect the mice.
4.2.3 The prophylactic 4'-s-EtdE treatment of intra-nasally infected BALB/c
mice
Previous experiments designed to determine the relative importance of the primary
acute infection on the establishment of viral latency in B-lymphocytes and general
disease pathology, failed to demonstrate a therapeutic benefit in shortening the acute
infection. However, anti-viral treatment was initiated only after the acute infection



























Figure 4.1.6 The sensitivity ofdifferent virus isolate to 4'-s-EtdU, reactivatedfrom of
the lungs (A and B) and splenocytes (C, D and E) removedfrom mice sampled on days
38 and 61 post infection, as determined by EC50 assay. The virus isolates were
generated by lung and splenocyte co-cultivation assay, from mice that were either left
untreated (black and brown), 4 '-s-EtdU treated and not withdrawn (blue) or 4 '-s-EtdU
treated and withdrawn on day 12 post infection (red, yellow and purple). The virus
isolates were compared to the original MHV-68 working stock (green). The data is
represented by the mean percentage plaquing efficiency, of the virus isolates at different
concentrations of 4 '-s-EtdU. The error bars represent the standard deviation and the
dotted lines represent 25%, 50%, and 75% plaquing efficiency levels (see Table 4.1 for
further details).
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Table 4.1 The summarised results from figure 4.1.6 (the EC50 assays carried
out on MHV-68, isolated from both 4'-s-EtdU treated and untreated,
long-term infected mice).
Graph Isolate Source Graph Line Mouse 'Day 2 Crude EC50
Colour number Sampled (ng/ml)
A MHV-68 working stock Green - - 61.4
A Group 1 Lung Black 1 38 64.7
A Group 1 Lung Brown 2 38 56.2
A Group 2B Lung Red 1 38 65.5
A Group 2B Lung Yellow 2 38 61.5
B MHV-68 working stock Green - - 41.1
B Group 1 Lung Black 1 61 35.6
B Group 1 Lung Brown 2 61 35.5
B Group 2B Lung Red 1 61 41.6
B Group 2B Lung Yellow 2 61 40.6
B Group 2B Lung Pink 3 61 38.5
C MHV-68 working stock Green - - 39.8
C Group 1 Spleen Black 1 61 39.6
C Group 2A Spleen Blue 2 61 49.4
C Group 2B Spleen Red 1 61 36.6
D MHV-68 working stock Green - - 25.8
D Group 1 Spleen Black 2 61 23.2
D Group 2A Spleen Blue 3 61 25.9
D Group 2B Spleen Red 2 61 30.8
E MHV-68 working stock Green - - 32.0
E Group 1 Spleen Black 3 61 38.7
E Group 2A Spleen Blue 4 61 39.3
E Group 2B Spleen Red 3 61 40.1
1 1
Key: - ~ Not applicable, ~ Time when mice were killed (days post infection), ~
Value calculated from the graph, assuming at straight line between points either side
of 50% inhibition. The Group 1 mice were left untreated, the Group 2 mice were
treated from day 3 post infection with 4'-s-EtdU and either left treated (A) or
withdrawn from treatment on day 12 post infection (B).
177
replication, at the site of acute infection, is necessary for the establishment of viral
latency in B-lymphocytes and/or to induce disease pathology, two experiments were
performed on mice treated with 4'-s-EtdU from 2 days prior to infection with MHV-
68.
Twenty eight BALB/c female mice, aged 3 to 4 weeks were randomly selected from
a batch of 48 age and sex matched animals and were put on drinking water
containing 0.3mg/ml 4'-s-EtdU. The remaining 20 animals remained on normal
drinking water. After 2 days of treatment, the mice on 4'-s-EtdU drinking water the
normal drinking water, were infected intra-nasally with 4xl05 pfu MHV-68. At day
12 post infection, 7 of the mice put onto 4'-s-EtdU drinking water were withdrawn
from treatment and put back onto normal drinking water. The remaining
prophylactically treated mice remained on the 4'-s-EtdU drinking water for the
duration of the experiment. The mice were sampled at days 3, 7, 12, 21 and 31 days
post infection.
4.2.4 The effect of prophylactic 4'-s-EtdU treatment on MHV-68 infection of
the lungs of mice.
Lungs were removed from all animals at all time points and infectious virus assays
carried out on the homogenates. Lung co-cultivation assays were also performed on
all lung tissues except for those from days 3 and 7 post infection. An acute viral
infection of the lungs occurred in the untreated mice following the intra-nasal
inoculation ofMHV-68. Relatively high titres of infectious virus could be detected
in the lungs of the untreated mice at both days 3 and 7 post infection. However, no
infectious virus was detectable by direct plaque assay, in the lungs of the
prophylactically 4'-s-EtdU treated mice at any time point tested, including those
normally associated with the acute infection (see figure 4.2.1).
Virus was reactivated from the lungs of all the untreated mice sampled at days 12, 21
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Figure 4.2.1 The infectious virus titres (as measured by direct plaque assay) detected in
the lungs ofmice infected intra-nasally with 4xl05 pfu MHV-68. The mice were either
left untreated (black), prophylactically 4'-s-EtdU treated and not withdrawn (blue) or
withdrawn from treatment day 12 post infection (red). Four mice were sampled from
each group at every time point (days 3, 7, 12 and 21 post infection) except day 31 post
infection. Four mice were sampledfrom the untreated group at day 31 post infection but
only 3 mice from the prophylactically treated (and not withdrawn) group and the
treatment withdrawn (at day 12 post infection) group. The values are represented by
geometric means and the error bars represent the standard deviation. The dotted line
represents the assay limit ofdetection.
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lungs of the mice withdrawn from the 4'-s-EtdU treatment, at both days 21 and 31
post infection. However, virus could only be reactivated from 2/11 mice not
withdrawn from treatment, 2/4 at the earliest time point, day 12 post infection, and
0/7 at the later 2 time points, days 21 and 31 post infection (see figure 4.2.2).
4.2.5 The effect of prophylactic 4'-s-EtdU treatment on the MHV-68 induced
splenomegaly in mice.
Spleens were taken from all mice, except those sampled at day 3 post infection. The
untreated mice experienced a splenomegaly (see figure 4.2.3). At day 7 post
infection, there was no significant difference between the mean number of
splenocytes observed in treated and untreated mice (P= 0.7 by student T-test).
However, the mean number of splenocytes observed in the untreated mice had
significantly increased by day 12 post infection. The splenocyte counts were still
significantly elevated at day 21 post infection but had decreased to a non-
significantly elevated level by day 31 post infection (P= 0.002, 0.004 and 0.15
respectively, by student T-test).
The prophylactically 4'-s-EtdU treated mice (both withdrawn and non-withdrawn
from treatment) did not experience splenomegaly, with the mean number of
splenocytes showing no significant change across the time course. There was no
significant differences between the mean number of splenocytes observed in the
mice withdrawn and not withdrawn from treatment. The 4'-s-EtdU treatment did not
appear to directly affect the number of splenic leukocytes observed in the mice, since
at day 7 post infection there was no significant difference between the treated and
untreated mouse groups. However, due to the splenomegaly experienced by the
untreated mice, the mean number of splenocytes was significantly elevated as
compared to the treated and not withdrawn mice, at days 12 and 21, and the mice
withdrawn from treatment, at day 21 post infection (P= 0.0024, 0.015 and 0.022
respectively, by student T-test). By day 31 post infection, the splenomegaly in the
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Figure 4.2.2 The levels of infectious virus reactivated (by co-cultivation assay) from the
lung tissue ofmice infected intra-nasally with 4x10: pfu MHV-68. The mice were either
left untreated (black), prophylactically 4 '-s-EtdU treated and not withdrawn (blue) or
withdrawn from treatment day 12 post infection (red). Four mice were sampled from
each group at every time point (days 3, 7, 12 and 21 post infection) except day 31 post
infection. Four mice were sampled from the untreated group at day 31 post infection
but only 3 mice from the prophylactically treated (and not withdrawn) group and the




Figure 4.2.3 The number of splenocytes observed in mice infected intra-nasally with
4xl05 pfu MHV-68. The mice were either left untreated (black), prophylactically 4'-s-
EtdU treated and not withdrawn (blue) or withdrawn from treatment day 12 post
infection (red). Four mice were sampledfrom each group at every time point (days 3, 7,
12 and 21 post infection) except day 31 post infection. Four mice were sampledfrom the
untreated group at day 31 post infection but only 3 mice from the prophylactically
treated (and not withdrawn) group and the treatment withdrawn (at day 12 post
infection) group. The values are represented by arithmetic means and the error bars
represent the standard deviation.
182
mean number of splenocytes observed in any of the three groups ofmice.
4.2.6 The effect of prophylactic 4'-s-EtdU treatment on the MHV-68 infection
of the splenocytes of mice.
The splenocyte infectious centre titre in the untreated mice followed the pattern,
commonly observed in BALB/c mice, following intra-nasal infection with MHV-68.
The splenic infectious centre titre was at a relatively low level at day 7 post
infection. By day 12 post infection, the infectious centre had significantly increased
(P=0.0003 by student T-test) to peaked levels. By day 21, the titre had significantly
decreased (P=0.0002 by student T-test) back to the base level, remaining unaltered at
day 31 post infection (P=0.59 by student T-test). No infectious centres were
observed in any of the mice not withdrawn from the prophylactic 4'-s-EtdU
treatment, at any time point. An infectious centre titre was not detected in the mice
withdrawn from the 4'-s-EtdU treatment, at day 21 post infection. However, 2 /3
mice assayed at day 31 post infection, gave rise to infectious centres, albeit on the
limits of the assay sensitivity (see figure 4.2.4).
Because the levels of splenic reactivation were potentially very low, for the mice
withdrawn and not withdrawn from the prophylactic 4'-s-EtdU treatment withdrawn,
splenocyte co-cultivation assays were performed, as well as by infectious centre
assays. The splenocyte co-cultivation assays confirmed that virus could be
reactivated from 2/3 mice withdrawn from treatment, sampled at day 31 post
infection. However, no virus could be reactivated from any of the mice not
withdrawn from treatment, sampled at days 12, 21 and 31 or the treatment
withdrawn mice, sampled at day 21 post infection (see Table 4.2).
4.2.7 The detection of MHV-68 genomic DNA in the splenocytes and lung
tissue of mice treated with 4'-s-EtdU.
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Figure 4.2.4 The latent virus titres (as measured by infectious centre assay) detected in
the spleens ofmice infected intra-nasally with 4xl05pfu MHV-68. The mice were either
left untreated (black), prophylactically 4 '-s-EtdU treated and not withdrawn (blue) or
withdrawn from treatment day 12 post infection (red). Four mice were sampled from
each group at every time point (days 3, 7, 12 and 21 post infection) except day 31 post
infection. Four mice were sampledfrom the untreatedgroup at day 31 post infection but
only 3 mice from the prophylactically treated (and not withdrawn) group and the
treatment withdrawn (at day 12 post infection) group. The values are represented by
geometric means and the error bars represent the standard deviation. The dotted line
represents the assay limit ofdetection.
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Table 4.2 The effect of prophylactic 4'-s-EtdU treatment on the MHV-68
infectious virus titres reactivated from splenocytes (by co-cultivation
assay) of intra-nasally infected mice.
Infectious virus titre (pfu) per splenocyte co-cuitivation
Mouse Day 21 post infection Day 31 post infection
Number Untreated Treated Withdrawn Untreated Treated Withdrawn
1 1600 <5 <5 1800 <5 <5
2 ND <5 <5 3000 <5 950
3 ND <5 <5 2000 <5 5900
4 ND <5 <5 8800 - -
Key: ND - Not done.
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prophy1actically 4'-s-EtdU treated mice, MHV-68 specific PCR was carried out on
DNA extracted from both splenocytes and lung tissue from the mice sampled at the
later experimental time points. The virus genomic DNA could not be detected in
DNA extracted from the splenocytes of the continually 4'-s-EtdU treated mice. First
round (40 cycle) PCR carried out on DNA extracted from the splenocytes of the
untreated mice, produced a MHV-68 specific band of 500bp with 3/4 mice sampled
at day 21 post infection and 2/3 mice sampled at day 31 post infection. However,
none of the treated mice either those withdrawn (0/7) or not withdrawn from
treatment (0/7), sampled at both days 21 and 31 post infection, gave rise to a MHV-
68 specific band of 500bp, after 40 cycles of PCR (see figure 4.2.5). After a further
25 cycles of nested PCR, the DNA extracted from the splenocyte samples, from all
the untreated mice, sampled at both days 21 (4/4) and 31 (3/3) post infection, gave
rise to a MHV-68 specific nested PCR band of 400bp. Of the mice withdrawn from
treatment, only 1/4 splenocyte DNA samples, from the mice sampled at day 21 post
infection, gave rise to a MHV-68 specific nested PCR band of 400bp. However, by
day 31 post infection, all splenocyte DNA samples, derived from the mice withdrawn
from treatment, gave rise to MHV-68 specific nested PCR bands at 400bp. Nested
PCR carried out on splenocyte DNA, derived from the treated mice that were not
withdrawn from treatment, sampled on both days 21 and 31 post infection, failed to
produced MHV-68 specific bands (0/4 and 0/3 respectively) (seefigure 4.2.6).
Contrary to the results from the PCR analysis carried out on the splenocyte DNA, the
lung tissue of all the mice, from all 3 groups, sampled at day 31 post infection, were
shown to harbour MHV-68 genomic DNA. DNA extracted from the lung tissue of
the untreated mice (4/4) and mice withdrawn from treatment (3/3), sampled at day
31 post infection, gave a MHV-68 specific PCR band of 500bp, after 40 cycles of
PCR (see figure 4.2.7). The DNA extracted from the lung tissue of all the treated
mice that were not withdrawn from treatment, failed to produce a MHV-68 specific
band after 40 cycles of PCR (0/3). However all the mice not withdrawn from
treatment (3/3) went on to produce a virus specific PCR band at 400bp, after a
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Figure 4.2.5
Figure 4.2.5 The effects ofprophylactic 4 '-s-EtdU treatment on the establishment ofviral
persistance in the splenocytes of mice infected infected by the intra-nasal and intra¬
peritoneal routes of infection, as determined byfirst round PCR. Fourjficycles ofMHV-68
specific PCR was carried out on 500ng ofDNA extracted from the lung tissue ofmice
which were either either infected intra-nasally MHV-68 and sampled at day 21 (lanes 6 to
15) and day 31 post infection (lanes 29 to 37) or infected intra-peritoneally and sampled
at day 24 post infection (lanes 16 to 28). The infected mice were either left untreated
(lanes 4 to 7, 16 to 20 and 29 to 31), prophylactically treated with 4'-s-EtdU and not
withdrawn (lanes 12 to 15, 25 to 28 and 35 to 37) or withdrawn from treatment at day 12
post infection (lanes 8 to 11, 21 to 24 and 32 to 34). Lane 2 represents the PCR positive
control and was carried out on 200ng of DNA extracted from MHV-68 persistently
infected NSO cells. Lane 3 represent the PCR negative control and was carried out on
500ng of DNA extracted from splenocytes of an uninfected BALB/c mouse. The PCR
products were visualised by 2% agarose gel electrophoresis and ethidium bromide
staining, viewed under UV. Product size was determined by comparison to lkbp Ladder
(lane 1). Forfurther details see table4.3.
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Table 4.3 The summarised results in figure 4.2.5 (the first round MHV-68
specific PCR, carried out on splenic DNA extracted from both 4'-s-
EtdU treated and untreated, MHV-68 infected mice).
Lane Sample Description Mouse Route ofMHV-68
1
Day PCR
Number Number Inoculation Sampled Result
1 1KB Ladder - - - -
2 2 Positive Control - - - +ve
3 3 Negative Control - - - -ve
4 Group 1 spleen 1 Intra-nasal 21 +ve
5 Group 1 spleen 2 Intra-nasal 21 -ve
6 Group 1 spleen 3 Intra-nasal 21 +ve
7 Group 1 spleen 4 Intra-nasal 21 +ve
8 Group 2B spleen 1 Intra-nasal 21 -ve
9 Group 2B spleen 2 Intra-nasal 21 -ve
10 Group 2B spleen 3 Intra-nasal 21 -ve
11 Group 2B spleen 4 Intra-nasal 21 -ve
12 Group 2A spleen 1 Intra-nasal 21 -ve
13 Group 2A spleen 2 Intra-nasal 21 -ve
14 Group 2A spleen 3 Intra-nasal 21 -ve
15 Group 2A spleen 4 Intra-nasal 21 -ve
16 Group 1 spleen 1 Intra-peritoneal 24 +ve
17 Group 1 spleen 2 Intra-peritoneal 24 +ve
18 Group 1 spleen 3 Intra-peritoneal 24 +ve
19 Group 1 spleen 4 Intra-peritoneal 24 +ve
20 Group 1 spleen 5 Intra-peritoneal 24 +ve
21 Group 2B spleen 1 Intra-peritoneal 24 -ve
22 Group 2B spleen 2 Intra-peritoneal 24 +ve
23 Group 2B spleen 3 Intra-peritoneal 24 -ve
24 Group 2B spleen 4 Intra-peritoneal 24 -ve
25 Group 2A spleen 1 Intra-peritoneal 24 -ve
26 Group 2A spleen 2 Intra-peritoneal 24 -ve
27 Group 2A spleen 3 Intra-peritoneal 24 -ve
28 Group 2A spleen 4 Intra-peritoneal 24 -ve
29 Group 1 spleen 1 Intra-nasal 31 +ve
30 Group 1 spleen 2 Intra-nasal 31 -ve
31 Group 1 spleen 3 Intra-nasal 31 +ve
32 Group 2B spleen 1 Intra-nasal 31 -ve
33 Group 2B spleen 2 Intra-nasal 31 -ve
34 Group 2B spleen 3 Intra-nasal 31 -ve
35 Group 2A spleen 1 Intra-nasal 31 -ve
36 Group 2A spleen 2 Intra-nasal 31 -ve
37 Group 2A spleen 3 Intra-nasal 31 -ve
Key: - ~ Not applicable, -ve ~ PCR negative, +ve ~ PCR positive,1 ~ Time when
mice were killed (days post infection), 2 ~ DNA extracted from MHV-68 infected
NSO cells,3 ~ DNA extracted from uninfected NSO cells. The Group 1 mice were
left untreated, the Group 2 mice were treated prophylactically with 4'-s-EtdU and
either not withdrawn (A) or withdrawn from treatment on day 12 post infection (B).
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Figure 4.2.6
Figure 4.2.6 The effects ofprophylactic 4 '-s-EtdU treatment on the establishment ofviral
persistance in the splenocytes of mice infected infected by the intra-nasal and intra¬
peritoneal routes of infection, as determined by nested PCR. A firther 25 cycle MHV-68
specific nested PCR carried out on 2pi of the products from the first round PCR,
originally carried out on 500ng ofDNA extracted from splenocytes ofMHV-68 infected
mice. The mice were either infected intra-nasally MHV-68 and sampled at day 21 (lanes 4
to 15) and day 31 post infection (lanes 16 to 24) or infected intra-peritoneally and
sampled at day 24 post infection (lanes 25 to 37). The infected mice were either left
untreated (lanes 4 to 7, 16 to 18 and 25 to 29), prophylactically treated with 4'-s-EtdU
and not withdrawn (lanes 12 to 15, 22 to 24 and 34 to 37) or withdrawn from treatment at
day 12 post infection (lanes 8 to 11, 19 to 21 and 32 to 34). Lane 2 represents the PCR
positive control and was carried out on 200ng of DNA extracted from MHV-68
persistently infected NSO cells. Lane 3 represent the PCR negative control and was
carried out on 500ng ofDNA extractedfrom splenocytes ofan uninfected BALB/c mouse.
The nest PCR products were visualised by 2% agarose gel electrophoresis and ethidium
bromide staining, viewed under UV. Product size was determined by comparison to lkbp
Ladder (lane 1). Forfurther information see Table 4.4.
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Table 4.4 The summarised results in figure 4.2.6 (the MHV-68 specific nested
PCR, carried out on splenic DNA extracted from both 4'-s-EtdU
treated and untreated MHV-68 infected mice).
Lane Sample Description Mouse Route ofMHV-68 1 Day Nested
Number Number Inoculation Sampled PCR
Result
1 1KB Ladder - - - -
2 2 Positive Control - - - +ve
3 3 Negative Control - - - -ve
4 Group 1 spleen 1 Intra-nasal 21 +ve
5 Group 1 spleen 2 Intra-nasal 21 +ve
6 Group 1 spleen 3 Intra-nasal 21 +ve
7 Group 1 spleen 4 Intra-nasal 21 +ve
8 Group 2B spleen 1 Intra-nasal 21 -ve
9 Group 2B spleen 2 Intra-nasal 21 -ve
10 Group 2B spleen 3 Intra-nasal 21 -ve
11 Group 2B spleen 4 Intra-nasal 21 +ve
12 Group 2A spleen 1 Intra-nasal 21 -ve
13 Group 2A spleen 2 Intra-nasal 21 -ve
14 Group 2A spleen 3 Intra-nasal 21 -ve
15 Group 2A spleen 4 Intra-nasal 21 -ve
16 Group 1 spleen 1 Intra-nasal 31 +ve
17 Group 1 spleen 2 Intra-nasal 31 +ve
18 Group 1 spleen 3 Intra-nasal 31 +ve
19 Group 2B spleen 1 Intra-nasal 31 +ve
20 Group 2B spleen 2 Intra-nasal 31 +ve
21 Group 2B spleen 3 Intra-nasal 31 +ve
22 Group 2A spleen 1 Intra-nasal 31 -ve
23 Group 2A spleen 3 Intra-nasal 31 -ve
24 Group 2A spleen 2 Intra-nasal 31 -ve
25 Group 1 spleen 1 Intra-peritoneal 24 +ve
26 Group 1 spleen 2 Intra-peritoneal 24 +ve
27 Group 1 spleen 3 Intra-peritoneal 24 +ve
28 Group 1 spleen 4 Intra-peritoneal 24 +ve
29 Group 1 spleen 5 Intra-peritoneal 24 +ve
30 Group 2B spleen 1 Intra-peritoneal 24 +ve
31 Group 2B spleen 2 Intra-peritoneal 24 +ve
32 Group 2B spleen 3 Intra-peritoneal 24 +ve
33 Group 2B spleen 4 Intra-peritoneal 24 +ve
34 Group 2A spleen 1 Intra-peritoneal 24 +ve
35 Group 2A spleen 2 Intra-peritoneal 24 +ve
36 Group 2A spleen 3 Intra-peritoneal 24 -ve
37 Group 2A spleen 4 Intra-peritoneal 24 -ve
Key: - ~ Not applicable, -ve ~ nested PCR negative, +ve ~ nested PCR positive, 1 ~ Time
when mice were killed (days post infection),2 ~ DNA extracted from MHV-68 infected NSO
cells, 3 ~ DNA extracted from uninfected NSO cells. The Group 1 mice were left untreated,
the Group 2 mice were treated prophylactically with 4'-s-EtdU and either not withdrawn (A)
or withdrawn from treatment on day 12 post infection (B).
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Figure 4.2.7
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Figure 4.2.7 The effects ofprophylactic 4 '-s-EtdU treatment on the establishment ofviral
persistence in the lungs ofmice infected infected by the intra-nasal and intra-peritoneal
routes of infection. First roundMHV-68 specific PCR was carried out on 500ng ofDNA
extracted from the lung tissue of mice which were either infected intra-nasally and
sampled at day 31 post infection (A) or infected intra-peritoneally and sampled at day 24
post infection (B). A further 25 cycles ofMHV-68 specific nested PCR was also carried
out on 10 pi of the first round PCR products thatfailed to produce a virus spesific band
at 500bp (C). The infected mice were either left untreated (lanes 6 to 9 and 20 to 24),
prophylactically treated with 4 '-s-EtdU and not withdrawn (lanes 10 to 12 and 25 to 28)
or withdrawn from treatment at day 12 post infection (lanes 13 to 15 and 29 to 32). Lane
2 represents the PCR positive control and was carried out on 200ng ofDNA extracted
from MHV-68 persistently infected NSO cells. Lane 3 represents a PCR blank control
and was carried out on 10pi of distilled water. Lanes 4 and 5 represent PCR negative
controls and were carried out on 500ng ofDNA extractedfrom lung tissue of uninfected
BALB/c mice. The products were visualised by 2% agarose gel electrophoresis and
ethidium bromide staining, viewed under UV. Product size was determined by
comparison to lkbp Ladder (lane 1). Forfurther information see Table 4.5.
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Table 4.5 The summarised results in figure 4.2.7 (the first round and nested
MHV-68 specific PCR, carried out on lung DNA extracted from both
4'-s-EtdU treated and untreated MHV-68 infected mice).
Lane Sample Description Mouse Route ofMHV-68
1
Day 1st Round Nested
Number Number Inoculation Sampled PCR PCR
Results Result
1 1KB Ladder - - - - -
2 2 Positive Control - - - +ve +ve
3 3 Blank - - - -ve -ve
4 Uninfected Lung 1 - - -ve -ve
5 Uninfected Lung 2 - - -ve -ve
6 Group 1 lung 1 Intra-nasal 31 +ve ND
7 Group 1 lung 2 Intra-nasal 31 +ve ND
8 Group 1 lung 3 Intra-nasal 31 +ve ND
9 Group 1 lung 4 Intra-nasal 31 +ve ND
10 Group 2A lung 1 Intra-nasal 31 -ve +ve
11 Group 2A lung 2 Intra-nasal 31 -ve +ve
12 Group 2A lung 3 Intra-nasal 31 -ve +ve
13 Group 2B lung 1 Intra-nasal 31 +ve ND
14 Group 2B lung 2 Intra-nasal 31 +ve ND
15 Group 2B lung 3 Intra-nasal 31 +ve ND
20 Group 1 lung 1 Intra-peritoneal 24 +ve ND
21 Group 1 lung 2 Intra-peritoneal 24 +ve ND
22 Group 1 lung 3 Intra-peritoneal 24 +ve ND
23 Group 1 lung 4 Intra-peritoneal 24 +ve ND
24 Group 1 lung 5 Intra-peritoneal 24 +ve ND
25 Group 2A lung 1 Intra-peritoneal 24 -ve -ve
26 Group 2A lung 2 Intra-peritoneal 24 -ve +ve
27 Group 2A lung 3 Intra-peritoneal 24 -ve -ve
28 Group 2A lung 4 Intra-peritoneal 24 -ve -ve
29 Group 2B lung 1 Intra-peritoneal 24 -ve -ve
30 Group 2B lung 2 Intra-peritoneal 24 +ve +ve
31 Group 2B lung 3 Intra-peritoneal 24 -ve -ve
32 Group 2B lung 4 Intra-peritoneal 24 -ve +ve
Key: - ~ Not applicable, ND ~ sample not tested, -ve ~ negative, +ve ~ positive,1 ~
Time when mice were killed (days post infection),2 ~ DNA extracted from MHV-68
infected NSO cells,3 ~ sterile distilled water. The Group 1 mice were left untreated,
the Group 2 mice were treated prophylactically with 4'-s-EtdU and either not
withdrawn (A) or withdrawn from treatment on day 12 post infection (B).
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further 25 cycles of nested PCR (see figure 4.2.7c).
4.2.8 The long-term effects of prophylactic 4'-s-EtdU treatment on the MHV-
68 infection.
A second experiment was set up to determine whether MHV-68 could persist in the
lungs long-term in the apparent absence of both productive viral replication and
latently infected circulating B-lymphocytes. It was also of interest to determine
whether a specific immune response was made to MHV-68 late antigens in the
prophylactically 4'-s-EtdU treated mice.
Thirty female BALB/c mice, 3 to 4 weeks old, were randomly selected from 50 and
put on drinking water containing 0.3mg/ml 4'-s-EtdU. After 24 hours treatment 4
mice on the 4'-s-EtdU drinking water and 4 of the 20 mice on the normal drinking
water were tail bled and the sera stored at -30°C. After 48 hours, 9 of the untreated
and 24 of the treated mice were infected with 4xl05 pfu MHV-68 via the intra-nasal
route. At day 6 post infection, 3 mice from each of the infected groups ofmice and 2
mice from the uninfected groups of mice were killed, heart bled and had their lungs
and spleens removed. The lung tissue and sera were stored at -80°C and -30°C
respectively. Infectious centre assays were carried out on the splenocytes. At day 12
post infection, 9 of the prophylactically 4'-s-EtdU treated mice were withdrawn from
the treatment and restored to normal drinking water. At day 18 post infection, 4
mice from each group were killed and spleens, lungs and sera removed and assayed,
as on day 6 post infection. On day 51 post infection, 4 of the 8 remaining 4'-s-EtdU
treated infected mice were withdrawn from treatment and restored to normal
drinking water. On day 54 post infection the experiment had to be terminated since
the mice treated with 4'-s-EtdU for 51 days or more, both infected and uninfected,
had developed peritoneal swelling. The swelling apon post-mortem examination,
was attributed to ascites fluid build up. All the mice from all the groups were
therefore killed, heart bled and spleens and lungs removed for analysis.
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4.2.9 The long-term effects of prophylactic 4'-s-EtdU treatment on the
production MHV-68 specific antibodies by infected mice.
Concurrent with the hypothesis that high dose 4'-s-EtdU treatment completely
inhibits productive virus replication in vivo, the prophylactically treated mice failed
to produce significant levels ofMHV-68 late antigen specific antibodies, following
intra-nasal infection. Whole virus lysate ELISA was carried out on the sera collected
from the mice sampled across the time course. The background level was determined
by the mean OD490 of the 4'-s-EtdU treated and untreated mouse bleeds taken prior
to infection. Significant MHV-68 specific antibody production was determined, at
the individual level, by a mouse sera giving an OD490 of greater than twice the
background level. At the group level, significant MHV-68 specific antibody
production was determined by OD490 comparison to the pre-infected sera, using
student T-test {see figure 4.3.1).
At day 6 post infection none of the infected mice, treated or untreated had produced
significant levels of MHV-68 specific antibodies. By day 18 post infection, all the
untreated infected mice sera gave ELISA readings significantly higher than the pre-
bleed values (P=0.011 by student T-test). However, the sera from the
prophylactically treated infected mice (that were not withdrawn from treatment)
remained non-significantly different from the pre-bleed sera (P=0.3 by student T-
test). The infected mice withdrawn from the 4'-s-EtdU treatment on day 12, were
border line with respect to MHV-68 specific antibody production. Of the 4 mice
tested, 2 had exactly twice the background pre-bleed OD490 value and 2 were below.
However, as a group, the OD490 values were significantly higher than the pre-bleed
values (P=0.002 by student T-test) and therefore the mice were judged, as a group, to
have started to produce significant levels of anti-MHV-68 antibodies. At day 54 post
infection, the ELISA readings for the untreated, infected mice further increased,
from the day 18 post infection values (P=0.0002 by student T-test). The ELISA
readings for the infected mice withdrawn from treatment on day 12 post infection,
also significantly increased, with all 5 animals clearly producing significant levels of
194
Figure 4.3.1
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Figure 4.3.1 levels of antibody production to late MHV-68 antigens (as measured by
whole virus ELISA) in mice infected intra-nasally with 4xl05 pfu MHV-68. The mice
were either left untreated (black), prophylactically 4 '-s-EtdU treated and not withdrawn
(blue) or withdrawn from treatment at day 12 post infection (red). The sera from the
infected mice was compared to sera from mock infected mice (green), which were bled
at the same time as the infected mice. Between 3 and 4 mice from each group were bled
at days -1, 6, and 18 post infection and 5 mice were bled at day 54 post infection. The
values represent arithmetic means and the error bars represent the standard deviation.
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anti-MHV-68 antibodies (P=0.0007 by student T-test). However, both the infected
mice that were not withdrawn from treatment and the mice withdrawn from the 4'-s-
EtdU treatment on day 51 post infection, remained negative with respect to MHV-68
specific antibody production (P=0.2 and 0.67 respectively by student T-test). There
was no significant differences seen between the non-withdrawn 4'-s-EtdU treated
mice, both infected and uninfected mice, the untreated uninfected mice, and the
infected mice withdrawn from treatment on day 51 post infection.
4.3.1 The long-term effects of prophylactic 4'-s-EtdU treatment on viral
persistence in the lung
An acute viral infection of the lung occurred in the untreated MHV-68 infected mice,
indicated by the high lung infectious virus titres observed at day 6 post infection.
However, no infectious virus was detected in the lungs of the prophylactically treated
infected mice, at any time point, by direct plaque assay (see figure 4.3.2). To
determine ifMHV-68 genomic DNA still persisted at this site, MHV-68 specific 40
cycle PCR was carried out on DNA samples extracted from the lung tissue of the
mice sampled at day 54 post infection. MHV-68 specific PCR bands at 500bp were
produced by all the untreated infected mice (4/4) and 3 of the 4 treatment withdrawn
(at day 12 post infection) mice. However, a MHV-68 specific PCR band was not
produced by the continually treated infected mice (0/4) or treatment withdrawn (at
day 51 days post infection) infected mice (0/4) (see figure 4.3.3a). A further 25
rounds of nested PCR was carried out on the DNA samples from the MHV-68
infected continually treated mice and the mice withdrawn from the treatment at days
12 and 51 post infection. All gave rise to MHV-68 specific nested PCR bands at
400bp (see figure 4.3.3b).
4.3.2 The long-term effects of prophylactic 4'-s-EtdU treatment on
splenomegaly induction and the establishment of viral latency in splenocytes.




Time (days post infection)
Figure 4.3.2 The infectious virus titres (as measured by direct plaque assay) detected in
the lungs ofmice infected intra-nasally with 4xl05 pfu MHV-68. The mice were either
left untreated (black), prophylactically 4 '-s-EtdU treated and not withdrawn (blue) or
withdrawn from treatment day 12 post infection (red). Three mice were sampledfrom
each group at day 6 and 4 mice at days 18 and 54 post infection. The values are
represented by geometric means and the error bars represent the standard deviation.
The assay limit ofdetection was 10pfu per lung.
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Figure 4.3.3
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Figure 4.3.3 The long term effects ofprophylactic 4's-EtdU treatment on the on viral
persistence in the lungs ofMHV-68 mice infected mice, as determined by PCR. First
round MFIV-68 specific PCR was carried out on 500ng ofDNA extracted from the lung
tissue of BALB/c mice, infected intra-nasally with 4xl05 pfu MHV-68 (A). A second
round of25 cycle MHV-68 spesific nested PCR was carried out on 10pi of the first round
PCR products (B). The infected mice were either left untreated (lanes 5 to 8),
prophylactically treated with 4'-s-EtdU and not withdrawn (lanes 9 to 12), withdrawn
from treatment at 12 days post infection (lanes 13 to 16) or withdrawn from treatment at
51 days post infection (lanes 17 to 20). All mice were sampled on day 54 post infection.
Lane 2 represents the PCR positive control and was carried out on 200ng of DNA
extracted from MHV-68 persistently infected NSO cells. Lanes 3 and 4 represent PCR
negative controls and were carried out on 500ng ofDNA extracted from lung tissue of
uninfected BALB/c mice. The products were visualised by 2% agarose gel
electrophoresis and ethidium bromide staining, viewed under UV. Product size was
determined by comparison to lkbp Ladder (lane 1). Forfurther information see Table 4.6.
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Table 4.6 The summarised results in figure 4.3.3 (the first round and nested
MHV-68 specific PCR, carried out on lung DNA extracted from both
4'-s-EtdU treated and untreated, MHV-68 infected mice).
Lane Sample Description Mouse Route ofMHV-68
1
Day 1st Round Nested




1 1KB Ladder - - - - -
2 2 Positive Control - - - +ve +ve
3 Uninfected lung 1 - - -ve -ve
4 Uninfected lung 2 - - -ve -ve
5 Group 1 Lung 1 Intra-nasal 54 +ve ND
6 Group 1 lung 2 Intra-nasal 54 +ve ND
7 Group 1 lung 3 Intra-nasal 54 +ve ND
8 Group 1 lung 4 Intra-nasal 54 +ve ND
9 Group 2A lung 1 Intra-nasal 54 -ve +ve
10 Group 2A lung 2 Intra-nasal 54 -ve +ve
11 Group 2A lung 3 Intra-nasal 54 -ve +ve
12 Group 2A lung 4 Intra-nasal 54 -ve +ve
13 Group 2B lung 1 Intra-nasal 54 -ve +ve
14 Group 2B lung 2 Intra-nasal 54 +ve +ve
15 Group 2B lung 3 Intra-nasal 54 +ve +ve
16 Group 2B lung 4 Intra-nasal 54 +ve +ve
17 Group 2C lung 1 Intra-nasal 54 -ve +ve
18 Group 2C lung 2 Intra-nasal 54 -ve +ve
19 Group 2C lung 3 Intra-nasal 54 -ve +ve
20 Group 2C lung 4 Intra-nasal 54 -ve +ve
Key: - ~ Not applicable, ND ~ sample not tested, -ve ~ negative, +ve ~ positive,1 ~
Time when mice were killed (days post infection),2 ~ DNA extracted from MHV-68
infected NSO cells. The Group 1 mice were left untreated, the Group 2 mice were
treated prophylactically with 4'-s-EtdU and either not withdrawn (A), withdrawn
from treatment on day 12 post infection (B) or withdrawn from treatment on day 51
post infection (C).
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the untreated, infected mice, but failed to occur in the continuously treated and
treatment withdrawn, infected mice (see figure 4.3.4). At day 6 post infection the
numbers of splenocytes observed in the untreated infected mice was not significantly
different from either the prophylactically treated infected mice or the uninfected
mice (P= 0.58 and 0.48 respectively by student T test). However, there was a
significant increase in the numbers of splenocytes observed in the untreated infected
mice at day 18 post infection, both with respect to the numbers observed in the
continually treated and treatment withdrawn infected mice and to the untreated
infected mice at day 6 post infection (P= 0.0004, 0.006 and 0.0007 respectively by
student T-test). By day 54 post infection, the splenomegaly in the untreated infected
animals had receded. There was no significant difference between the number of
splenocytes observed in the any of the different groups of mice, both infected and
uninfected. No significant increase in the numbers of splenocytes was observed
across the time course with the continually treated and treatment withdrawn mice.
At day 6 post infection, splenic infectious centres were detected in 2/3 untreated
infected mice. By day 18 post infection, splenic infectious centres were detectable in
all of the untreated infected mice, averaging 787 infectious centres per spleen. By
day 54 post infection, the levels of infectious centres had decreased to an average of
9 infectious centres per spleen with infectious centres only being detectable in 2/5
mice. Infectious centres were not detectable in any of the mice not withdrawn from
the prophylactic 4'-s-EtdU treatment, at any of the experimental time points. No
infectious centres were detected in any of the mice withdrawn from treatment (on
day 12 post infection), sampled at day 18 post infection. However, by day 54 post
infectious centres were detected in 3/5 mice withdrawn from treatment, giving an
average of 11 infectious centres per spleen, which was indistinguishable from the
untreated mice, at the same time point (see figure 4.3.5). No infectious centres were
detected, at day 54 post infection, in the mice withdrawn from the 4'-s-EtdU






Figure 4.3.4 The number of splenocytes observed in mice infected intra-nasally with
4xl05 pfu MHV-68. The mice were either left untreated (black), prophylactically 4'-s-
EtdU treated and not withdrawn (blue) or withdrawn from treatment day 12 post
infection (red). Three mice from the untreated group were sampled at day 6, 4 mice at
day 18 and 5 mice at day 31 post infection. Three mice from the prophylactically
treated (and not withdrawn) group were sampled at day 6 and 4 mice at days 18 and 54
post infection. Four mice from the treatment withdrawn (at day 12 post infection) group
were sampled at day 18 and 5 mice at day 54 post infection. The values are represented
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Figure 4.3.5 The latent virus titres (as measured by infectious centre assayj detected in
the spleens ofmice infected with 4x105 pfu MHV-68, via the intra-nasal route. The mice
were either left untreated (black), prophylactically 4 '-s-EtdU treated and not withdrawn
(blue) or withdrawn from treatment day 12 post infection (red). Three mice from the
untreated group were sampled at day 6, 4 mice at day 18 and 5 mice at day 31 post
infection. Three mice from the prophylactically treated (and not withdrawn) group were
sampled at day 6 and 4 mice at days 18 and 54 post infection. Four mice from the
treatment withdrawn (at day 12 post infection) group were sampled at day 18 and 5
mice at day 54 post infection. The values are represented by geometric means and the
error bars represent the standard deviation. The assay limit of detection was 5
infectious centres per spleen.
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MHV-68 specific 40 cycle PCR was carried out on DNA samples extracted from the
splenocytes of the mice sampled at day 54 post infection. MHV-68 specific PCR
bands of 500bp was produced by 3/4 untreated infected mice tested and with all mice
withdrawn from treatment at day 12 post infection (4/4). However, a MHV-68
specific PCR band was not produced by the infected mice which were either not
withdrawn from treatment (0/4) or withdrawn on day 51 post infection (0/4) (see
figure 4.3.6a). A further 25 rounds of nested PCR was carried out on the DNA
samples from the infected mice which were either not withdrawn from treatment,
withdrawn from treatment on days 51 post infection or left untreated. All the
untreated mice splenic DNA samples (4/4) gave rise to a MHV-68 specific nest PCR
band at 400bp. However, a MHV-68 specific PCR band was not produced by any of
the mice that were either not withdrawn from treatment (0/4) or withdrawn from
treatment on day 51 post infection (0/4) (see figure 4.3.6b).
4.3.3 The prophylactic 4'-s-EtdU treatment of BALB/c mice, infected via the
intra-peritoneal route.
MHV-68 infections initiated in the peritoneal cavity, give rise to a more systemic
infection than when initiated in the lungs. Viral latency can be detected earlier in the
spleens of mice infected via the intra-peritoneal route and the associated
splenomegaly is more severe, than with mice infected via the intra-nasal route. An
experiment was therefore set up to compare and contrast the effects of prophylactic
4'-s-EtdU treatment on mice infected via the intra-peritoneal route. An experiment
to determine whether productive virus replication is required merely as a means of
crossing the lung epithelium or whether it plays a more fundamental role in the
establishment of viral latency in splenic B-lymphocytes.
Thirteen BALB/c female mice, aged 3 to 4 weeks were randomly selected from a
batch of 22 age and sex matched animals and were put on drinking water containing
0.3mg/ml 4'-s-EtdU. The remaining 9 animals remained on normal drinking water.
After 2 days of treatment, the mice on 4'-s-EtdU drinking water and the normal
203
Figure 4.3.6
Figure 4.3.6 The long term effects ofprophylactic 4'-s-EtdU treatment on the on viral
persistence in the spleen ofMHV-68 mice infected mice, as determined by PCR. First
round 40 cycle MHV-68 specific PCR was carried out on 500ng ofDNA extracted from
splenocytes ofBALB/c mice, infected intra-nasally with 4xl05 pfu MHV-68 (A). A second
round of25 cycle MHV-68 specific nested PCR was also carried out on 10pi of the first
round PCR products (B). The infected mice were either left untreated (lanes 5 to 8),
prophylactically treated with 4'-s-EtdU and not withdrawn (lanes 9 to 12), withdrawn
from treatment at 12 days post infection (lanes 13 to 16) or withdrawn from treatment at
51 days post infection (lanes 17 to 20). All mice were sampled on day 54 post infection.
Lane 2 represents the PCR positive control and was carried out on 200ng of DNA
extracted from MHV-68 persistently infected NSO cells. Lanes 3 and 4 represent PCR
negative controls and were carried out on 500ng ofDNA extracted from splenocytes of
uninfected BALB/c mice. The products were visualised by 2% agarose gel
electrophoresis and ethidium bromide staining, viewed under UV. Product size was
determined by comparison to lkbp Ladder (lane I). For further information see Table
4.7.
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Table 4.7 The summarised results in figure 4.3.6 (the first round and nested
MHV-68 specific PCR, carried out on splenic DNA extracted from
both 4'-s-EtdU treated and untreated MHV-68 infected mice).
Lane Sample Description Mouse Route ofMHV-68
1
Day 1st Round Nested




1 1KB Ladder - - - - -
2 2 Positive Control - - - +ve +ve
3 Uninfected spleen 1 - - -ve -ve
4 Uninfected spleen 2 - - -ve -ve
5 Group 1 spleen 1 Intra-nasal 54 -ve +ve
6 Group 1 spleen 2 Intra-nasal 54 +ve +ve
7 Group 1 spleen 3 Intra-nasal 54 +ve +ve
8 Group 1 spleen 4 Intra-nasal 54 +ve +ve
9 Group 2A spleen 1 Intra-nasal 54 -ve -ve
10 Group 2A spleen 2 Intra-nasal 54 -ve -ve
11 Group 2A spleen 3 Intra-nasal 54 -ve -ve
12 Group 2A spleen 4 Intra-nasal 54 -ve -ve
13 Group 2B spleen 1 Intra-nasal 54 +ve ND
14 Group 2B spleen 2 Intra-nasal 54 +ve ND
15 Group 2B spleen 3 Intra-nasal 54 +ve ND
16 Group 2B spleen 4 Intra-nasal 54 +ve ND
17 Group 2C spleen 1 Intra-nasal 54 -ve -ve
18 Group 2C spleen 2 Intra-nasal 54 -ve -ve
19 Group 2C spleen 3 Intra-nasal 54 -ve -ve
20 Group 2C spleen 4 Intra-nasal 54 -ve -ve
Key: - ~ Not applicable, ND ~ sample not tested, -ve ~ negative, +ve ~ positive,1
~ Time when mice were killed (days post infection),2 ~ DNA extracted from MHV-
68 infected NSO cells. The Group 1 mice were left untreated, the Group 2 mice
were treated prophylactically with 4'-s-EtdU and either not withdrawn (A),
withdrawn from treatment on day 12 post infection (B) or withdrawn from treatment
on day 51 post infection (C).
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drinking water were infected via the intra-peritoneal route, with 4xl05 pfu MHV-68.
At day 12 post infection, 4 of the mice put onto 4'-s-EtdU drinking water were
withdrawn from treatment. The remaining prophylactically treated mice remained
on the 4'-s-EtdU drinking water for the duration of the experiment.
4.3.4 The effect of prophylactic 4'-s-EtdU treatment on the dissemination of
MHV-68 to the lungs of mice following intra-peritoneal infection.
The mice infected via the intra-peritoneal route were sampled at day 10 and 24 post
infection and lungs and spleens removed for analysis. No infectious virus could be
detected in the lungs of any of the mice infected intra-peritoneally at either days 10
or 24 post infection, by direct plaque assay. However, by co-cultivation assay, virus
was reactivated from the lungs of all the untreated mice tested (4/4). Virus could not
be reactivated from any of the lung tissue samples derived from the prophylactically
treated (0/4) mice and only 1/4 mice withdrawn from treatment, sampled at day 24
post infection (seefigure 4.4.1).
MHV-68 specific PCR was carried out on DNA extracted from lungs derived from
the mice sampled at day 24 post infection. The DNA extracted from the lungs of all
the untreated mice (5/5) gave rise to aMHV-68 specific band after 40 cycles of PCR,
as did 1/4 mice withdrawn from the 4'-s-EtdU treatment (the same mouse which was
virus positive by lung co-cultivation and splenic infectious centre assay). However, a
MHV-68 specific band at 500bp, was not produced from any of the lung DNA
samples derived from the 4'-s-EtdU treated mice that were not withdrawn from
treatment (see figure 4.2.7b). After a further 25 cycles of nested PCR, only 2/4 and
1/4 mice prophylactically treated and either withdrawn or not withdrawn from
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Figure 4.4,1 The levels of infectious virus reactivated (by co-cultivation assay) from the
lung tissue ofmice infected intra-peritoneally with 4xl(f pfu MHV-68. The mice were
either left untreated (black), prophylactically 4'-s-EtdU treated and not withdrawn
(blue) or withdrawn from treatment day 12 post infection (red). Four mice per group
were sampled at both days 10 and 21 post infection. The assay limit ofdetection was 5
pfu per co-cultivation.
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4.3.5 The effect of prophylactic 4'-s-EtdU treatment on splenomegaly
induction, following intra-peritoneal infection.
A pronounced splenomegaly occurred in the untreated mice infected via the intra¬
peritoneal route. The numbers of splenocytes observed, at both day 10 and day 24
days post infection, was approximately double the number which would normally be
expected in uninfected mice (see figure 4.4.2). A splenomegaly was not observed in
either the prophylactically treated mice which were not withdrawn from treatment, at
both days 10 and 24 post infection, or the mice withdrawn from treatment, sampled
at day 24 post infection. There were significantly more splenocytes observed in the
untreated mice than the mice withdrawn from the prophylactic treatment as well as
the non-withdrawn mice, sampled at both days 10 and 24 post infection (P=0.046,
0.003 and 0.021 respectively, by student T test). There was no significant difference
in the number of splenocytes observed in the 4'-s-EtdU treated mice, withdrawn and
non-withdrawn, sampled at day 24 post infection (P=0.94).
4.3.6 The effect of prophylactic 4'-s-EtdU treatment on the dissemination of
MHV-68 to the spleen, following intra-peritoneal infection
All the untreated mice gave rise to infectious centres at both days 10 and 24 post
infection, averaging 8.9xl03 and 1.3xl02 infectious centres per spleen, respectively.
Conversely, only 1/4 prophylactically 4'-s-EtdU treated mice, at day 10 post
infection and 0/4 and 1/4 mice withdrawn and non-withdrawn from treatment,
respectively, had a detectable infectious centre titre (see figure 4.4.3).
The DNA extracted from the splenocytes of all 5 untreated mice sampled at day 24
post infection, gave rise to a MHV-68 specific band at 500bp, after 40 cycles of
PCR, as did 1/ 4 mice withdrawn from the 4'-s-EtdU treatment (the same mouse
which was virus positive by lung co-cultivation assay and splenic infectious centre
assay). However, MHV-68 specific bands was not produced by any of the DNA
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Figure 4.4.2 The number of splenocytes observed in mice infected (ip) with 4xl05 pfu
MHV-68. The mice were either left untreated (black), prophylactically 4'-s-EtdU
treated and not withdrawn (blue) or withdrawn from treatment day 12 post infection
(red). Four mice per group were sampled at both days 10 and 21 post infection. The





















Time (days post infection)
Figure 4.4.3 The latent virus titres (as measured by infectious centre assay) detected in
the spleens ofmice infected with 4x1O* pfu MHV-68 via the intra-peritoneal route. The
mice were either left untreated (black), prophylactically 4 '-s-EtdU treated and not
withdrawn (blue) or withdrawn from treatment day 12 post infection (red). Four mice
per group were sampled at both days 10 and 21 post infection. The assay limit of
detection was 5 infectious centres per mouse.
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figure 4.2.5). After a further 25 cycles of nested PCR, all the mice withdrawn (4/4)
and 2/4 mice not withdrawn from the 4'-s-EtdU treatment, gave rise to MHV-68
specific bands, at 400bp (see figure 4.2.6).
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Discussion
4.3.7 The potency of 4'-s-EtdU at inhibiting the productive replication of
MHV-68, in vivo
The earlier in vitro studies provided clear evidence of the ability of 4'-s-EtdU to
inhibit the productive replication of MHV-68 in infected tissue culture cell lines.
However in vitro anti-viral activity does not always translate well to the in vivo
situation. The ability of 4'-s-EtdU to significantly inhibit the productive replication
of MHV-68 was demonstrated by the fact that treatment from day 3 post infection,
significantly shortened the acute lung infection, following intra-nasal infection. No
infectious virus was detectable in the lungs after 4 days of treatment, a time point at
which infectious virus was readily detected in all the mock-treated mice. The
absence of infectious virus was unlikely to have been due to 4'-s-EtdU carryover
from the lung tissue, since earlier studies have shown that 4'-s-EtdU treatment
(lmg/mouse/day from day 3 post infection) does not prevent the plaquing ofMHV-
68 present in the lungs of mice (Barnes et al, unpublished data). At day 12 post
infection, treatment continued via 4'-s-EtdU supplemented drinking water. The
administration of 4'-s-EtdU via drinking water was an effective means of treatment,
since no infectious virus was detected in the lungs of the mice transferred to 4'-s-
EtdU supplemented drinking water (at the point of infection), by day 3 post
infection.
The evidence from the experimental time course carried out, where treatment started
at day 3 post infection, did not determine the exact extent of the levels of viral
inhibition exerted by the 4'-s-EtdU. However the evidence provided by the 2 time
courses following intra-nasally infected, prophylactically 4'-s-EtdU treated mice,
strongly suggested that the oral administration (via drinking water at 0.3mg/ml) of
4'-s-EtdU, completely inhibited the productive replication of MHV-68. The
evidence in part, comes from the fact that no infectious virus could be detected in the
lungs of the intra nasally infected mice at days 3, 6 and 7 post infection. The
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untreated mice had infectious virus titres of 1.6x104, 1.8xl05 and 7xl04 pfu per lung
respectively at these time points. As previous discussed, it is unlikely that the
absence of detectable pfu in the lungs of the prophylactically treated mice was due to
the presence of 4'-s-EtdU (within the lung tissue) carrying over into the in vitro assay
and prevented virus plaquing.
Supporting this evidence is the fact that for up to 54 days post infection, the
prophylactically treated mice failed to produce antibodies specific to MHV-68 late
antigens. Failure of the treated mice to produce antibodies anti-MHV-68 specific
antibodies occurred despite the presence of MHV-68 genomic DNA in the lung
tissue. Had the viral DNA (or undetected virus, potentially present at other sites
within the mouse) represented virus that underwent a very low level of productive /
chronic viral replication in the mice, the mice would have been expected to have
mounted a detectable humoral response to the viral antigens expressed. A
pronounced humoral response was readily detectable in the untreated positive
control mice (by day 18 post infection) and the mice withdrawn from treatment at
day 12 post infection mice.
4.3.8 The role of productive virus replication in the establishment and
maintenance of viral latency in the spleen
As shown by earlier work, mice treated with 4'-s-EtdU from day 3 post infection,
experienced a short term but significant delay in the appearance of splenic infectious
centres. At day 7 post infection, the spleens from all the untreated mice (3/3), but
known of the treated mice (0/4) were infectious centre positive. The infectious
centre titre in the treated mice was also significantly lower than in the untreated
mice, at day 12 post infection, which was the peak infectious centre time point for
the untreated mice. However, by day 26 post infection, there was no significant
difference between the infectious centre titres observed in the mice treated and not
withdrawn, treated and withdrawn and those left untreated. This remained the case
throughout the rest of the experiment. Clearly the suppression of viral latency in
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splenocytes, seen at the early time points, did not have a significant effect on the
establishment or maintenance of long-term viral latency. The reason for the delay in
the appearance of splenic infectious centre was presumably due to the decreased
severity of the acute lung infection and hence an initial reduction in the number of
infected circulating B-lymphocytes. This data is therefore in agreement with other
studies carried out to determine the effect of ACV treatment on EBV infected
patients (Zutter et al, 1988, Yao et al, 1989a & b Luxton et al, 1993). In these
studies the anti-viral treatment failed to significantly affect the levels of viral B-cell
latency in the patients. Similarly, ACV, VACV or FCV in vivo treatment initiated
after infection, despite being highly potent inhibitors of HSV replication, do not
prevent the establishment and maintenance of latency in neurones (Field et al, 1981
& 1997 and Thackray et al, 1996a).
The data from the prophylactic 4'-s-EtdU treatment experiments strongly suggests
that treatment ofmice with 4'-s-EtdU, at the level used in this experiment (from day
3 post infection) completely inhibits productive viral replication of MHV-68. It is
reasonable then to assume that the 4'-s-EtdU treatment inhibited all productive viral
replication for the duration of the treatment. Selective outgrowth of 4'-s-EtdU
resistant viral variants did not occur during treatment, since virus reactivated from
the lungs and splenocytes of treated and treatment withdrawn mice failed to show
any loss of sensitivity to 4'-s-EtdU. The data from this study is therefore consistent
with the hypothesis that the long-term maintenance of viral latency in B-lymphocytes
does not have a requirement for productive or chronic viral replication (up to day 61
post infection), either within the lymphocyte compartment or at other sites, such as
the lungs. It also implies that the long term treatment of infected mice does not
affect the ability to detect latently infected splenocytes by infectious centre assay (as
was the case for infected NSO cell lines - see chapter 3).
Virus failed to spread to the spleen in the prophylactic 4'-s-EtdU treated mice which
were not withdrawn from treatment, as determined by nested PCR and by splenocyte
co-cultivation assay. In immunologically normal MHV-68 infected mice, the spleen,
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being the largest lymphoid organ and a major site for lymphocyte trafficking,
normally possesses the highest density of latently infected B-lymphocytes, within the
lymphatic (or blood) system (Sunil-Chandra et al, 1992). Despite this, viral genomic
DNA remained undetectable by nested PCR in all prophylactic 4'-s-EtdU treated
mice not withdrawn from treatment, up to 54 days post infection (0/11 mice over
both time courses). Virus genomic DNA was detectable (by either first round or
nested PCR) in all the untreated, infected mice tested in both the prophylactic 4'-s-
EtdU treatment experiments (11/11). These results clearly demonstrate the need for
productive replication (probably at the sight of the acute infection) to establish a
latent infection of circulating B-lymphocytes, following intra-nasal infection.
The evidence provided by the prophylactic 4'-s-EtdU treatment of mice infected via
the intra-peritoneal route, suggests other sites of viral persistence may exist in the
mouse, other than the lungs and lymphoid cells. Although the possibility can not be
ruled out that persistent virus may reside at sites other than the lungs, following
intra-nasally infection, it is hard to conceive how the virus could pass from the lungs
to a different site in the mouse without coming into contact with circulating B-
lymphocytes (in vitro cell lines including those of B-cell origin can be infected in the
presence of high doses 4'-s-EtdU - see chapter 3). After the 4'-s-EtdU treatment was
withdrawn, the virus disseminated to the spleen. However, dissemination occurred
gradually, over a period of weeks. Virus could be reactivated from the lungs of all
the mice withdrawn from treatment on day 12 post infection, by day 21 post
infection (9 days after withdrawal). However, at day 21 post infection, virus could
not be reactivated from the splenocytes of the same mice and only 1/4 mice had virus
genomic DNA present in the splenocyte DNA preparations, as determined by nested
PCR. However, all the mice withdrawn from the prophylactic 4'-s-EtdU treatment
eventually established a splenic infection. All the mice tested 19 days after
treatment withdrawal (3/3) were virus positive by nested PCR and (2/3) by infectious
centre assay. However, even after 19 days of treatment withdrawal, the levels of
viral DNA present in the spleen appeared to be lower than in the untreated mice.
MHV-68 DNA could not be detected in the treatment withdrawn mice (0/3) by first
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round PCR, when it could in 2/3 untreated mice. By day 54 post infection (42 days
post treatment withdrawal) levels of viral latency in the spleens of the mice
withdrawn from treatment had risen to equivalent (if not higher) titres to those
observed in the untreated mice. Virus could be reactivated from 3/5 mice withdrawn
from treatment on day 12 post infection, whereas virus was only reactivated from 2/5
of the untreated mice. Also, all the mice tested (4/4) produced bright virus specific
bands by first round PCR, whereas only 3/4 untreated mice produced virus specific
bands, all of which were of low intensity.
4.3.9 The role of productive virus replication in the induction of splenomegaly
Despite the obvious in vivo potency of 4'-s-EtdU and the suppression of latent virus
titres associated with the spleen at early time points, the treatment failed to prevent
the viral induction of splenomegaly in mice treated from day 3 post infection. The
splenocyte counts in the treated mice failed to show any significant differences from
those of the untreated mice, at any of the time points studied (days 7, 12, 26, 38, 48
and 61). Therefore is it seems likely that productive replication (or late gene
expression) does not play a role in the induction of splenomegaly or
lymphoproliferation. Similar results have been seen with the ACV treatment of
patients with EBV associated infectious mononucleosis and LPD. Treatment reduces
the viral shed from the oro-pharynx, but failed to impact on the course of the disease,
or the levels of viral latency in B-lymphocytes (Zutter et al, 1988 and Yao et al,
1989a). However, unlike with the EBV studies, the anti-viral treatment, in this
study, started at least 4 days prior to the proliferation of lymphocytes.
The splenomegaly normally seen in mice infected with MHV-68 has been shown to
depend on the presence of infected B-lymphocytes and CD4 positive T-cells
(Usherwood et al, 1995 & 1996a). None of the prophylactically 4'-s-EtdU treated
mice, infected via the intra nasal route, developed splenomegaly. This was
presumably due to the lack of viral dissemination to the spleens of the infected mice.
However, splenomegaly was not observed in the mice withdrawn from the 4'-s-EtdU
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treatment in which, over time, viral latency was established in splenocytes.
Moreover, by nested PCR it was shown that the virus reached the spleen of a number
of prophylactically treated mice infected intra peritoneally, albeit at a low level.
Splenomegaly did not occur in the prophylactically treated mice infected via the intra
peritoneal route. This data suggests that splenomegaly is induced by a sudden influx
of latently infected B-lymphocytes and does not occur if latently infected B-cells
accumulate in the spleen gradually and at very low levels.
4.4.1 The role of productive virus replication in the establishment and
maintenance of viral persistence in the lung
The lung has previously been described as a site of viral persistence, both in normal
inbred mice (Sunil-Chandra - PhD thesis) and in pMT and class II knockout mice
(Usherwood et al, 1995 and Cardin et al, 1996). The evidence from the pMT study
demonstrated that viral persistence in the lung could be established and maintained
in the absence of a latent population of circulating B-cells. The evidence from the
class II knock out mouse study, demonstrated clear evidence of a chronic infection in
the lung at delayed late time points.
After the acute infection, virus could not be detected by direct plaque assay, in the
lungs of any of the mice. However, virus could be reactivated from the lung tissue of
the untreated mice and the mice withdrawn from treatment. It is at present not
known which cells in the lung tissue harbour the persistent virus. A possible
candidate would be latently infected circulating B-lymphocytes, since the lungs were
not perfused prior to dissection. However, this is unlikely since 4'-s-EtdU treatment
prevented the reactivation of infectious virus from the lungs but not from splenocytes
(both by co-cultivation assay) from the same animals. Virus was reactivated from the
lungs of all the mock-treated and mice withdrawn from treatment (9/9 and 10/10
respectively), but generally not from the lungs of the mice that were treated but not
withdrawn (1/12). Despite this, there was no significant difference in the ability to
reactivate virus from splenocytes derived from the mice from either the mock-
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treated, treated and withdrawn or treated not withdrawn mice (7/8, 11/12 and 10/12
respectively). Therefore the fact that virus could not be reactivated from the lungs of
the treated and not withdrawn mice, could not be attributed to a lower number of
latently infected B-lymphocytes, detected by infectious centre assay. It would
therefore appear that the persistent virus present in the lung tissue of the intra-nasally
infected mice was independent of latently infected B-cells.
The fact that the 4'-s-EtdU treatment appeared to have an inhibitory effect on the
persistent virus infection of the lungs, implies viral persistence at this site has a
chronic aspect. This result is highly reminiscent of chronic EBV associated
syndromes, such as OHL (Renick el al, 1988 and Thomas et al, 1991) and
cryptogenic fibrosing alveolitis (Egan et al, 1995), both of which have been
associated with the chronic replication ofEBV oro-respiratory tract.
The evidence from prophylactic 4'-s-EtdU treatment experiments also supports the
evidence from the 4'-s-EtdU treatment from day 3 post infection experiment, that
there is normally a chronic element to the viral persistence in the lungs, in
immunologically normal inbred mice. Virus could be reactivated from the lung
tissue of the untreated mice and the treated mice once withdrawn, at the later time
points day 21 and 31 post infection. However, as was shown with the mice treated
from day 3 post infection, virus could be reactivated far less efficiently from the lung
tissue of the mice not withdrawn from treatment and only at the earliest time point
(day 12 post infection). The level of viral DNA was also lower in the mice not
withdrawn from treatment than in the lungs of the untreated and treatment
withdrawn mice, tested at day 21,31 and day 54 post infection. Virus genomic DNA
could be readily detected by first round PCR in the lungs of virtually all the untreated
and treatment withdrawn mice and did not requiring a second round of nested PCR.
Virus could not be detected in the lung tissue of the continually treated mice, by first
round PCR. However, MHV-68 genomic DNA could be detected in the lung tissue
of all the continually treated mice by nested PCR. This result suggests that the
reason why virus could not be reactivated from the lung tissue of continually treated
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mice, (i.e. the prophylactically treated mice and in all likelihood the mice treated
from day 3 post infection) was due to a decrease in viral load and not due to
elimination of persistent virus from this site. The increased viral load observed in
the lungs of the untreated mice and mice withdrawn from treatment, is strong
evidence of a low level chronic infection occurring in the lungs since 4'-s-EtdU
should not affect the viral genome copy number in a 'tightly' latent infection.
However, the evidence from the prophylactic 4'-s-EtdU treatment experiments also
strongly suggests that viral persistence in the lungs is not dependant on chronic /
productive virus replication or the presence of latently infected circulating B-
lymphocytes for low level establishment and maintenance. Virus DNA could be
detected in all the prophylactically treated mice following intra-nasal infection, up to
day 54 of continuous treatment, by nested PCR. Therefore viral persistence, at the
DNA level, could not have been reliant on productive and hence chronic virus
replication in the lungs, or by reseeding, from latently infected circulating B-cells.
The viral persistence observed in the lungs of the prophylactically treated mice is
reminiscent of the viral persistence seen in 4'-s-EtdU treated infected MGC-7 cells
and must either represent a form of latent infection or a form of herpesvirus
persistence hitherto undefined. It is unlikely that that the persistent virus seen in the
lungs was due to cell free virus from the inoculum, because MHV-68 is a highly cell
associated virus which, at room temperature or higher, rapidly loses viability in a cell
free environment (unpublished observations).
4.4.2 The viability of persistent MHV-68 in the lungs of the prophylactically
4'-s-EtdU mice following intra-nasal infection
Although the virus present in the lungs of the prophylactically 4'-s-EtdU treated
mice, up to 12 days post infection, was shown to be viable (by co-cultivation assay
on withdrawal of the treatment), the virus genomic DNA there after, was not
formally shown to be viable. This was due to the unexpected development of 4'-s-
EtdU associated renal toxicity in the experiment designed to determine the long-term
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effects of prophylactic 4'-s-EtdU treatment. Twelve days is sufficient time for
supercoiling, methylation and conversion to chromatin to occur within a cell.
However, on withdrawal of the treatment, productive replication occurred, denoted
by the sera conversion of the mice to MHV-68 late antigens, and the virus
dissemination to the spleen (as determined by PCR, infectious centre and splenocyte
co-cultivation assay). It is therefore considered likely that the persistent viral
genomic DNA, observed in the prophylactically treated mice after day 12 post
infection, represented potentially viable MHV-68 genomes. Although 12 days is a
relatively short period of time compared to 54 days, MHV-68 can exist in both NSO
and MGC7 cell lines, in the presence of inhibiting doses of 4'-s-EtdU, for in excess
of 60 days without the loss of virus viability (see Chapter 3).
The evidence from 1/ the progressive seeding of virus to the spleen after withdrawal
of treatment, which was 2/ accompanied by the production of antibodies specific to
MHV-68 late antigens and 3/ preceded by an increase in the levels of viral DNA in
the lungs and an increase in the ability to reactivate virus from the lungs, is
concurrent with the hypothesis that MHV-68, in the absence of productive
replication, is held in the lung tissue, following intra-nasal infection and can not
disseminate to the lymphoid compartments of the mouse. Only on removal of the
productive virus replication block, can the virus then seed to B-lymphocytes and
hence to the spleen.
4.4.3 The role of productive virus replication in the dissemination of MHV-68
following infection initiating in the peritoneum
Infection of mice with MHV-68 via the intra-peritoneal route normally results in a
greater systemic infection than infection via the intra-nasal route. Despite this the
prophylactic 4'-s-EtdU treatment still greatly hampered the establishment of splenic
latency. Only 1/8 prophylactically treated mice had an assayable splenic infectious
centre titre and only 2/4 mice tested, were virus positive by nested PCR. In contrast,
all the untreated mice (9/9) had an assayable infectious centre titre and virus DNA
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could be detected in the splenocytes of all the mice tested, by first round PCR, as
opposed to nested PCR. Even after the treatment had been withdrawn for 12 days,
only 1/4 mice were infectious centre and first round PCR positive, although all four
mice were virus DNA positive by nested PCR. This suggests that productive
replication is essential for the efficient establishment of viral latency in B-
lymphocytes, when infected via the intra-peritoneal route. A possible explanation
for this is that the inflammatory response made at the sites of acute or chronic virus
infection is necessary for the recruitment of B-cells to the site and hence the efficient
infection there of.
Virus could be detected in the lungs of all the untreated mice tested, by both co-
cultivation assay (9/9) and by first round PCR (5/5), demonstrating the natural
tropism of MHV-68 for this site. However, the lungs of only 1/4 mice
prophylactically 4'-s-EtdU treated and not withdrawn, and 2/4 mice withdrawn from
treatment on day 12 post infection mice, were MHV-68 DNA positive, by nested
PCR. The treated and not withdrawn mice, which had MHV-68 DNA present in the
lung, also contained detectable MHV-68 DNA in the spleen. This indicates that the
initial infecting virus inoculum achieved better systemic spread than with the other
mice of the same group. No mouse of any group had detectable virus DNA in the
lungs in the absence of virus in the spleen. However, 2/4 mice not withdrawn from
treatment, did not have detectable virus in either the spleen or the lungs. Despite the
low numbers of mice sampled, these results suggest there may well be a third site of
viral persistence, other than the lungs or circulating B-lymphocytes. Further research
will be necessary to identify the alternative site of persistence open to
gammaherpesviruses.
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Chapter 5: The potential role of productive viral replication in the
oncogenesis ofMHV-68.
5.1.1 Summary
A number of experiments were carried out in an attempt to generate a reliable model
for MHV-68 LPD development in mice. This was done with the overall aim to
determine the potential therapeutic value of 4'-s-EtdU in the treatment of
gammaherpesvirus associated LPD. Also to determine the value of 4'-s-EtdU as a
tool for the study of LPD in mice with impaired immune systems. MHV-68
infections are accompanied with a greater degree of lytic virus replication than has
been described for other gammaherpesviruses, potentially leading to severe
complications in immunocompromised hosts. C57BL/6 mice were
immunosuppressed with CsA for 2 week, during the post acute MHV-68 infection.
The mice were kept under observation for 2 years, to determine whether MHV-68
associated tumour development occurred as readily in mice of the C57BL/6
background, as has been reported for mice of the BALB/c background. Despite a
significant increase in viral latency in splenocytes, during the CsA treatment, the
latent virus titres returned to normal after withdrawal of treatment. No lymphomas
or lymphoproliferative disease were observed in any of the mice. SCID mice were
also infected with MHV-68 following adoptive transfer with syngeneic splenocytes.
The SCID mice could be protected from the otherwise lethal MHV-68 infection by
both 4'-s-EtdU supplemented drinking water or CD8 depleted or non-depleted
splenocyte adoptive transfers, from both infected and uninfected donor mice. Latent
virus could be detected in the spleens of the splenocyte adoptive transfer recipient,
MHV-68 infected SCID mice, at early time points (up to day 21 post adoptive
transfer) but only rarely in the later time point mice (day 36 to 60 post infection
mice). None of the mice developed splenic lymphomas or lymphoproliferative
disease, as defined by increased in latent virus load or increase in splenocyte count.
The study failed to demonstrate a role for CD8 T-cells in either the control of latent
virus titres or disease development.
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Introduction
5.1.2 The role of CsA in the development of EBV associated
lymphoproliferative disease
CsA can suppress both T and B cell proliferation, by antagonising the calcium ion
signal pathways. Calcium signalling is essential for IL-2 synthesis leading to T-cell
activation and proliferation. As with other immunosuppressive regimes CsA
treatment is associated with the development of EBV associated LPD (see
introduction), making it a good in vivo reagent to study herpesvirus infection under
immunosuppressive conditions (Jayasuriya et al, 1983 and Veronese et al, 1992).
CsA has been used in many animal model systems as an immunosuppressant or
tolerance inducers (For general review see - Thomson et al, 1989). CsA is also used
in vitro, to promote the out-growth of, EBV-immortalised, LCLs from PBLs donated
by EBV sera positive, individuals (Rickinson et al, 1986).
5.1.3 The role of CsA in MHV-68 associated lymphoproliferative disease
Previous studies carried out on the MHV-68 long-term infection of inbred mice
strains (predominantly BALB/c), have shown that 9% of mice develop LPD over a
period of 9 month to 3 years post infection. Nine of the twenty LPD (45%) cases,
were judged to be high grade lymphomas. The lymphomas were comprised of both
light chain restricted B-cells and infiltrating T-cells. However, 60% of mice, treated
early on in the infection with CsA (50mg/kg) and allowed to fully recover, went on
to develop LPD over a 12 month period. Over the same period of time 20% of the
untreated (MHV-68 infected) mice developed LPD. No lymphomas were seen in the
300 uninfected control mice, however, no uninfected mice were CsA treated.
Inbred mice strains lacking specific elements of the immune system would be ideal
for the study of the in vivo oncogenic potential ofMHV-68. However, it is hard to
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study the tumour forming abilities of MHV-68 in mice with a significantly impaired
immune system, since infection often results in a lethal infection, associated with
chronic or disseminated virus replication (Ehtisham et al, 1993, Cardin et al, 1996,
Week et al, 1996 and Nash and Dutia personal communication). The lethality of
these infections could be potentially circumvented with the application of an
effective productive replication inhibitor, such as 4'-s-EtdU.
5.1.4 The use of SCID mice as a model for EBV associated LPD.
SCID mice have no adaptive immune system and do not reject allogeneic or xeno-
tissue grafts. Humanised SCID mice have been used to model EBV associated LPD
development. Injection of PBLs from healthy EBV sera positive individuals into
SCID mice results in up to approximately 90% of recipient mice developing EBV
positive B-cell LPD, after 1 to 3 months (Cannon et al, 1990 and Rowe et al, 1991).
However, latently infected human B-cells alone, do not appear to efficiently induce
LPD in immunodeficient mice. Injection of SCID mice with purified B-cells from
EBV positive human donors, leads low efficiency LPD development. Furthermore,
similar results were found after injection of PBLs from EBV positive human donors
into immunodeficient mouse strains which accept B-cell but not T-cell xenografts,
such as beige/nude/xid (BNX) mice. In these models of EBV associated LPD
development, the further addition of T-cells, either CD4 or CD8, or exogenous virus
was required for efficient LPD development (Dosch et al, 1991 and Veronese et al,
1992).
5.1.5 The potential role of herpesvirus replication inhibitors in the study of
MHV-68 associated lymphoproliferative disease
Gammaherpesvirus associated LPD and neoplastic disorders have predominately
been associated with immune disorders. This has been demonstrated by the high
prevalence of both EBV associated LPD and BL and KSHV associated KS in
immunosuppressed transplant patients and AIDS patients (see introduction). It is
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therefore likely that MHV-68 associated lymphomas and LPD will also be associated
with immune disorders. Many inbred and transgenic mice have been bred, that have
components of the immune system made dysfunctional. Mice have been generated
which have disrupted antigen presentation, such as MHC class II knock out mice,
that lack specific killing mechanisms, such as fas and perforin knockout mice, that
lack a specific cytokine, such as IL-6 and INFy knock out mice or that lack a specific
cytokine receptor such as INF-a/-P or INF-y receptor knock mice. Other mice have
been generated which lack cellular components of the immune system, such as beige
mice, which lack natural killer cells, pMT mice which lack B-lymphocytes, nude
mice which lack T-lymphocytes and severely combined immune deficient (SCID)
mice which lack both B and T lymphocytes.
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Results
5.1.6 Transient CsA induced immunosuppression of MHV-68 infected
C57BL/6 mice.
In an attempt to replicate the earlier work carried out by Dr Sunil-Chandra et al,
1994, 190 C57BL/6 female mice, 3 to 4 weeks of age were split into 2 groups. One
consisted of 126 mice, which were infected with 4x103 pfu MHV-68 (in 0.2 ml), via
the intra peritoneal route. A second group consisted of 64 mice, which were injected
(ip) with 0.2 ml BHK homogenate. At day 17 post infection, 4 mice were sampled
from each group to assess the establishment of infection. At day 18 post infection,
group 1 mice were divided into 2 groups (groups l.A and l.B) of 61 mice. The mice
in group 1.2 and group 2 were injected (ip) with 0.2 ml CsA (lOOmg/kg mouse) and
the mice in group 1.1 were injected (ip) with 0.2 ml olive oil. Further administration
ofCsA (50mg/kg) or olive oil (by ip injection) took place on days 21, 24 and 27 post
infection. Four mice from each group were sampled on day 24 post infection and a
further 3 mice from each group were sampled on day 37 post infection. The
remaining mice remained under observation for signs of tumour development or
general distress, for up to 2 years post infect. After 2 years the experiment was
terminated and the mice killed.
5.1.7 The FACS analysis carried on splenocytes from MHV-68 infected
C57BL/6 mice immunosuppressed CsA.
FACS analysis using, monoclonal antibodies specific to the CD4, CD8 and B220
antigens, was performed on the splenocyte preparations derived from all the mice
sampled at days 17, 24 and 37 post infection (see figure 5.1.1). The infected mice
underwent splenomegaly. This resulted in a disproportionate increase in the
proportion of T-cells present in the spleen, especially CD8 T-cells, which was not
affected by the CsA treatment. The mean percentage of CD8 positive splenocytes
was significantly higher in the infected (group 1) mice than in the uninfected (group
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Figure 5.1.1
Time (days post infection)
Figure 5.1.1 The relative proportions ofdifferent lymphocyte sub-populations present
in the spleens of C57BL/6 mice infected with MHV-68 (ip) and then either
immunosuppressed with CsA from day 17 post infection (red) or left untreated (blue).
These were compared to non-infected mice which also immunosuppressed with CsA
from day 17 post infection (green). The proportion of the different lymphocyte sub-
populations was determined by FACS analysis. Monoclonal antibodies specific for
B220 (A), CD4 (B), CD8 (C) were used to determine the proportion ofB-cells, CD4 T-
cells and CD8 T-cells respectively. The proportion ofnull cells (D) was determined by
the proportion of splenocytes cumulatively negative for CD4, CD8 and B220 cell
markers. The data values are represented by arithmetic means and the error bars
represent the standard deviations. The level ofdetection was approximately 1 %>.
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2) mice, at all 3 time points tested (P=0.005, 0.013 and 0.0019 respectively, by
student T-test). The mean percentage of CD8 positive splenocytes was also
significantly higher in the infected CsA treated (group l.B) mice than in the
uninfected (group 2) mice (P=0.0018 and 0.049 respectively, by student T-test), at
both days 24 and 37 post infection {see figure 5.1.1B). The mean percentages CD4
positive splenocytes was also higher in both the infected (group l.A) and the infected
CsA treated (group 1 .B) mice, at all 3 time points, than in the uninfected (group 2)
mice {seefigure 5.1.1A). However, the differences were not statistically significant.
Conversely, the proportion ofB-cells present in the spleens of the infected mice was
suppressed during splenomegaly. This again was not affected by the CsA treatment.
The mean percentage of B220 positive splenocytes was significantly lower in the non
CsA treated infected (group l.A) mice than in the uninfected (group 2) mice, at all 3
time points tested (P=0.0035, 0.0065 and 0.015 respectively, by student T-test). The
mean percentage of B220 positive splenocytes was also significantly lower in the
infected CsA treated (group l.B) mice, at both days 24 and 37 post infection, than in
the uninfected (group 2) mice (P=0.0018 and 0.049 respectively, by student T-test)
{see figure 5.1.1C). There were no significant differences between the percentages
of CD4, CD8 and B220 positive splenocytes observed in the infected (group l.A)
mice and the infected CsA treated (group 1 .B) mice at either of the 2 time points
tested.
5.1.8 The effect of CsA immunosuppression on the total numbers splenic
lymphocyte sub-populations in MHV-68 infected C57BL/6 mice.
The number of splenocytes were evaluated for each mouse sampled on days 17, 24
and 37 post infection {see figure 5.1.2A). On day 17 post infection, the number of
splenocytes observed in the infected mice was almost twice that of the uninfected
mice (1.5xl08 leukocytes as opposed to 0.8xl08 leukocytes, P=0.0032 by student T-
test). The number of splenocytes remained higher in infected compared to the
uninfected mice at day 24 (1.15xl08 leukocytes as opposed to 0.9xl08 leukocytes).
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Figure 5.1.2
Time (days post infection)
Figure 5.1.2 The total number ofsplenocytes and lymphocyte sub-populations present
in the spleens of C57BL/6 mice infected with MHV-68 (ip). The infected mice were
either immunosuppressed with CsA, from day 17 post infection, (red) or left untreated
(blue). The infected mice were compared to non-infected mice which were also
immunosuppressed with CsA, from day 17 post infection, (green). The total number of
splonocytes present per spleen (A) was determined by haemocytometer counts ofwater
lysed splenocyte preparations. The proportion of the different lymphocyte sub-
populations was determined by FACS analysis. Monoclonal antibodies to B220 (B),
CD4 (C), CD8 (D) were used to determine the proportion ofB-cells, CD4 T-cells and
CD8 T-cells respectively. The individual numbers ofB-cells, CD4 T-cells and CD8 T-
cells was calculated from the total number of splenocytes for each mouse. The data
values are represented by arithmetic means and the error bars represent the standard
deviations. The level ofdetection was 1% ofthe total splenocyte count.
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However, the difference was no longer statistically significant, remained so for all
later time points.
The total numbers of CD4 T-cells, CD8 T-cells and B220 positive B-cells was
determined (per spleen) for each of the mice sampled on days 17, 24 and 37 post
infection (see figure 5.1.2B, C and D). The total number of T-cells observed in the
infected mice remained significantly higher than in the uninfected mice, even after
the splenomegaly had subsided. There were significantly higher numbers of CD8 T-
cells observed in both the infected (group 1A) mice (P= 0.0065, 0.029 and 0.022
respectively, by student T-test), and the infected CsA treated (group IB) mice (P=
0.0029 and 0.015 respectively, by student T-test), than in the uninfected (group 2)
mice, on all 3 time points tested, days 17, 24 and 37 post infection. There were also
significantly higher numbers of CD4 T-cells observed in both the infected (group
1A) mice (P= 0.0045, 0.19 and 0.03 respectively, by student T-test) and the infected
untreated (group IB) mice (P= 0.0064 and 0.011 respectively, by student T-test) than
in the uninfected (group 2) mice.
However, the total number of B-cells observed in the infected (group 1A) mice was
only significantly higher than the uninfected (group 2) mice, at the first time point,
day 17 post infection, during peak splenomegaly (P=0.02 by student T-test). There
was no significant differences between the number of B-cells observed in either the
infected (group 1 A) or infected CsA treated (group IB) mice, than the uninfected
(group 2) mice, at either of the latter 2 time points, days 24 and 37 post infection.
Once again, the CsA treatment appeared to have no significant effect on the numbers
of splenic B and T lymphocytes, in the infected mice. There was no significant
difference in the numbers of CD4, CD8 or B220 positive splenocytes cells observed
in the infected (grouplA) mice and the infected CsA treated (group IB) mice at
either of the 2 time points tested, days 24 and 37 post infection.
230
5.1.9 The effect of CsA immunosuppression on latent and productive virus
replication in MHV-68 infected C57BL/6 mice.
The number of latently infected splenocytes was determined, by infectious centre
assay, for the infected (group 1A), infected CsA treated (group IB) and uninfected
(group 2) mice (see figure 5.1.3). Infectious centres were detected only in the
infected mice. At day 24 days post infection (day 6 post CsA treatment), the
infectious centre titre observed in the CsA treated (group IB) mice was significantly
higher than both the untreated (group 1A) mice (P=0.01 by student T-test). The
infectious centre titre observed in the CsA treated (group IB) mice was also
significantly higher than observed in the mice during peak splenomegaly, sampled
prior to treatment, on day 17 post infection (P=0.49 by student T-test). However, by
day 37 post infection (10 days after the last CsA injection) both the treated and
untreated mice (groups 1A and IB) had decreased to an equally low titre. Only 2 of
the 3 mice tested from both groups gave rise to infectious centres with the mean
titres showing no significant difference (P=0.87 by student T-test).
To determine if an increase in productive viral replication had occurred in the CsA
treated mice, infectious virus assays were carried out on the lungs, spleens and
adrenal glands of the infected mice (groups 1A and IB), sampled at days 17, 24 and
37 post infection. No infectious virus was detectable in any of the 3 organs tested in
any of the mice, by direct plaque assay (data not shown).
5.2.1 The effect of CsA immunosuppression on LPD development in MHV-68
infected C57BL/6 mice.
Through out the course of the next 2 years the mice were regularly checked for signs
of illness or tumour development. Although a small percentage showed signs of
illness, none of these animals showed signs of tumour development. Infectious virus
and infectious centre assays were carried out on the lungs and spleens respectively




Time (days post infection)
Figure 5.1.3 The levels ofviral latency in MHV-68 infected and uninfected mice, as
determined by infectious centre assay. The mice were infected with 4xl05 pfu MHV-
68, via intra-peritoneal injection. The infected mice were either CsA treated (red) or
left untreated (Blue). All the uninfected mice (green) were also CsA treated. CsA
treatment (50mg/Kg) was initiated on day 18 post infection and was carried out, by
intra-peritoneal injection, at 3 day intervals. The last CsA injection tookplace at day
27 post. Four mice were sampled at days 17 and 24 post infection and 3 mice were
sampled at day 37 post infection. The data is represented by geometric means and
the error bars represent the standard deviations.
232
detectable levels of infectious virus in the lungs or had elevated splenic infectious
centre titres. After 2 years the mice were killed and spleens and mesenteric lymph
nodes removed. None resembled either the high or low grade lymphomas previously
described by Sunil-Chandra et al, 1994.
5.2.2 The adoptive transfer of syngeneic splenocytes into SCID mice from
MHV-68 infected donors.
A separate set of experiments were carried out to determine whether MHV-68
infected B-cells could give rise to lymphomas or lymphoproliferative disease in
SCID mice. Fourteen female BALB/c mice, 3 to 4 weeks of age, were infected (ip)
with 4x105 pfu MHV-68 in a pilot study. The mice were put on drinking water
supplemented with 4'-s-EtdU on day 6 post infection and killed on day 11 post
infection. The ficoll purified splenocytes were injected (ip) into 2 groups of SCID
mice (7x10 cells per mouse), 4 to 5 weeks of age. Groups 1 mice were placed on
drinking water supplemented with 4'-s-EtdU (0.3 mg/ml) from 2 days prior to
adoptive transfer and remained until the experiment was terminated, while the group
2 mice remained untreated. The 2 Groups were further split into a CD8 depleted (IB
and 2B) and undepleted (1A and 2A) group. Groups IB and 2B received splenocytes
mixed with anti-CD8 antibody (lmg / 7x10 splenocytes) and on day 3 post adoptive
transfer, were injected (ip) with a further dose of CD8 depleting antibody (lmg /
mouse). On day 21 days post adoptive transfer the mice were killed for analysis.
5.2.3 FACS analysis carried out on splenocytes from SCID mice following the
adoptive transfer of cells from MHV-68 infected donors.
FACS analysis was carried out on donor splenocytes and splenocyte preparations
derived from the SCID mice sampled on day 21 post adoptive transfer (see figure
5.2.1). The proportions of CD4, CD8 and IgM positive splenocytes were lower in
the SCID mice, than the donor splenocytes used in the adoptive transfer. On








Figure 5.2.1 The relative proportions of different splenic lymphocytes sub-
populations observed in SCID mice adoptive transfer recipients. The SCID mice all
received 2x107 pooled splenocytes (black) from MHV-68 infected (ip) BALB/c mice,
sampled day 11 post infection. Group 1 mice were placed on drinking water
supplemented with 4 '-s-EtdU (0.3 mg/ml), 2 days prior to adoptive transfer, while the
group 2 mice remained untreated. Half the mice from both groups received CD8 T-
cell depleted splenocytes (B) whilst the other halfreceived non-depleted splenocytes.
Each of the resultant 4 groups ofmice, 1A, IB, 2A and 2B (red, yellow, blue and
green respectively) contained 3 mice which were all sampled at day 21 post adoptive
transfer. The proportions of CD4, CD8 and IgMpositive lymphocytes, present per
mouse spleen, was determined by FACS analysis and the proportion ofnull cells was
derivedfrom the cumulative proportion ofCD4, CD8 and IgM negative splenocytes.
The data is represented by arithmetic means and the error bars represent the
standard deviations. The limit ofdetection was 1%.
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in the SCID mice, as compared to the donor splenocytes (6% as opposed to 64%
respectively). The decrease in CD4 and CD8 positive splenocytes was an average
2.5 and 2 fold respectively, in the SCID mice as compared to the donor splenocytes.
As a result, the largest sub-population of splenocytes observed in the SCID mice
recipients were null cells (cells negative for CD4, CD8 and IgM), which were
approximately 90% of the total splenocytes. This compares to a null cell population
of only 20% of the total donor cells. The levels ofCD8 positive splenocytes present
in the CD8 depleted groups of SCID mice (IB and 2B) were both indistinguishable
from the negative controls, and below accurate evaluation by FACS analysis.
The total number of splenocytes and the number of CD4, CD8 and IgM positive cells
was determined for each spleen (see figure 5.2.2). The number of splenocyte per
spleen in the CD8 depleted SCID mice recipients (groups IB and 2B) were both
lower than the undepleted groups (1A and IB). However, the differences were not
significant, and the average splenocyte counts for all the SCID mouse groups,
totalled approximately 1/10 of the number, injected during adoptive transfer.
Despite the numbers of cells being relatively low, significant numbers of CD4 and
IgM positive splenocytes were detectable in all the recipient SCID mice (averaging,
2.4xl05 and 4xl05 cells per spleen, respectively), and 2.1xl05 CD8 positive cells
were observed in the non-depleted SCID recipients (groups 1A and 2A).
5.2.4 The levels of latent and productive virus replication in SCID mice
receiving splenocytes from MHV-68 infected donors.
Latently infected cells could be detected in all the SCID mice except 1 mouse in
group 1A, by infectious centre assay. The total number of infectious centres per
spleen was relatively low (at least 10 fold lower than the number injected in during
adoptive transfer) in all the SCID mice groups (see figure 5.2.3A). However, the
number of infectious centres relative to the number of total splenocytes or B-cells


















Figure 5.2.2 The total numbers of splenocytes and CD4, CD8 and IgM positive
lymphocytes present in the spleens ofSCID mouse adoptive transfer recipients. The
SCID mice all received 2xl07 pooled splenocytes (black) from MHV-68 infected (ip)
BALB/c mice, sampled day 11 post infection. Group 1 mice were placed on drinking
water supplemented with 4'-s-EtdU (0.3 mg/ml), 2 days prior to adoptive transfer,
while the group 2 mice remained untreated. Half the mice from both groups received
CD8 T-cell depleted splenocytes (B) whilst the other half received non-depleted
splenocytes. Each of the resultant 4 groups ofmice, 1A, IB, 2A and 2B (red, yellow,
blue and green respectively) contained 3 mice which were all sampled at day 21 post
adoptive transfer. The number of splenocytes per mouse was evaluated using a
haemocytometer and was multiplied by the proportion ofCD4, CD8 and IgMpositive
lymphocytes, as determined by FACS analysis. The data is represented by arithmetic
means and the error bars represent the standard deviations. The limit ofdetection for
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Donor Group 1A Group 1B Group 2A Group 2B
SCID mice
Figure 5.2.3 The latent virus titre, per spleen (A), relative to the number of
splenocytes present per spleen (B) and relative to the number of splenic B-
lymphocytes present per spleen (C ), in SCID mice recipients ofadoptive transfers.
The SCID mice all received 2x107 pooled splenocytes (black) from MHV-68 infected
(ip) BALB/c mice, sampled day 11 post infection. Group 1 mice were placed on
drinking water supplemented with 4'-s-EtdU (0.3 mg/ml), 2 days prior to adoptive
transfer, while the group 2 mice remained untreated. Half the mice from both groups
received CD8 T-cell depleted splenocytes (B) whilst the other half received non-
depleted splenocytes. Each of the resultant 4 groups of mice, 1A, IB, 2A and 2B
(red, yellow, blue and green respectively) contained 3 mice which were all sampled
at day 21 post adoptive transfer. Levels of splenic latency were evaluated by
infectious centre assay. The data is represented by geometric means and the error
bars represent the standard deviations.
238
splenocytes (see figure 5.2.3B and C). There was no significant differences in
infectious centre titre between the 4'-s-EtdU treated mice and the non-treated mice.
There was also no significant differences between the CD8 depleted and no depleted
groups, despite both CD8 depleted groups having a greater average infectious centre
titre than the respective undepleted groups.
Infectious virus assays were carried out on the donor splenocytes, and the lungs,
spleen and adrenal glands from the sampled SCID mice. No infectious virus could
be detected in any of the mice organs tested nor in the donor splenocytes (data not
shown).
5.2.5 The MHV-68 infection of reconstituted SCID mice.
Studies into the transforming activities of EBV, have shown that inoculation of cell
free infectious virus into humanised SCID mice that lack T-cells, greatly increases
the incidence of LPD development. The implication from this work is that latently
infected B-cells contained within PBLs taken from healthy EBV sera positive
individuals, do not directly give rise to LPD. Although the SCID mice in the
previous experiment received splenocyte adoptive transfers from MHV-68 infected
mice that contained both CD4 and CD8 T-cells, no free virus was detected either in
the splenocytes constituting the adoptive transfer or in the SCID mice after
reconstitution. Therefore to determine whether LPD could be induced in
reconstituted SCID mice following infection with cell free virus, groups of SCID
mice were adoptively transferred with CD8 depleted and non-depleted splenocytes
from both infected and uninfected BALB/c donor and then infected (ip) with cell free
virus.
Twenty one female BALB/c mice, 3 to 4 weeks of age were infected (ip) with 4xl05
pfu MHV-68 while the splenocytes from a further 30 mice were injected (ip) into 2
groups of 16 SCID mice (4xl07 splenocytes per mouse, in 0.4ml). The group 1
SCID mice received whole splenocyte adoptive transfers. The group 2 mice received
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whole splenocyte adoptive transfers but were then CD8 depleted via injected (ip)
with anti-CD8 monoclonal antibodies (lmg/4xl07 cells). Twenty four hours post
adoptive transfer, the non-CD8 depleted (group 1) mice were divided into a further 2
groups (1A and IB) of 8 mice. The group IB mice along with the CD8 depleted
(groups 2) mice were infected (ip) with 4xl04 pfu MHV-68. On day 3 post adoptive
transfer, the group 2 mice were injected with a further dose of anti-CD8 monoclonal
antibody (1 mg/mouse). On day 6, the CD8 depleted (group 2) mice were split into a
further 2 groups (2A and 2B) of 8 mice. The group 2B mice were put on drinking
water supplemented with 4'-s-EtdU (0.3mg/ml), for the remainder of the experiment.
The group 2A and group 1 mice remained on non-supplemented drinking water (see
figure 5.3.1 and table 5.1 for a summary ofthe different SCID mouse groups).
On day 10, the MHV-68 infected BALB/c mice were killed and the splenocytes from
which, injected (ip) into 2 groups (3 and 4) of 8 and 16 SCID mice respectively
*7
(4x10 splenocytes per mouse, in 0.4ml) and a group of 8 uninfected BALB/c mice
controls (group 6). The group 4 mice were CD8 depleted via injection (ip) with anti-
n
CD8 monoclonal antibodies (lmg/4xl0 cells), whilst the group 3 mice remained
undepleted. This left a group of 8 SCID mice (group 5), that did not receive an
adoptive transfer. Half the group 4 mice (group 4B) along with all the non-
reconstituted (group 5) SCID mice were then injected (ip) with 4xl04 pfu MHV-68.
The remaining group 4 mice (group 4A) SCID mice were not super infected with
MHV-68. On day 13, the CD8 depleted SCID mice (groups 4A and 4B) were
injected (ip) with a second dose of anti-CD8 antibody (1 mg/mouse). On day 16, the
MHV-68 infected non-reconstituted (group 5) SCID mice were split into a further 2
groups of 4 mice (groups 5A and 5B). The group 5B mice, along with the
superinfected CD8 depleted (group 4B) SCID mice were put on drinking water
supplemented with 4'-s-EtdU (0.3mg/ml), which they remained on through out the
experimental time course. The group 5A mice remained on normal drinking water.
Mice were sampled at days 7, 36 and 60 post adoptive transfer (see figure 5.3.1 and
table 5.1 for a summary of the different SCID mouse groups).
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Figure 5.3.1
62 x SCID and 8 x BALB/c mice
Adoptive transfers from
uninfected hosts
(Groups 1 & 2)
Adoptive transfers from
MHV-68 infected hosts




















Group Group Group Group Group Group Group Group Group Group
1A IB 2A 2B 6 3 4A 4B 5A 5B
Figure 5.3.1 The summarised procedures carried out on the different groups of recipient mice in sections
5.2.5 and 5.2.7 (Also see Table 5.1). All the groups ofmice received an adoptive transfer ofsplenocytes
(except for the group 5 mice), via intra-peritoneal injection. The donor mice were all sex matched,
syngeneic BALB/c mice. All the groups comprised of 8 x SCID mice except for the group 6 mice (which
comprised of8x BALB/c mice) and groups 5A and 5B (which comprised of8x SCID mice). CD8 depletion
was carried out via intra-peritoneal injection of anti-CD8 monoclonal antibodies and days 0 and 3 post
adoptive transfer. MHV-68 inoculation was carried out on day 1 post adoptive transfer, via intra-peritoneal
injection of 4x10s pfu MHV-68. 4 '-s-EtdU treatment initiated on day 6 post adoptive transfer and delivery
occurred via drinking water.
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Table 5.1 The summarised procedures carried out on the different groups of
splenocyte adoptive transfer recipient mice in sections 5.2.5 and
5.2.7
Group Mice Donor BALB/c CD8 Exogenous 4'-s-EtdU
Mice Depletion Infection Treated
1
A 8xSCID Uninfected - - -
B 8xSCID Uninfected - + -
2
A 8xSCID Uninfected + + -
B 8xSCID Uninfected + + +
3 8xSCID *Infected - - -
4
A 8xSCID *Infected + - -
B 8xSCID *Infected + + +
5
A 4xSCID - - + -
B 4xSCID - - + +
6 8xBALB/c * Infected - - -
Key: - ~ procedure not done, + ~ procedure carried out. * Donor BALB/c mice were
infected with 4xl05 pfu MHV-68 (ip) 11 days prior to the mice being killed and the
splenocyte adoptive transfers taking place.
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5.2.6 Retention of lymphocytes in the SCID mouse recipients of splenocytes
from uninfected BALB/c mice.
The proportion of CD4 T-cells, CD8 T-cells and IgM positive B-cells present in the
uninfected donor splenocytes and their respective SCID mouse recipients (groups 1
and 2) was evaluated by FACS analysis, at days 37 and 60 post adoptive transfer. A
significant proportion of the splenocytes derived from all the SCID mice recipients
were CD4 positive (see figure 5.3.2A). The proportion of CD8 splenocytes in the
non-depleted mice (groups 1A and IB) was equal or greater than the proportion seen
in the donor splenocytes (see figure 5.3.2B). However, in the CD8 depleted SCID
mice (groups 2A and 2B) the number of CD8 cells was below the level of detection
by FACS analysis. The numbers of IgM positive B-cells, in all the groups of
reconstituted SCID mice was low, relative to the donor splenocytes (see figure
5.3.2C). This was especially true for the CD8 depleted mice (groups 2A and 2B).
The combined average proportion of IgM positive cells (for all 4 groups) was under
5%, at both day 36 and 60 post adoptive transfer. As was the case in the pilot study,
the single largest sub-population of splenocytes were the null (CD4, CD8 and IgM
negative cells, calculated assuming the cells positive for CD4, CD8 and IgM were
mutually exclusive) cells (see figure 5.3.2D). The proportion of null cells was higher
in the CD8 depleted groups ranged (across the time point) from an average of 92%
(+/- 6.6) in the group 2B mice to an average of 50% (+/- 20) in the group IB mice.
5.2.7 Virus latency in SCID mice reconstituted with uninfected splenocytes
and infected post adoptive transfer.
The level of viral latency in the spleen was assessed in the mice sampled at each
time point with the infectious centre assay (see figure 3.3.3). At day 7 post adoptive
transfer, relatively high titres of viral latency were detected in all 3 groups of
infected mice (groups IB, 2A and 2B). However, at day 36 and 60 post adoptive
transfer, latent virus was barely detected (see figure 5.3.3). From the 6 mice
sampled, at day 36, only 1 mouse (in group 2A) from the 3 infected SCID mouse
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Figure 5.3.2
Time (days post adoptive transfer)
Figure 5.3.2 The relative proportion ofCD4 (A), CD8 (B) IgM (C) and null positive
splenocytes observed groups 1A, IB, 2A, and 2B (blue, yellow, red and green
respectively) splenocyte adoptive transfer recipient SCID mice. The mice in each group
received 4xl07 splenocytes (pooled from uninfected BALB/c mice) via intra-peritoneal
injection (0.4ml per mouse). Groups 2A and 2B received CD8 T-cell depleted
splenocytes and groups IB, 2A and 2B were infected with 4x104 pfu MHV-68, via intra¬
peritoneal injection, 24 hours after the adoptive transfers. The group 2B mice were
placed on drinking water supplemented with 4'-s-EtdU (0.3mg/ml) from day 6 post
adoptive transfer. The proportions of CD4, CD8 and IgM positive splenocytes were
determined by FACS analysis and the number of null cells was calculated as the
cumulative proportion ofCD4, CD8 and IgM negative cells. FACS analysis was carried
out on the splenocyte preparations from the mice sampled on days 36 and 60 post
adoptive transfer (2 and 4 mice respectivelyper group). The day 0post adoptive transfer
value represents the adoptive transfer splenocytes. The data is represented by













Time (days post adoptive transfer)
Figure 5.3.3 The levels ofviral latency, as determined by infectious centre assay, in
groups 1, 2, 3 and 4 (blue, yellow, red and green respectively) of the splenocyte
adoptive transfer recipient SCID mice. The mice in each group received 4x107
splenocytes (pooled from uninfected BALB/c mice) via intra-peritoneal injection
(0.4ml per mouse). Groups 3 and 4 received CD8 T-cell depleted splenocytes.
Groups 2, 3 and 4 were infected with 4x104 pfu MHV-68, via intra-peritoneal
injection, 24 hours after the adoptive transfers. The group 4 mice were placed on
drinking water supplemented with 4'-s-EtdU (0.3mg/ml) from day 6 post adoptive
transfer. Mice sampled on days 7, 36 and 60 post adoptive transfer (2, 2 and 4 mice
respectively). The day 0 post adoptive transfer value represents the number of
latently infected cells injected (ip) into each mouse. The data is represented by
geometric means and the error bars represent the standard deviations.
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groups (IB, 2A and 2B) had a detectable infectious centre titre. Further more from
the 12 mice sampled at day 60, only 1 mouse (in group IB) from the 3 infected
groups had a detectable infectious centre titre. There was no significant increase in
spleen cell numbers nor lymphoma development, in any of the mice over the time
course (data not shown).
5.2.8 Retention of lymphocytes in the SCID mouse recipients of splenocytes
from MHV-68 infected BALB/c mice.
The proportion of CD4 T-cells, CD8 T-cells and IgM positive B-cells was also
evaluated by FACS analysis for the splenocytes derived from MHV-68 infected
donors and their respective recipients (groups 3, 4A, 4B and the normal BALB/c
recipients) sampled at days 37 and 60 post adoptive transfer. A significant
proportion ofCD4 T-cells were detected in the splenocytes derived from all the mice
tested at every time point (see figure 5.3.4A). The proportions of CD4 positive
splenocytes were lower in the 3 SCID mouse recipient groups (3, 4A, 4B) than in the
normal BALB/c recipients. However, only the SCID mice in group 4B, which
received CD8 depleted splenocytes, were infected (ip) with MHV-68 and treated
with 4'-s-EtdU, had a significantly lower proportion of CD4 T-cells than the other
SCID groups. Across the time course, the group 4B average CD4 count was 4.7%
(+/- 1.9), as compared to 9.4% (+/- 2.9), 9.1% (+/- 2.7) and 13.1 (+/- 4.9) for groups
3, 4A and normal BALB/c recipients respectively (P=0.005, 0.005 and 0.022
respectively by Student T-test). Significant numbers of CD8 T-cells were also
detected across the time course in the non-CD8 depleted mice (groups 3). The levels
of CD8 positive splenocytes were below the limit of detection at every time point in
the CD8-depletey mice (groups 4A and 4B), with the exception of the 2 group 4A
mice sampled at day 7 post adoptive transfer, the CD8 counts for which were 1.2%
and 1.6% (see figure 5.3.4B). The proportion of IgM positive splenocytes was low in
all the SCID mice recipients (groups 3, 4A and 4B) compared to both the normal
BALB/c recipients and the donor splenocytes, at every time point tested (see figure
5.3.4C). The null cells were the largest splenocyte sub-population present in the
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Figure 5.3.4
Time (days post adoptive transfer)
Figure 5.3.4 The relative proportions of CD4 (A), CD8 (B), lgM (C) and null (D)
positive splenocytes observed in groups 3, 4A, 4B and 6 splenocyte adoptive transfer
recipient mice. Groups 3, 4A and 4B (blue, yellow and red, respectively) comprised of
SCID mice and group 6 (green) comprised ofBALB/c mice. The mice of each group
received 4xl07 splenocytes (pooledfrom BALB/c mice at day 11 post (ip) infection) via
intra-peritoneal injection (0.4ml per mouse). Groups 4A and 4B received CD8 T-cell
depleted splenocytes. Group 4B mice were infected with 4xl04 pfu MHV-68, via intra¬
peritoneal injection, 24 hours post adoptive transfers and then placed on drinking water
supplemented with 4'-s-EtdU (0.3mg/ml) from day 6 post adoptive transfer. The
proportions of CD4, CD8 and IgM positive splenocytes was determined by FACS
analysis and the number of null cells was calculated as the cumulative proportion of
CD4, CD8 and IgM negative cells. FACS analysis was carried out on the splenocyte
preparations from the mice sampled on days 36 and 60 post adoptive transfer (2, 2 and
3 mice respectively per group). The day 0 post adoptive transfer value represents the
adoptive transfer splenocytes. The data is represented by arithmetic means and the
error bars represent the standard deviations. The limit ofdetection was 1%.
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reconstituted SCID mice. The average proportion of null cells across the time course
was 91.3% (+/- 4), 86.3% (+/- 2.1), 78.6% (+/- 4.7) and 54% (+/- 9.6) for the group
3, 4A, 4B and normal BALB/c mice respectively (see figure 5.3.4D).
5.2.9 Virus latency in SCID mice reconstituted with splenocytes from MHV-68
infected BALB/c donors.
Infectious centre assays were carried out on the spleen cells on all the mice sampled
(see figure 5.3.5). At day 7 post adoptive transfer, the infectious centre levels in the
spleen was relatively high in the CD8 non-depleted SCID mice (groups 3) and the
normal BALB/c recipients. However, only 1 of the 2 mice sampled from each CD8
depleted group (4A and 4B) gave rise to detectable infectious centres (both positive
mice being on the limit of detection for the assay). At day 36 and 60, infectious
centres were difficult to detect in the SCID mice. Only 2/6 SCID mice, sampled on
day 36 post adoptive transfer (1/2 group 3 and 1/2 group 4A mice) and 1/12 SCID
mice, sampled at day 60 post infection (1/4 group 4A mice) gave rise to detectable
infectious centres. At day 37 and 60 post adoptive transfer 2/2 and 2/4 normal
BALB/c mouse recipients gave rise to infectious centres. There was no significant
increase in spleen cell numbers or lymphoma development, in any of the mice
sampled across the time course (data not shown).
5.3.1 The effect of MHV-68 infection on SCID mice not reconstituted with
spleen cells.
The SCID mice not reconstituted with splenocytes (groups 5A and 5B) were
monitored daily for signs of illness. The non 4'-s-EtdU treated SCID mice (group
5B) all showed signs of illness on day 12 post infection, and 3 of the 4 mice were
dead by the day 13 post infection (the fourth mouse was killed due to signs of severe
distress). The 4'-s-EtdU mice did not show signs of illness through out the
experimental time course and were killed at day 59 post infection.
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Figure 5.3.5
Figure 5.3.5 The levels ofviral latency, as determined by infectious centre assay, ii
groups 5, 6, 7 and 10 ofthe splenocyte adoptive transfer recipient mice. Groups 5, 6
and 7 (blue, yellow and red, respectively) comprised of SCID mice and group 10
(green) comprised of normal BALB/c mice. The mice within each group received
4xl07 splenocytes (pooled from infected BALB/c mice) via intra-peritoneal injection
(0.4ml per mouse). Groups 6 and 7 received CD8 T-cell depleted splenocytes.
Groups 7 mice were infected with 4xl04 pfu MHV-68, via intra peritoneal injection,
24 hours post adoptive transfers and then placed on drinking water supplemented
with 4'-s-EtdU (0.3mg/ml), from day 6 post adoptive transfer. Mice were sampled
from each group on days 7, 36 and 60 post adoptive transfer (2, 2 and 4 mice
respectively). The day 0 post adoptive transfer value represents the number of
latently infected cell injected (ip) into each mouse. The data is represented by
geometric means and the error bars represent the standard deviations.
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Discussion
5.3.2 The effect of CsA on the MHV-68 infection in C57BL/6 mice.
The CsA treatment of the mice did not appear to directly affect the proportions of B
or T-cells in the spleens of either the infected or uninfected mice. There was no
significant differences in either the proportions or total numbers of the different
lymphocyte sub-sets observed in the spleens of the mock infected mice (at the gross
level), before and after CsA treatment. Likewise, there were no significant
differences in either the proportions or total numbers of the different lymphocyte
sub-sets observed in the spleens of the CsA treated and non-treated MHV-68 infected
mice (when compared at the same time point). However, the CsA treatment did
appear to directly affect the viral latency levels. After 6 days of CsA treatment a
significant increase in splenic infectious centres was observed, as compared to both
the titres seen 1 day prior to treatment, and to the untreated infected mice sampled in
parallel of the treated mice. This effect appeared to be transient since by day 37 post
infection (10 days after the last CsA injection) the infectious centre levels, of both
the treated and untreated mice had, decreased to barely detectable level.
The CsA treatment was started after the acute infection had subsided and directly
after peak splenic latency titres, based on previous observations (Sunil-Chandra et al,
1992 and Nash et al, 1996). The infected mice were therefore undergoing
splenomegaly when treatment started. This was shown by the significant increase
the number splenocytes observed at day 17 post infection, in the infected mice, as
compared to the mock infected mice. There were marked differences in the
proportions of the splenic lymphocyte sub-populations detected in the infected and
uninfected mice. The infected mice contained a significantly higher proportion of
CD8 T-cells and a significantly lower proportion of B-cells. Whilst the numbers of
splenocytes was significantly higher, there were significantly more CD4, CD8 and
B220 positive cells in the infected than the uninfected mice. After the increase in
splenocytes reduced to a non-significant level, the number of B-cells per spleen
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became indistinguishable from the number seen in the uninfected mice. However,
the numbers ofCD8 and CD4 T-cells remained significantly higher up to day 37 post
infection.
5.3.3 The apparent absence of LPD development in long-term MHV-68
infected mice.
After a period of 2 years the mice were killed, however none appeared to have
developed grossly enlarged lymphoid organs indicative of LPD development as
previously described by earlier studies (Sunil-Chandra et al, 1994). Clearly this
experiment failed to reproduce the finding of Dr Sunil-Chandra et al, (1994), who
reported 9% of MHV-68 infected mice (predominately BALB/c, but including
C57BL/6 mice) developed LPD over a period of 9 months to 3 years post infection.
It was also reported that 60% of mice treated with CsA, early on in the infection
went on to develop LPD over a 12 month period.
Perhaps the most obvious explanation for the difference is that the previous study
was predominately carried out with BALB/c mice where this study used C57BL/6
mice. It is possible that the BALB/c mice are more susceptible to MHV-68
associated LPD development. It is also possible that differences in husbandry may
have affected the susceptibility to lymphoma development. However, a number of
differences in the methodology could also account for the differences. The mice in
the previous study were infected via the intra-nasal route where as the mice in this
study were infected via the intra peritoneal route. Subtle differences in the initial
establishment of viral persistence or the relative severity of the initial acute infection
at discrete sights may play a role in the development of malignancies or priming of
the immune system. The CsA treatments were also slightly different. In the
previous study weekly ip injections of CsA (50mg/kg) were given from day 4 to day
38 post infection. In this experiment the injections were twice weekly starting at day
18 post infection and finishing on day 27 post infection. Although this regime may
have incorrectly induced long-term sensitivity (or immune tolerance) to tumour
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development, it would not have affected the untreated infected mice.
5.3.4 The adoptive transfer of splenocytes into SOD mice.
The number of splenocytes detected in the spleens of the SCID adoptive transfers
was compared to the total number injected into each mouse. The splenocyte
adoptive transfers were injected in the SCID mouse recipients by the intra peritoneal
route. Injection by the intra venous route may have been a more efficient route but
due to the technical difficulties of working in an isolator, it was not possible. The
CD4 and CD8 T-cells appeared to transfer more efficiently than the B-cells and were
detected in higher numbers at every time point studied, in the SCID recipients. IgM
positive B-cells represented approximately 5% of the total splenocytes present in the
SCID recipient mice. The CD8 T-cell depletions appeared effective in both the first
(pilot) and second experiment, as determined by splenocyte FACS analysis.
However, splenocyte adoptive transfers to the groups which received the CD8
depleted splenocytes appeared to be less efficient, than the non-CD8 depleted
splenocytes. The total splenocyte count tended to be lower in the CD8 depleted
groups as did the CD4 T-cell and B-cell counts. However, significant numbers of
donor splenocytes were generally detectable in the spleens of all the recipient SCID
mice, at all the time points studied.
5.3.5 The levels of viral latency observed in SOD mice 21 days after adoptive
transfer.
In the pilot experiment, latent virus was detected (by infectious centre assay) in
11/12 of the mice sampled at day 21 post adoptive transfer. The BALB/c splenocyte
donors were treated with 4'-s-EtdU, at doses previously shown to inhibit productive
viral replication in vivo, for at least 4 days prior to adoptive transfer. It is therefore
reasonable to assume that no free virus was transferred with the splenocytes, hence
any virus transferred to the SCID mice came from latently infected cells. The
number of splenic infectious centres detectable in the SCID mice recipients, were
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generally at least 10 fold lower than the total number present in the adoptive transfer.
Despite the infectious centre levels being higher in the CD8 depleted mice, the
differences were not significant. No apparent viral reactivation occurred at the gross
level in the SCID recipients since no virus was detected in either the lungs, spleen or
adrenal gland, all of which have been previously described as sites of acute viral
productive replication (Sunil-Chandra et al, 1992). Further more there was no
apparent difference between the mice treated with 4'-s-EtdU and those that were not,
with respect to splenic infectious centres.
5.3.6 The levels of viral latency observed in SOD mice splenocyte recipients
over a 60 day time course.
EBV has been shown to be more oncogenic in humanised SCID mice when added
exogenously. Relatively high levels of infectious centres were seen at day 7 post
adoptive transfer, in the mice who received splenocytes from uninfected donors and
then infected (ip) with MHV-68. Although infectious virus assays were not carried
out on the splenocytes, the numbers of infectious centres observed in the 4'-s-EtdU
treated mice was essentially the same as the non-4'-s-EtdU treated mice. However,
by day 36 the levels of viral latency had decreased to below the limit of detection in
for the majority of the SCID mice recipients (as was the case at day 60 post adoptive
transfer). Again higher levels of infectious centres were observed in the CD8
depleted mice than the non-depleted mice, but with only 2 mice per group sampled,
the significance of this observation is difficult to determine.
The mice that received splenocyte adoptive transfers from infected mice followed a
similar pattern. At day 7 post adoptive transfer, infectious centres could readily be
detected in the non-CD8 depleted SCID recipients and the normal BALB/c
recipients. Infectious centres could not be readily detected in the CD8 depleted
recipients, even those super-infected with MHV-68 and then placed on 4'-s-EtdU.
The implication from this is that either the latently infected B-cells failed to traffic to
the spleen or suffered a loss of viability, presumably due to the anti-CD8 antibody. It
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has been observed in the past that splenocytes can form large non-specific clumps in
the presents of anti-CD8 antibody, once warm. Infectious centres could not readily
be detected in the SCID mice recipients, at the latter time points. Interestingly
infectious centres could be detected in half the normal BALB/c mice tested (2/4) at
day 60 post adoptive transfer, when infectious centres could not be detected in any of
the parallel SCID mouse group (0/4 non-CD8 depleted recipients). However,
whether this result means that latently infected B-cells survive better in a normal
immunocompetent mouse than a SCID mouse, would require a far more thorough
investigation, specifically designed to test this hypothesis.
5.3.7 The oncogenesis of MHV-68 in SCID mice recipients.
There was no obvious signs of lymphoma development associated with the lymphoid
organs in any of the SCID mice. Neither was there any gross increase in the number
of splenocytes. EBV positive PBLs generally give rise to LPD after 1 month post
adoptive transfer. Clearly this was not observed in either the SCID mouse recipients
of either uninfected splenocytes, which were then infected or splenocytes from
infected mice. This could have been due to insufficient time allowed for lymphoma
development, however it could equally be due to the authenticity of this model. The
incidence of LPD development in humanised SCID mice (or in cotton top tamarins)
is far higher than is ever experienced in EBV positive immunocompromised or
immunosuppressed humans. Other inconsistencies exist, such as the fact that LPD
develops in humanised SCID mice despite the presence of the cells (such as CD8 T-
cells) believed to be responsible for preventing LPD development in the original
donor. Treatment with immunosuppressants such as CsA, greatly reduces the
incidence of LPD development in the SCID mice (Veronese et al, 1992), where in
humans it could be considered a prerequisite.
5.3.8 The MHV-68 infection of SCID mice.
All the mice were inffected with 4xl04 pfu MHV-68 via the intra peritoneal route of
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infection. The infection was lethal in the SCID mice which were not treated in any
other way. Although time did not permit analysis of the tissues retrieved from the
mice by post-mortem. However, death was probably caused by disseminated
infection since the mice treated with 4'-s-EtdU showed no signs if illness for up to
day 60 post infection. The mice that received splenocyte adoptive transfers also
failed to develop disease from the infection. Interestingly the mice that received
CD8 depleted splenocytes likewise failed to develop disease. This is in direct
contrast to the intra-nasal infection of BALB/c mice, which when CD8 depleted
using the same monoclonal antibody as was used in this experiment, have been
shown to develop lethal disease (Ehtisham et al, 1993). This may be accounted for
by the fact that the SCID mice were infected with 10 fold less virus, than was used in
the CD8 depletion study. However, the intra-peritoneal route of inoculation
generally gives rise to a more severe acute infection in immunocompromised mice
than more natural routes of infection (Dutia et al, 1997, Sarawar et al, 1997 and
Week et al, 1997). The adoptively transfer process may also have affected the
immune response to infection, mediated by the splenocytes, or there affects on the




A number of gammaherpesviruses have now had there genomes either partially or
completely DNA sequenced. This has allowed cross-species comparisons between
different gammaherpesviruses, with respect to genetic conservation rather than
comparisons based purely on genomic architecture and cellular tropism. MHV-68
can clearly be identified along with the other gamma-2 herpesviruses, encoding
homologues for CRP, cyclin D, GCR and the BHVIE1 / KSHV K3 protein (Virgin et
al, 1997). Also common to gammaherpesviruses, MHV-68 encodes a homologue to
the EBV R transactivator and a Bcl-2 homologue (Virgin et al, 1997). Despite the
genetic similarity of MHV-68 to other gammaherpesviruses, MHV-68 is not
associated with the development of MCF-like diseases, as is seen in AHV-1 and
OHV-2 infections of cows and deer respectively (see Table 1.4). Likewise, MHV-68
does not acutely transform either B or T lymphocytes in vitro, like EBV or HVS
(Pope et al, 1968 and Medveczky et al, 1984). MHV-68 does not encode
homologues to the transformation determinants of either EBV or HVS or host
intcrlcukin molecules. However, the pathology of the MHV-68 infection of mice
does share much in common with other B-cell tropic gammaherpesviruses, such as
the patterns and titres of latently infected B-cells and the splenic
lymphoproliferations observed post acute infection (Sunil-Chandra et al, 1992A and
B, Ehtisham et al, 1993 and Nash et al, 1994 and 1996).
This study was aimed at determining the oncogenic potential of MHV-68 and to
elucidate the mechanisms by which MHV-68 initiates infection, establishes latency
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and induces splenomegaly in inbred mice strains. The method used to study the
early events of the MHV-68 infection of mice, was achieved using a new and highly
potent inhibitor of herpesvirus replication termed 4'-s-EtdU. 4'-s-EtdU is a deoxy
uridine / thymidine homologue which has been shown to inhibit the replication of
alphaherpesviruses such as HSV and VZV (Rahim et al, 1996). In this study the
effect of 4'-s-EtdU on the replication ofMHV-68 in a number of different in vitro
cell lines was examined. Initially the potency of 4'-s-EtdU was determined by
plaque reduction (EC50) assay, using the anti-viral ACV as a comparative standard.
MHV-68 has been shown previously to be sensitive the ACV (Sunil-Chandra et al,
1994B), but in this study, over 10 times less potent than 4'-EtdU. The EC50 of 4'-S-
EtdU was found to be 35ng/ml (0.13pM) and 450 ng/ml (2pM) for ACV. The
effects of 4'-s-EtdU on the replication of MHV-68 was studied in 3 different cell
lines, known to be infected by MHV-68. The 3 cell lines were chosen because each
supported a distinct pattern of virus replication. The myeloma derived NSO cell line,
being of mouse B-cell origin, supports a predominantly latent MHV-68 infection
(Sunil-Chandra et al, 1993). Although persistently infected cultures always contain
productively infected cells, the culture never reaches crisis, with the number of
productively infected cells remaining constant over time. Both the fibroblastoid
BHK cell line and the transformed glial MGC-7 cell line support lytic MHV-68
replication, leading to plaque formation and an infected culture inevitably
undergoing crisis. Plaque formation in the MGC-7 cells takes significantly longer
than in BHK cells (Terry et al, personal communication).
Persistently infected NSO cultures where treated with 4'-s-EtdU at the minimum dose
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required to prevent plaque formation in BHK cells (over 4 days), 200ng/ml and at a
saturating dose, 10 fold higher, 2pg/ml. Both concentrations of 4'-s-EtdU
significantly reduced the amount of productive viral replication detected in the
cultures by infectious virus assay. No infectious virus was detected in the cultures
after the first week of 4'-s-EtdU treatment at 2pg/ml. Likewise MHV-68 antigen
expression was also eliminated from the persistently infected cultures treated with
2pg/ml 4'-s-EtdU. Immunofluorescent staining was carried out on the treated
cultures using both anti-MHV-68 rabbit hyperimmune sera and sera taken from
MHV-68 infected mice. Both seras failed to detect viral antigen expression in the 4'-
s-EtdU treated cultures. Treatment at the lower of the two 4'-s-EtdU doses,
200ng/ml, failed to eliminate infectious virus and hence productive viral replication
from the persistently infected NSO cultures. However, the titres of infectious virions
present in the culture was decreased 1000 fold, to levels that were on the limits of
detection. The conclusions from these results were that 4'-s-EtdU at 200ng/ml
significantly reduced the rate ofMHV-68 productive replication but did not prevent
it. Although 4'-s-EtdU at both 200ng/ml and 2jj.g/ml were sufficient to prevent
plaque formation in BHK monolayers, over a 4 day period, only at 2pg/ml was the
4'-s-EtdU completely inhibiting productive viral replication in the cells.
Co-cultivation of the MHV-68 infected NSO cells from the 4'-s-EtdU treated cultures
over the time course, showed that despite eliminating all detectable infectious virus
from the cultures it was not possible to eliminate infected cells from the cultures.
The infectious centre titre decreased in an inverted exponential manner for the
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duration of treatment with both doses of 4'-s-EtdU. This result implied 4'-s-EtdU
inhibited the ability of latently infected cells to reactivate and undergo productive
replication after withdrawal of treatment. At 200ng/ml 4'-s-EtdU, this effect was
relatively short lived since on withdrawal of treatment, both infectious virus and
infectious centre titres returned to the pre-treatment titres. The suppression of viral
reactivation was far more pronounced in the culture treated with 2pg/ml 4'-s-EtdU.
The infectious centre titres remained for the duration of the experiment (23 days) at
the level observed just prior to treatment withdrawal. Productive virus replication
was detected 3 days after withdrawal of the 4'-s-EtdU treatment, however, again
titres failed to return to the pre-treatment titres. The suppression of viral reactivation
observed in the 4'-s-EtdU treated cultures was not due to a lower number ofMHV-
68 infected NSO cells present in the cultures. PCR analysis carried out on the
genomic DNA derived from cells cloned from both treated and untreated NSO
cultures demonstrated that the number of cells harbouring viral genome remained
insignificantly altered. It is also unlikely that the suppression observed was due to
viral genomes becoming non-viable, since infectious virus was recovered from the
MHV-68 genome positive cell lines cloned from the 4'-s-EtdU treated cultures. The
suppression of reactivation observed could be similar to the effects of FCV on the
HSV reactivation in vivo (Field et al, 1995a & b and Thackray et al, 1986 and 1987).
The 4'-s-EtdU treatment ofMHV-68 infected MGC-7 cells gave surprisingly similar
results to the treatment of the infected NSO cells. Infection ofMGC-7 cells at a MOI
of 1 pfu MHV-68 / cell, would normally result in the culture undergoing crisis within
2 to3 days. However, MGC-7 cultures infected at a MOI of 1 and then treated with
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4'-s-EtdU at either 200ng/ml or 2pg/ml, despite an initial toxicity, failed to under go
crisis. Treatment at 200ng/ml failed to protect the cultures for more than 2 to 3
weeks, presumably due to low level productive viral replication. However, 4'-s-
EtdU treatment of the infected MGC-7 cells at 2pg/ml protected the infected cultures
for over 2 months of continual culture. The treated cells were MHV-68 antigen
negative by immunofluorencent staining using both anti-MHV-68 rabbit hyper¬
immune sera and sera taken from late time point MHV-68 infected mice. However,
on withdrawal of treatment, the MHV-68 harboured in the culture reactivated, as
determined by anti-MHV-68 antigen immunofluorecent staining of the cells. All the
cells had died by day 10 post treatment withdrawal and were MHV-68 antigen
positive. Hence on withdrawal of treatment the cells were killed by lytic viral
replication. By cloning the MHV-68 infected 4'-s-EtdU treated MGC-7 cells, it was
determined that 1/3 of the cells within the culture harboured MHV-68 virus. These
results were interesting since MHV-68 could clearly maintain genomic copy number,
in the apparent absence of productive replication in a cell line which was previously
believed to support only lytic viral replication.
Treatment ofMHV-68 infected BHK cells with 4'-s-EtdU at 2pg/ml failed to protect
the cultures at high MOI. Treated cells infected at a MOI of 4 were mostly dead by 5
days post infection and only partial protection was observed in the cells infected at
an MOI of 0.4. However, short term protection up to 2 weeks, was observed in the
cultures infected at an MOI of 0.04 or less. Again the virus was not lost from these
cultures because after 2 weeks following withdrawal of treatment viral plaques
developed in the cultures leading to all the cells dying. The studies on the effect of
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4'-s-EtdU treatment of MHV-68 infected BHK cells was greatly hampered by the
spontaneous outgrowth of 4'-s-EtdU resistant virus which generally arose after 2-3
weeks of treatment.
Polyclonal MHV-68 preparations were generated from the 4'-s-EtdU treated MHV-
68 infected NSO cultures after 47 days of continual treatment. However, no
increased sensitivity to 4'-s-EtdU was observed by EC50 assay. A polyclonal MHV-
68 preparation was also generated from a long-term 4'-s-EtdU treated MHV-68
infected MGC-7 culture, which spontaneously under went crisis whilst still being
treated. The polyclonal MHV-68 preparation was found to be resistant to 4'-s-EtdU
and MHV-68 isolates were cloned and partially characterised. Preparations of 4'-s-
EtdU resistant MHV-68 were also generated from the infected BHK cultures which
spontaneously developed plaques during treatment. It was interesting to observe that
resistant variants only arose from the infected cell lines which under normal
circumstance support lytic virus replication. Also that spontaneous generation of 4'-
s-EtdU resistant variants took much greater time to emerge from the infected MGC-7
cells than the infected BHK cell. Since MHV-68 productively replicates slower in
MGC-7 than BHK cells, it could be hypothesised that the time it takes for
development of resistant variants is inversely linked to the rates of productive virus
replication supported by the infected cell line. However, further research would be
required to verify this hypothesis. Many more cell lines which support the latent /
persistent / lytic replication of MHV-68 would have to be studied. Also, a longer
duration of treatment would be required for cell lines such as NSO so as to give them
time, if it is at all possible, to spontaneously develop 4'-s-EtdU resistant virus
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variants.
The 4'-s-EtdU resistant MHV-68 isolates cloned from the MGC-7 culture, termed
MERV isolates, were found to be resistant to 4'-s-EtdU up to lOpg/ml. At the gross
level, the MERV isolates were indistinguishable from wild type MHV-68 with
respect to rates of plaque formation in BHK cells and virus titres, measured in pfu,
recovered from BHK cells infected at a MOI of 0.01. The MERV isolates also were
indistinguishable from wild type virus with respect to sensitivity to ACV, when
measured by EC50 assay. The results strongly implied that resistance to 4'-s-EtdU
was not due to the deletion of the TK gene but was due to point mutations in either
the TK gene or the virus encoded DNA polymerase. However, the mechanism by
which MHV-68 becomes resistant to 4'-s-EtdU, without affecting ACV sensitivity
can not be resolved until the DNA polymerase and the TK encoding genes of the
MERV clones are cloned and sequenced.
In vivo, the oral treatment ofmice with 4'-s-EtdU at a dose of 1 mg/mouse/day was
found to be sufficient to not only reduce the productive replication ofMHV-68 but to
prevent the productive replication of MHV-68. The evidence for this came from a
number of observations. Treatment of mice at 1mg/mouse/day eliminated infectious
virus from the lungs of mice infected via the intra-nasal route during the acute
infection, when determined by infectious virus assay. Prophylactic 4'-s-EtdU
treatment of mice, infected via the intra-nasal route, prevented not only the
production ofMHV-68 specific antibodies, by the mice during prolonged courses of
treatment, but also prevented dissemination of virus from the lungs to other parts of
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the body, such as the spleen, despite infection being established.
Initial in vivo experiments were carried out to determine the effect of 4'-s-EtdU
(lmg/mouse/day) treatment starting 3 days post infection. The treatment resulted in
the acute infection of the lung being rapidly resolved, following intra-nasal infection,
when determined by infectious virus assay. Treatment also caused a delay in the
accumulation of latently infected B-cells in the spleens of the treated mice, when
determined by infectious centre assay. However, 4'-s-EtdU treatment failed to have
an long term effect on latent virus titres in the spleen and also failed to prevent the
development of the post acute splenomegaly. The conclusions from these results
were that although severity of the primary acute infection of the lungs may have
influenced the number of B-cells that initially became latently infected, it did not
directly effect the development of splenomegaly (post acute lymphoproliferitive
disease) and had no long-term effect on the levels of viral latency in the spleen.
More over, on the assumption that by approximately 24 hours after initiation of
treatment (day 4 post infection), productive viral replication in the mice was
arrested, we further concluded that productive virus replication did not play a direct
role in the development of splenomegaly and was not required for long term
maintenance of B-cell latency. This was concluded since latently infected B-cells
can not generally be detected in the spleen of mice until days 6 to 7 post infection
and along with the development of splenomegaly, titres do not peek until days 12 to
15 post infection. It could be argued that 4'-s-EtdU resistant variants spontaneously
arose in vivo and so allowed productive virus replication to occur in the presence of
the treatment. However, virus preparations were generated by co-cultivation of lung
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tissue and splenocytes though out the time course and no decreased sensitivity to 4'-
s-EtdU was observed in any mouse at any time point. These results are in full
agreement with the observation made with the attempted treatment of patients with
EBV post acute infectious mononucleosis (Pang et al, 1997 and Niedobitek et al,
1997).
A further observation in this experiment was that MHV-68 could be far less readily
reactivated from the lungs of the infected mice during 4'-s-EtdU treatment than the
untreated mice. Because MHV-68 could be reactivated from the splenocytes at late
time points of the treated mice at the same efficiency as the untreated mice, it is
unlikely that viral persistence in the lungs was due to latently infected B-cells present
in the tissue. Further more, the results imply that the viral persistence in the lungs of
mice involved low level chronic virus replication but that chronic replication did not
have a role in viral persistence in the spleen. The reason MHV-68 was not detected
in the lungs of untreated mice at the late time points by direct plaque assay, was
presumably due virus titres being below the limits of detection. Likewise, the 4'-s-
EtdU treatment of the mice further reduced the virus titre to below the co-cultivation
assay limit of detection, since on withdrawal of treatment virus was once more
detected in the lungs of the formally treated mice.
The next set of in vivo experiments were carried out to determine the effect of
prophylactic 4'-s-EtdU treatment (lmg/mouse/day) starting 2 days prior to intra¬
nasal infection. The treatment resulted in there being no detectable productive virus
replication in the lungs, during the times normally associated with the acute lung
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infection. Virus also failed to disseminate to the spleen in the treated animals, as
determined by both co-cultivation assay and nested PCR. Further more, the treated
mice failed to under go splenomegally or produce MHV-68 specific antibodies.
However, infection was established in the prophylactically treated mice since on
withdrawal of treatment, viable virus was detected first in the lungs and then later in
the spleen. PCR and nested PCR analysis on DNA extracted from the lungs and
spleens of the treated, untreated and treatment withdrawn mice clearly
demonstraighted that viral infection was established in the lungs of the mice
following intra-nasal infection even in the prophylactically treated mice. However,
there was significantly more virus genome present in the lungs of the untreated mice
than the treated. Viral genomic DNA remained present in the lungs of the treated
mice and remained absent in the spleen of mice at all time points sampled (up to 54
days post infection). Upon withdrawal of treatment, the levels of viral DNA
increased in the lungs of the mice and over a period of weeks became detectable in
the spleen. Dissemination of the virus from the lungs to the spleen coincided with
the production ofMHV-68 specific antibodies by the infected mice.
From these experiments it was concluded that productive virus replication was not
required for the long-term establishment of the MHV-68 infection in the lungs of
mice, inoculated via the intra-nasal route. At the cellular level, in vitro experiments
carried out earlier in this study had already shown that MHV-68 readily infected
NSO, MGC-7 and BHK cells, in the presence of saturating doses of 4'-s-EtdU. It was
further concluded that viral persistence in the lungs was not dependent on either
productive virus replication or the existence of latently infected B-cells. However, as
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was concluded from the experiment in which 4'-s-EtdU treatment was initiated day 3
post infection, productive or chronic virus replication was responsible for a large
proportion the persistent virus present in the lungs of infected mice under normal
circumstances. There were striking similarities between the viral persistence in the
lungs of mice during 4'-s-EtdU treatment and the viral persistence in the in vitro cell
lines also during treatment. This study has provided clear evidence, both in vitro and
in vivo, that in the presence of high doses of 4'-s-EtdU and the apparent absence of
productive viral replication, MHV-68 can persist in cell lines and tissues (of non
lymphoid origin) which are usually associated with lytic or productive virus
replication.
Evidence from the study on the effects of prophylactic 4'-s-EtdU treatment on the
intra-nasal MHV-68 infection of mice also showed that productive viral replication
had a major role in the aetiology of the MHV-68 infection. It was concluded that
productive virus replication was essential for virus dissemination to the spleen and
hence essential for the initial establishment of viral latency in B-lymphocytes. Also,
productive virus replication was essential for development of splenomegally. Earlier
experiments had already established that productive virus replication does not play a
direct role in inducing splenomegaly, however it was required to initiate the events
which lead to the development of splenomegaly. This is presumably due to
productive replication being required to establish latent infections of B-cells and so
supports the work carried out on the pathogenesis of the MHV-68 infection of pMT
mice (Usherwood et al, 1996b).
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A further experiment was also carried out on the effects of prophylactic 4'-s-EtdU
treatment on the MHV-68 infection of mice. In this experiment the virus was
inoculated via the intra-peritoneal route. Again the infection failed to disseminate to
the same degree as with the untreated mice. Productive virus replication was again
not detected in the mice during treatment and the mice failed to develop
splenomegaly. A number of the treated mice did establish viral latency in the
spleens however, latent virus titres were far lower than in the untreated mice as
determined by both infectious centre assay and PGR. In the majority of the treated
mice, virus had not established an infection in the lungs and half the mice failed to
establish infections in either the lungs or the spleen, as determined by nested PCR.
Again all the mice appeared to become infected since on withdrawal of the 4'-s-
EtdU treatment viral genome was detected in both the lungs and spleen of all the
mice.
It was hard to draw many conclusions from this experiment since this study was
much smaller than the other in vivo studies and the MHV-68 infection has been less
well described when initiated via the intra-peritoneal route as opposed to the intra¬
nasal route. The effects of the 4'-s-EtdU treatment were perhaps far greater than
might be expected from a systemic route of challenge such as the intra-peritoneal
route of infection. The study did clearly demonstrate the essential role of productive
virus replication for viral dissemination. However, the efficiency of dissemination
along with the levels of viral genome present in tissues appeared to have a far greater
degree of variability in the treated mice infected via the intra-peritoneal route than
via the intra-nasal route. It was interesting to observe that viral latency was
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established in some of the prophytactically treated mice and the results implied a
tissue other than the lungs or spleen may be harbouring persistent virus. The levels
of latent virus observed in the spleens of the prophylactically treated mice was very
low. However, further experiments would be required to determine whether it would
have remained low over longer periods of time. Greater numbers ofmice and a wide
range of tissues would have to be studied to determine the extent of viral
dissemination in the absence of productive viral replication, following intra¬
peritoneal inoculation. The results from this experiment implied that the
development of splenomegaly might require either some productive virus replication
or a threshold level of B-cells to become latently infected. This would probably best
be resolved by inoculating MHV-68 at different doses into prophylactically 4'-s-
EtdU treated mice via the intra-venous route. It could therefore be guarantied that
high levels of viral latency would be established in B-cells in the absence of
productive viral replication.
The final set of experiments undertaken in this study were to establish whether
MHV-68 induced tumour formation in mice and if so the role of productive virus
replication in the disease pathology. A number of gammaherpesviruses have
transforming properties in vitro and are associated with the development of
malignancies in vivo (see Table 1.4 for summery). Further more the prevalence ofB-
cell lymphoma development has been reported to be elevated in elderly MHV-68
infected mice compared to uninfected controls (Sunil-Chandra et al, 1994b). A large
scale experiment was carried out where large groups of C57B1/6 mice were either
infected or mock infected with MHV-68. Half of the infected mice and all the
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uninfected mice were then transiently immunosuppressed with cyclosporin A.. The
treatment lasted for 10 days, initiated during splenomegaly, day 17 post infection.
The treatment appeared to cause a transient elevation of latent MHV-68 titres in the
spleens of the infected animals, which on withdrawal of treatment returned to base
line levels. However, unlike the earlier report, which described up to 60% of mice
developing LPD (Sunil-Chandra et al, 1994b), none of the mice went on to develop
malignancies over the next 2 years.
Further experiments were carried out using lymphocyte repopulated SCID mice.
Since SCID mice have no specific immunity they are highly prone to viral disease.
SCID mice have been used extensively in the study of EBV induced LPD.
Development of LPD can be developed in SCID mice by adoptively transferring PBL
from EBV positive human donors LPD (Cannon et al, 1990 and Rowe et al, 1991).
In an attempt to mimic this type of experiment, splenocytes were adoptively
transferred from syngeneic MHV-68 donor mice into SCID mice. Despite the fact
that latently infected B-cells were detected in the spleens of the SCID mice
recipients 21 days after adoptive transfer, the virus titres were very low, even in the
CD8 T-cell depleted groups.
A larger scale experiment was then carried out using SCID mice as recipients of
MHV-68 infected splenocytes, using greater numbers of SCID mice over a longer
time course. Splenocytes were adoptively transferred from MHV-68 infected mice
into SCID mice as well as naive immunocompetent syngeneic mice. Further more,
splenocytes were also adoptively transferred into SCID mice from uninfected mice
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and then the SCID mice were infected with MHV-68 1 hour later. The mice were
sampled up to 60 days after adoptive transfer but again, despite the fact that latent
virus was detected in all the mice 7 days after transfer, none of the mice went on to
develop LPD. Further more, the MHV-68 titres in the spleens of the SCID mice
recipients appeared to substantially decrease over time and could not be detected in
the majority of the mice 60 days after transfer. Latent virus appeared to persist better
in the normal BALB/c recipients than in the SCID mice. CD8 T-cell depletion of the
splenocytes did not appear to affect latency levels in the SCID recipients which is
surprising given previous reports suggesting CD8 T-cells were essential for control
of MHV-68 associated disease (Etisham et al, 1993). The study did however
demonstrate at a specific immune system is essential to protect mice against lethal
MHV-68 infection. SCID mice inoculated with MHV-68 via the intra-peritoneal
route gave rise to a lethal infection, death occurring after 2 weeks. Death was
presumably due to disseminating chronic virus replication since mice infected and
then treated with 4'-s-EtdU from day 6 post infection did not show signs of disease
until the experiment was terminated 59 days later. This series of experiments failed
to provide evidence of MHV-68 involvement in the development of malignancies
and hence it was concluded that ifMHV-68 did have oncogenic potential it was not
readily observed under the described experimental conditions.
To summarise the findings of the study presented in this thesis, productive virus
replication is essential for dissemination ofMHV-68 from the lungs ofmice infected
via the intra-nasal route to other mouse tissues such as lymphoid tissue. Productive
virus replication also appeared to play a major role in viral dissemination even when
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MHV-68 was inoculated by systemic routes such as the intra-peritoneal route.
Productive virus replication is not required to establish infection in either cell lines
in vitro or the host in vivo. Productive virus replication is not required to maintain
levels of latently infected B-cells and does not play a direct role in the development
of post acute non-malignant splenic lymphoproliferation. The lungs are a major site
of MHV-68 persistence and persistence at this site is predominantly due to chronic
virus replication. However, MHV-68 can persist in cell lines in vitro, and tissues
such as the lungs, in vivo, in the prolonged absence of productive viral replication,
despite being associated with productive virus replication and not with classical
gammaherpesvirus latency.
The study highlights the importance of MHV-68 as a model by which the
pathogenesis of gammaherpesvirus infections can be studied under controlled
experimental conditions in the natural host. Although MHV-68 may not be a good
model for the study of gammaherpevirus induced / associated malignancies it allows
a unique means to study the early events in gammaherpesvirus infections. The study
also highlights the potential of MHV-68 as a model for the study and testing of
antiviral agents and therapies both in vitro and in vivo.
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